Muscle banding protein inhibitors

Abstract

The present invention relates to Fascin inhibitors of formula (I), stereoisomers thereof, tautomers thereof, deuterated derivatives thereof, pharmaceutically acceptable salts thereof, pharmaceutically acceptable salts of stereoisomers thereof, pharmaceutically acceptable salts of tautomers thereof or pharmaceutically acceptable salts of deuterated derivatives thereof, as well as pharmaceutical compositions containing them and uses thereof. Formula (I).

Description

Cross-reference to related applications

[0001] This application claims priority to PCT / CN2023 / 104448, filed on June 30, 2023; and PCT / CN2023 / 111636, filed on August 8, 2023, the entire contents of which are incorporated herein by reference. Technical Field

[0002] This invention relates to myofascitis inhibitors, compositions containing such inhibitors, and their uses. Background Technology

[0003] Fascin is a myosin-binding protein widely distributed in various cells, stabilizing and organizing actin bundles through direct interaction with actin filaments (F-actin). This interaction is crucial for many biological processes, such as cell migration, cell polarity, and cell division. Studies have shown that Fascin is expressed at low levels or not at all in normal tissues (such as nerves, intestinal epithelium, and muscle), but its expression typically increases significantly when cells (such as epithelial cells) transform into cancer cells. Increased Fascin expression can enhance the invasiveness and migration ability of tumor cells, thereby promoting tumor spread and metastasis. Therefore, aberrant expression or regulation of Fascin activity is associated with the progression of many diseases, particularly in many types of cancer, including gastric, lung, breast, colon, and ovarian cancer. Overexpression of Fascin has also been found to be associated with poor prognosis in cancer patients. In some cancers, such as non-small cell lung cancer, Fascin expression levels can be used as an independent prognostic biomarker to predict disease progression and survival. Therefore, treatment strategies targeting Fascin can not only inhibit tumor growth and spread, but also improve patients' survival rate and quality of life.

[0004] The biochemical properties and functions of Fascin present several challenges for drug design and development. For example, the interaction between Fascin and actin filaments is achieved through large-area protein-protein contact, making it extremely difficult to find small molecule compounds that can effectively block this interaction. Furthermore, Fascin also plays an important role in normal tissues, so any therapeutic strategy targeting Fascin must carefully consider its potential impact on normal physiological processes to avoid adverse reactions or toxicity. In recent years, although some preliminary studies have shown that certain small molecule compounds can inhibit Fascin function by directly interacting with it or indirectly affecting its expression or activity—for example, some compounds can block Fascin function by interfering with its interaction with actin filaments, while others can alter its activity by affecting Fascin expression or phosphorylation status—these compounds often exhibit poor selectivity for Fascin and frequently cause toxicity to other cells. Therefore, developing selective inhibitors of Fascin and validating the efficacy and safety of these compounds is crucial. Invention Overview This invention provides a compound of formula (I): Formula (I) Its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein each variable is defined as follows.

[0006] The present invention also provides intermediates for preparing the compounds of the present invention.

[0007] This invention also provides a process for preparing the compounds of this invention.

[0008] The present invention also provides a pharmaceutical composition comprising an effective therapeutic amount of the compound of the present invention, a stereoisomer, a tautomer, a deuterated derivative thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer, a pharmaceutically acceptable salt of the tautomer or a pharmaceutically acceptable salt of the deuterated derivative thereof, and at least one pharmaceutically acceptable excipient.

[0009] The present invention also provides the use of the compounds of the present invention, their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of the stereoisomers, pharmaceutically acceptable salts of the tautomers or pharmaceutically acceptable salts of the deuterated derivatives, or pharmaceutical compositions of the present invention for the preparation of medicaments for treating cancers associated with Fascin overexpression.

[0010] The present invention also provides a method for treating a subject with cancer associated with Fascin overexpression, the method comprising administering to the subject a therapeutically effective amount of the compound of the present invention, its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative.

[0011] The present invention also provides the use of compounds, their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers or deuterated derivatives, or pharmaceutical compositions thereof for the treatment of cancers associated with Fascin overexpression.

[0012] Detailed description This invention provides the following disclosures: 1. A compound of formula (I), including its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of its stereoisomers, pharmaceutically acceptable salts of its tautomers, or pharmaceutically acceptable salts of its deuterated derivatives: Formula (I) in, R1 is selected independently from hydrogen, halogen, and -C each time it appears. 1-6 Alkyl, Halogenated C 1-6 Alkyl, -C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, -NH2, -NH(C 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group, or 5-10 membered heteroaryl group; wherein, R1 can be independently selected from halogen, -C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, oxo, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group or 5-10 membered heteroaryl group substituted with 1, 2, 3, 4, 5 or 6 substituents; R2 is selected independently from hydrogen, halogen, and -C each time it appears. 1-6 Alkyl, Halogenated C 1-6 Alkyl, -C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, -NH2, -NH(C 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group, or 5-10 membered heteroaryl group; wherein, the R2 can be independently selected from halogen, -C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, oxo, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group or 5-10 membered heteroaryl group substituted with 1, 2, 3, 4, 5 or 6 substituents; Alternatively, R1 and R2, together with the atoms they are respectively connected to, make the equation (I) The following groups are formed: or ; when yes hour, X1 is selected from N or CR7; X2 is selected from N or CR8; X3 is selected from N or CR9; X4 is selected from N or CR 10 ; R7 is selected independently from hydrogen, halogen, and -C each time it appears. 1-6 Alkyl, Halogenated C 1-6 Alkyl, -C 2-6 Alkoxy, halogenated C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, -NH2, -NH(C 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group, or 5-10 membered heteroaryl group; wherein, the R7 can be independently selected from halogen, -C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, oxo, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group or 5-10 membered heteroaryl group substituted with 1, 2, 3, 4, 5 or 6 substituents; R8 is selected from hydrogen, -C(=O)N(R 81 )2、-NHC(=O)(R 81 -S(=O)N(R) 81 )2、-NHS(=O)(R 81 -S(=O)2N(R) 81 )2 or -NHS(=O)2(R 81 ); The R 81 Each occurrence is independently selected from 3-10 membered carbon rings, 3-10 membered heterocycles, phenyl, or 5-10 membered heteroaryl; the R 81 Can be selected from halogens, -C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, oxo, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C)1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group or 5-10 membered heteroaryl group substituted with 1, 2, 3, 4, 5 or 6 substituents; R9 is selected from hydrogen, -(C 1-6 (alkylene)-R 91 -C(=O)(OR) 92 -S(=O)(OR) 92 -S(=O)2(OR) 92 -C(=O)-NHR 92 -S(=O)-NHR 92 -S(=O)2-NHR 92 -C(=O)(R) 93 -S(=O)(R) 93 -S(=O)2(R) 93 -OC(=O)(R) 93 -OS(=O)(R) 93 -OS(=O)2(R) 93 ), -NH-C(=O)(R 93 ), -NH-S(=O)(R 93 -NH-S(=O)2(R) 93 ); The R 91 Each time it appears, it is selected independently from -C. 2-6 Alkoxy, halogenated C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6Alkyne, -CN, -NO2, -N3, -NH2, -NH(C 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl groups, 3-10 membered carbon rings, 3-10 membered heterocycles, 6-12 membered aryl groups, or 5-10 membered heteroaryl groups; The R 92 Each is independently selected from 3-10 membered carbon rings, 3-10 membered heterocycles, phenyl, or 5-10 membered heteroaryl; the R 92 Can be selected from halogens, -C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, -C 2-6 alkenyl, -C 2-6Alkyne, -CN, -NO2, -N3, oxo, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 The alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group or 5-10 membered heteroaryl group are substituted with one or more substituents; The R 93 Each occurrence is independently selected from halogens and -C. 2-6 Alkoxy, halogenated C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, -NH2, -NH(C 1-6 alkyl), -N(C) 1-6Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl groups, 3-10 membered carbon rings, 3-10 membered heterocycles, 6-12 membered aryl groups, or 5-10 membered heteroaryl groups; X2 and X3 cannot both be N; When X2 is CR8 and X3 is CR9, only one of R8 and R9 is hydrogen; R 10 Each time it appears, it is independently selected from hydrogen, halogen, -C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, -C 2-6 Alkoxy, halogenated C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, -NH2, -NH(C 1-6alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl), 3-10 membered carbon rings, 3-10 membered heterocycles, 6-12 membered aryl or 5-10 membered heteroaryl; wherein, the R 10 Independently selectable from halogens, -C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, oxo, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group or 5-10 membered heteroaryl group substituted with 1, 2, 3, 4, 5 or 6 substituents; When fragment for hour: n4 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; n5 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; Y2 is selected from -C(RY2)2-, -RY2C=CRY2-, -C≡C-, -O-, -NRY3-, -S-, -C(=O)-, -S(=O)-, -S(=O)2-, -C(=O)O-、 -C(=O)NRY4-、 -NRY4C(=O)-、 -S(=O)NRY4-、 -NRY4S(=O)-、 -S(=O)2NRY4- or -NRY4S(=O)2-; Representation and fragment The connection point; R Y2 Each time it appears, it is independently selected from hydrogen, halogen, -C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, -C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, -NH2, -NH(C 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group, or 5-10 membered heteroaryl group; wherein, R1 can be independently selected from halogen, -C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, oxo, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group or 5-10 membered heteroaryl group substituted with 1, 2, 3, 4, 5 or 6 substituents; R Y3 Each time it appears, it is independently selected from hydrogen and -C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, -C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl group, -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 alkyl) 2, 3-10 membered carbon rings, 3-10 membered heterocycles, 6-12 membered aryl or 5-10 membered heteroaryl; said R Y3 It can be independently represented by 1, 2, 3, 4, 5, or 6 R's. Y31 Replace; R Y31 Each occurrence is independently selected from halogens and -C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, -C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, -NH2, -NH(C 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl groups, 3-10 membered carbon rings, 3-10 membered heterocycles, 6-12 membered aryl groups, or 5-10 membered heteroaryl groups; the RY 31 It can be independently represented by 1, 2, 3, 4, 5, or 6 R's. Y32 Replace; R Y32 Each occurrence is independently selected from halogens and -C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, oxo, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl groups, 3-10 membered carbon rings, 3-10 membered heterocycles, 6-12 membered aryl groups, or 5-10 membered heteroaryl groups; R Y4 Each time it appears, it is independently selected from hydrogen and -C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl group, -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 alkyl) 2, 3-10 membered carbon rings, 3-10 membered heterocycles, 6-12 membered aryl or 5-10 membered heteroaryl; said R Y4 Independently selectable from halogens, -C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, oxo, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group or 5-10 membered heteroaryl group substituted with 1, 2, 3, 4, 5 or 6 substituents; R4 is selected independently from -H, halogen, and -C each time it appears. 1-6 Alkyl or halogenated C 1-6 alkyl; R5 is selected independently from -H, halogen, and -C each time it appears. 1-6 Alkyl or halogenated C 1-6 alkyl; R6 is selected independently from -H, halogen, and -C each time it appears. 1-6 Alkyl, -OC 1-6 Alkyl or halogenated C 1-6 alkyl; The Y1 Selected from non-existent, -C(R) Y1A )2-、-R Y1A C=CR Y1A -、-C≡C-、-N(R Y1B )2-, -O-, -S-, -C(=O)-, -S(=O)-, -S(=O)2-, -C(=O)O- -OC(=O)- -N(R) Y1B )-C(=O)- -C(=O)-N(R) Y1B )- -N(R) Y1B )-S(=O)- -S(=O)-N(R) Y1B )- -N(R) Y1B )-S(=O)2- or -S(=O)2-N(R) Y1B )- ; Indicates the connection point with ring B; The R Y1A Selected from -H, halogen, -C 1-6 Alkyl or halogenated C 1-6 alkyl; The R Y1B Selected from -H or -C 1-6 alkyl; Ring B is selected from 3-14 membered carbon rings, 3-14 membered heterocycles, 6-14 membered aromatic rings, or 5-14 membered heteroaromatic rings; R S1 R S2 or R S3 Each occurrence is independently selected from halogens and -C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, -C 2-6 Alkoxy, halogenated C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl), 3-10 membered carbon rings, 3-10 membered heterocycles, 6-12 membered aryl or 5-10 membered heteroaryl; wherein, the R S1 R S2 or R S3 Independently selectable from halogens, -C 1-6 Alkyl, Halogenated C 1-6 Alkyl, -C 2-6 Alkoxy, halogenated C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group or 5-10 membered heteroaryl group substituted with 1, 2, 3, 4, 5 or 6 substituents; n1 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; n2 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; n3 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; Each time the heterocycle appears, it independently contains 1, 2, 3, 4, 5 or 6 heteroatoms selected from N, O, S, S(=O), S(=O)2; Each occurrence of the heteroaryl group independently contains 1, 2, 3, 4, 5, or 6 heteroatoms selected from N, O, or S.

[0013] 2. A compound of formula (I-1) or (I-2), its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives:

[0014] Among them, X1, X2, X3, X4, R4, R5, R6, ring B, Y1, Y2, R S1 R S2 R S3 The definitions of n1, n2, n3, n4 and n5 are the same as those in section 1 above.

[0015] 3. A compound of formula (I-1), its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of its stereoisomers, pharmaceutically acceptable salts of its tautomers, or pharmaceutically acceptable salts of its deuterated derivatives: Formula (I-1) Among them, X1, X2, X3, X4, R4, R5, R6, ring B, Y1, R S1 R S2 The definitions of n1 and n2 are the same as those in section 1 above.

[0016] 4. The compounds of formula (I) or (I-1) of any one of the preceding items 1-3, including their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of the stereoisomers, pharmaceutically acceptable salts of the tautomers, or pharmaceutically acceptable salts of the deuterated derivatives. X1 is selected from N or CR7; X2 is selected from N or CR8; X3 is selected from N or CR9; X4 is selected from N or CR 10 And at most one of X1, X2, X3, and X4 is N; or X1 is selected from N or CR7; X2 is selected from N or CR8; X3 is selected from N or CR9; X4 is selected from N or CR 10 And at most two of X1, X2, X3, and X4 are N; or X1 is selected from N or CR7; X2 is selected from N or CR8; X3 is selected from N or CR9; X4 is selected from N or CR 10 Furthermore, at most three of X1, X2, X3, and X4 are N.

[0017] 5. The compounds of formula (I) or (I-1) of any one of the preceding items 1-4, including their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of the stereoisomers, pharmaceutically acceptable salts of the tautomers, or pharmaceutically acceptable salts of the deuterated derivatives. X1 is selected from CR7, X2 is selected from CR8, X3 is selected from CR9, and X4 is selected from CR 10 ;or X1 is selected from N, X2 is selected from CR8, X3 is selected from CR9, and X4 is selected from CR. 10 ;or X1 is selected from CR7, X2 is selected from N, X3 is selected from CR9, and X4 is selected from CR. 10 ;or X1 is selected from CR7, X2 is selected from CR8, X3 is selected from N, and X4 is selected from CR. 10 ;or X1 is selected from CR7, X2 is selected from CR8, X3 is selected from CR9, and X4 is selected from N; or X1 is selected from N, X2 is selected from N, X3 is selected from CR9, and X4 is selected from CR. 10 ;or X1 is selected from N, X2 is selected from CR8, X3 is selected from N and X4 is selected from CR8. 10 ;or X1 is selected from N, X2 is selected from CR8, X3 is selected from CR9, and X4 is selected from N; or X1 is selected from CR7, X2 is selected from N, X3 is selected from CR9, and X4 is selected from N; or X1 is selected from CR7, X2 is selected from CR8, X3 is selected from N and X4 is selected from N.

[0018] 6. A compound of formula (I) or (I-1) of any one of the preceding 1-5, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein the compound has any of the following structures: , , , , , , , , or ; R4, R5, R6, R7, R8, R9, R 10 Ring B, Y1, R S1 R S2 The definitions of n1, n2, and n3 are the same as those in section 1 above.

[0019] 7. A compound of formula (I-1-1), its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of its stereoisomers, pharmaceutically acceptable salts of its tautomers, or pharmaceutically acceptable salts of its deuterated derivatives: Formula (I-1-1) R4, R5, R6, R7, R8, R9, R 10 Ring B, Y1, R S1 R S2 The definitions of n1 and n2 are the same as those in section 1 above.

[0020] 8. The stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of the stereoisomers, pharmaceutically acceptable salts of the tautomers, or pharmaceutically acceptable salts of the deuterated derivatives of any one of the preceding items 1-7: R8 is selected from -H, -NHC(=O)(R 81 -NHS(=O)(R) 81 -NHS(=O)2(R) 81 -C(=O)N(R) 81 )2、-C(=O)NH(R 81 -S(=O)N(R) 81 )2、-S(=O)NH(R 81 -S(=O)2N(R) 81 )2 or -S(=O)2NH(R 81 ); The R 81 Each is independently selected from 3-10 membered carbon rings, 3-10 membered heterocycles, phenyl, or 5-10 membered heteroaryl; the R 81 Can be selected from halogens, -C 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, oxo, -CN, -OH, -SH, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 The alkyl group, 3-7 membered carbon ring, 3-7 membered heterocyclic ring, phenyl or 5-10 membered heteroaryl group are substituted with one or more substituents; 9. The compound of formula (I) or formula (I-1-1) as described in any one of 1-8 above, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R8 is selected from -C(=O)N(R) 81 )2、-C(=O)NH(R 81 -S(=O)N(R) 81 )2、-S(=O)NH(R 81 -S(=O)2N(R) 81 )2 or -S(=O)2NH(R 81 ); The R 81 Each time, it is independently selected from 3-7 membered carbon rings, 3-7 membered heterocycles, or 5-6 membered heteroaryl groups; the R 81 Can be selected from halogen, -CN, -C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C(=O)(OC) 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2 or -NHS(=O)2(C 1-3 One or more substituents of alkyl group are used for substitution; Preferably, R8 is selected from -C(=O)N(R 81 )2、-C(=O)NH(R 81 -S(=O)N(R) 81 )2、-S(=O)NH(R 81-S(=O)2N(R) 81 )2 or -S(=O)2NH(R 81 ); The R 81 Each time, it is independently selected from 3-7 membered carbon rings, 3-7 membered heterocycles, or 5-6 membered heteroaryl groups; the R 81 Can be selected from halogen, -CN, -C 1-3 Alkyl or -C(=O)(OC) 1-3 One or more substituents of alkyl group are used for substitution; More preferably, R8 is selected from -NHC(=O)(R 81 -S(=O)2NH(R) 81 ) or -NHS(=O)2(R 81 ); The R 81 Selected from , , , , , Thiophene, furanyl, pyridinyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl; the R 81 It may be substituted by one or more substituents selected from -Cl, -F, -Br, -CN, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C(=O)(OCH3), -C(=O)(OCH2CH3), -C(=O)(OCH2CH2CH3), or -C(=O)(OCH(CH3)2); more preferably, R8 is selected from... , , , , , , , , , , , , , , , , , , , , or ; More preferably, R8 is selected from or .

[0021] More preferably, R8 is selected from .

[0022] More preferably, R8 is selected from .

[0023] 10. The compound of formula (I), formula (I-1), or formula (I-1-1) as described in any one of 1-9 above, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R9 is selected from -H, -(C 0-3 (alkylene)-R 91 -C(=O)-N(R) 92 )2、-S(=O)-N(R 92 )2、-S(=O)2-N(R 92 )2、-C(=O)(R 93 -S(=O)(R) 93 ) or -S(=O)2(R 93 ); The R 91 Each is independently selected from -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 2-3 Alkoxy, halogenated -C 2-3 Alkoxy, oxo, -CN, -OH, -SH, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3Alkyl), 3-7 membered carbocyclic group, 3-7 membered heterocyclic group, phenyl or 5-10 membered heteroaryl; said R 92 Each is independently selected from 3-7 membered carbocyclic groups, 3-7 membered heterocyclic groups, phenyl groups, or 5-6 membered heteroaryl groups; the R 92 It can be optionally selected by one or more halogens, -C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 Alkyne, oxo, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Substituents of alkyl, 3-7 membered carbon cyclo group, 3-7 membered heterocyclic group, phenyl or 5-10 membered heteroaryl group; The R 93 Each is independently selected from halogens.

[0024] 11. The compound of formula (I), formula (I-1), or formula (I-1-1) as described in any one of 1-10 above, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R9 is selected from -H, -(C 1-3 (alkylene)-R 91 -C(=O)-N(R) 92 )2、-S(=O)-N(R92 )2、-S(=O)2-N(R 92 )2、-C(=O)(R 93 -S(=O)(R) 93 -S(=O)2(R) 93 ), the R 91 Each time, it is independently selected from -CN, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl groups, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl)2, -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2, -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2, -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl) or -S(=O)2N(C 1-3 Alkyl)2; the R 92 Each is independently selected from phenyl or 5-10 heteroaryl groups; the R 93 Each halogen is selected independently; Preferably, R9 is selected from -H, -CH2-R 91 -CH2CH2-R 91 -CH2CH2CH2-R 91 -CH2(CH2)-R 91 -C(=O)-N(R) 92 )2、-S(=O)-N(R 92 )2、-S(=O)2-N(R 92 )2、-C(=O)(R 93 -S(=O)(R) 93 -S(=O)2(R) 93 ), the R 91Each time, it is independently selected from -CN, -OH, -O-CH3, -O-CH2CH3, -O-CH2CH2CH3, -O-CH(CH3)2, -SH, -S-CH3, -S-CH2CH3, -S-CH2CH2CH3, -S-CH(CH3)2, -NH2, -NH(CH3), -N(CH3)2, -NH(CH2CH3), -C(=O)OH, -C(=O)(OCH3), -C(=O)(OCH2CH3), -C(=O)(OCH(CH3)2), -C(=O)NH2, -C(=O)NH(CH3), -C(=O )NH(CH2CH3), -C(=O)NH(CH2CH2CH3), -C(=O)NH(CH(CH3)2), -C(=O)N(CH3)2, -S(=O)NH2, -S(=O)NH(CH3), -S(=O)NH(CH2CH3), -S(=O)NH(CH2CH2 R 92 Each is independently selected from hydrogen, phenyl, pyrrolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, tetrazolyl, pyrazolyl, triazolyl, thiadiazolyl, oxadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, indole, isoindoleyl, or indoleazinyl; said R 93 Each time it is independently selected from -F, -Br, or -Cl; More preferably, R9 is selected from -CH2-CN, -CH2-OH, -CH2-O-CH3, -CH2-O-CH2CH3, -CH2-O-CH2CH2CH3, -CH2-O-CH(CH3)2, -CH2-SH, -CH2-S-CH3, -CH2-S-CH2CH3, -CH2-S-CH2CH2CH3, -CH2-S-CH(CH3)2, -CH2-NH2, -CH2-NH(CH3), -CH2-N(CH3)2, -CH2-NH(CH2CH3), -CH2-C(=O)OH, -CH2-C(=O)(OCH3), -CH2-C(=O)(OCH2CH3), -CH2-C(=O)(OCH2CH2CH3), -CH2-C(=O)(OCH(CH3)2), -CH2-C(=O)NH2, -CH2-C(=O)NH(CH3), -CH2-C(=O)NH(CH2CH3), -CH2-C(=O)NH(CH2CH2CH3), -CH2-C(=O)NH(CH(CH3)2), -CH2-C(=O)N(CH3)2, -CH2-S(=O)NH2, -CH2-S(=O)NH(CH3), -CH2-S(=O)NH(CH2CH3), -CH2-S(=O)NH(CH2CH2CH3), -CH2-S(=O)NH(CH(CH3)2), -CH2-S(=O)N(CH3)2, -CH2-S(=O)2NH2, -CH2-S(=O)2NH(CH3), -CH2-S(=O)2NH(CH2CH3), -CH2-S(=O)2NH(CH2CH2CH3), -CH2-S(=O)2NH(CH(CH3)2), -CH2-S(=O)2N(CH3)2, , , , , , , , , , , , , , , , , , , , , , , , , 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 , , , , , , , -C(=O)-Cl, -S(=O)-Cl or -S(=O)2-Cl; More preferably, R9 is selected from , , , or .

[0025] 12. The compound of formula (I), formula (I-1), or formula (I-1-1) as described in any one of 1-11 above, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R7 is selected from hydrogen, halogens, and -C. 1-3 Alkyl, Halogenated -C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 1-3 Alkoxy, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3Alkyl group, 3-7 membered carbon cyclo group, 3-7 membered heterocyclic group, phenyl group or 5-10 membered heteroaryl group; Preferably, each R7 is independently selected from -H, halogen, and -C. 1-3 Alkyl or halogenated -C 1-3 alkyl.

[0026] More preferably, each of the R7 groups is independently selected from -H, -Cl, -F, -Br, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CHFCH3, -CF2CH3; More preferably, R7 is -H.

[0027] 13. The compound of formula (I), formula (I-1), or formula (I-1-1) as described in any one of 1-12 above, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R 10 Selected from hydrogen, halogens, -C 1-3 Alkyl, Halogenated -C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 1-3 Alkoxy, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl group, 3-7 membered carbon cyclo group, 3-7 membered heterocyclic group, phenyl group or 5-10 membered heteroaryl group; Preferably, R 10 Each is independently selected from -H, halogen, and -C. 1-3 Alkyl or halogenated -C 1-3 alkyl; More preferably, R 10 Each is independently selected from -H, -Cl, -F, -Br, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CHFCH3, -CF2CH3; More preferably, R 10 It is -H.

[0028] 14. The compound of formula (I), formula (I-1), or formula (I-1-1) as described in any one of 1-13 above, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Selected from , , , , , , , , , , , , , , , , , , , , , , , , , or ; Preferably, Selected from , , or .

[0029] Preferably, Selected from or .

[0030] Preferably, Selected from or .

[0031] Preferably, yes .

[0032] Preferably, yes .

[0033] 15. A compound of formula (I-2), its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of its stereoisomers, pharmaceutically acceptable salts of its tautomers, or pharmaceutically acceptable salts of its deuterated derivatives: Formula (I-2) Among them, R4, R5, R6, Y1, Y2, ring B, R S1 R S2 R S3 The definitions of n1, n2, n3, n4 and n5 are the same as those in section 1 above.

[0034] 16. The compound of formula (I) or formula (I-2) as described in any one of 1-2 and 15 above, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Y2 is selected from -C(R) Y2 )2-、-O-、-NR Y3 -、-S-、 -C(=O)NR Y4 -、 -NR Y4 C(=O)-、 -S(=O)NR Y4 -、 -NR Y4 S(=O)-、 -S(=O)2NR Y4 -or -NR Y4S(=O)2-; Representation and fragment The connection point; More preferably, Y2 is selected from -C(R Y2 )2-、-O-、-S-、-NR Y3 -、 -C(=O)NR Y4 -or -NR Y4 C(=O); Representation and fragment The connection point; More preferably, Y2 is selected from -NR Y3 -; R Y2 R Y3 and R Y4 The definition is the same as the definition in the previous text [1].

[0035] In some implementations, Y2 is selected from -C(R) Y2 )2-.

[0036] In some implementations, Y2 is selected from -NR Y3 -

[0037] In some implementations, Y2 is selected from -O-.

[0038] In some implementations, Y2 is selected from -S-.

[0039] In some implementations, Y2 is selected from... -C(=O)NR Y4 ; Representation and fragment The connection point.

[0040] In some implementations, Y2 is selected from... -NR Y4 C(=O); Representation and fragment The connection point.

[0041] 17. The compound of formula (I) or formula (I-2) as described in any one of 1-2 and 15-16 above, including its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein the compound is selected from any of the following structures: , , , , , , , , , ; Among them, R4, R5, R6, R S1 R S2 R S3 n1, n2, n3, n4, n5, R Y2 R Y3 R Y4 The definitions of Y1 and ring B are the same as those in section 1 above.

[0042] 18. The compound of formula (I) or formula (I-2) as described in any one of 1-2 and 15-17 above, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, n4 is selected from 0, 1, 2, 3, 4, 5 or 6; Preferably, n4 is selected from 0, 1, 2, 3 or 4; Preferably, n4 is selected from 0, 1, or 2.

[0043] In some implementations, n4 is 0.

[0044] In some implementations, n4 is 1.

[0045] In some implementations, n4 is 2.

[0046] 19. The compound of formula (I) or formula (I-2) as described in any one of 1-2 and 15-18 above, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, N5 is selected from 0, 1, 2, 3, 4, 5, or 6; Preferably, n5 is selected from 0, 1, 2, 3 or 4; Preferably, n5 is selected from 0, 1, or 2.

[0047] In some implementations, n5 is 0.

[0048] In some implementations, n5 is 1.

[0049] In some implementations, n5 is 2.

[0050] 20. The compound of formula (I) or formula (I-2) as described in any one of 1-2 and 15-19 above, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, n4 is 0 and n5 is 1; or n4 is 0 and n5 is 2; or n4 is 1 and n5 is 0; or n4 is 2 and n5 is 0; or n4 is 1 and n5 is 1; or n4 is 1 and n5 is 2; or n4 is 2 and n5 is 1; or n4 is 2 and n5 is 2.

[0051] 21. The compound of formula (I) or formula (I-2) as described in any one of 1-2 and 15-20 above, including its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein n4 is 1 and n5 is 1.

[0052] 22. The compound of formula (I) or formula (I-2) as described in any one of 1-2 and 15-21 above, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R Y2 Selected from hydrogen, halogens, -C 1-3 Alkyl, Halogenated -C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 1-3 Alkoxy, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl), 3-7 membered carbon cycloyl, 3-7 membered heterocyclic, phenyl or 5-10 membered heteroaryl.

[0053] Preferably, R Y2 Selected from -H, halogen, -C 1-3 Alkyl or halogenated -C 1-3 alkyl.

[0054] Preferably, R Y2 Selected from -H, -Cl, -F, -Br, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CHFCH3 or -CF2CH3; Preferably, R Y2 It is -H; In some implementations, R Y2 Selected from -H or -C 1-3 Alkyl; preferably, R Y2 Selected from -H, -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2; more preferably, R Y2 Yes, it's -H.

[0055] 23. The compound of formula (I) or formula (I-2) as described in any one of 1-2 and 15-22 above, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Selected from , , , , , , , , or ; Preferably, Selected from , or .

[0056] 24. The compound of formula (I) or formula (I-2) as described in any one of 1-2 and 15-21 above, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R Y3 Selected from -H, -C 1-6 Alkyl group, -C(=O)(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), 3-7 membered carbocyclic group, 3-7 membered heterocyclic group, phenyl or 5-10 membered heteroaryl; said R Y3 It can be independently selected by 1, 2, 3, 4, 5 or 6 Rs. Y31 replace; The R Y31 Each is independently selected from halogens and -C 1-3 Alkyl, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-4 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-4 Alkyl), -C(=O)N(C 1-3 Alkyl)2, -S(=O)NH2, -S(=O)NH(C 1-4 Alkyl), -S(=O)N(C 1-3 Alkyl)2, -S(=O)2NH2, -S(=O)2NH(C 1-4Alkyl) or -S(=O)2N(C 1-3 Alkyl)2; the R Y31 It can be independently selected by 1, 2, 3, 4, 5 or 6 Rs. Y32 replace; The R Y32 Each time, each is independently selected from -C 2-3 Alkoxy, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl groups or 5-10 heteroaryl groups; Preferably, R Y3 Selected from -H, -C 1-3 Alkyl group, -C(=O)(C 1-3 Alkyl), 3-7 membered carbon cycloyl or 3-7 membered heterocyclic; the R Y3 It can be independently selected by 1, 2 or 3 Rs. Y31 replace; The R Y31 Each is independently selected from -C 1-3 Alkyl, -OH, -O(C) 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-4 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-4 Alkyl) or -C(=O)N(C 1-3 Alkyl)2; the R Y31 It can be independently selected by 1, 2, 3, 4, 5 or 6 Rs. Y32 Replace; the RY 32 Each is independently selected from -C 2-3 Alkoxy, -OH, -O(C) 1-3 Alkyl groups or 5-10 heteroaryl groups; More preferably, R Y3 Selected from -H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C(=O)(CH3), -C(=O)(CH2CH3), -C(=O)(CH2CH2CH3), -C(=O)(CH(CH3)2), , , , , , , , , , or The R Y3Each is independently controlled by 1, 2, or 3 Rs. Y31 Replace; the R Y31 Each is independently selected from -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -OH, -O-CH3, -O-CH2CH3, -O-CH2CH2CH3, -O-CH(CH3)2, -C(= O)CH3, -C(=O)(CH2CH3), -C(=O)-CH(CH3)2, -C(=O)OH, -C(=O)(OCH3), -C(=O)(OCH2CH3), -C(=O)(OCH2CH2C H3), -C(=O)(OCH(CH3)2), -C(=O)(OC(CH3)3), -C(=O)NH2, -C(=O)NH2, -C(=O)NH(CH3), -C(=O)NH(CH2CH3), -C(=O)NH(CH2CH2CH3), -C(=O)NH(CH(CH3)2), -C(=O)NH(C(CH3)3), -C(=O)N(CH3)2 or -C(=O)N(CH2CH3)2; the R Y31 Each is independently controlled by 1, 2, 3, 4, 5, or 6 R's. Y32 Replace; the R Y32 Each time it appears, it is independently selected from -CH3-O-CH3, -CH2CH3-O-CH3, -CH2-O-CH2CH3, -CH(CH3)-O-CH3, -OH, -O-CH3, -O-CH2CH3, -O-CH(CH3)2, thiophene, furanyl, pyridinyl, pyrimidinyl, pyridininyl, pyrazinyl, pyrrolyl, imidazoleyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, or isoxazolyl. More preferably, R Y3 Selected from -H, -CH3, -CH2CH3, -C(=O)(CH3), , , or The R Y3 Each is independently controlled by 1, 2, or 3 Rs. Y31 Replace; the R Y31 Each is independently selected from -CH3, -CH2CH3, -OH, -C(=O)CH3, -C(=O)OH, -C(=O)(OC(CH3)3), -C(=O)NH2, -C(=O)NH(CH3), -C(=O)NH(CH2CH3), -C(=O)NH(CH(CH3)2) or -C(=O)NH(C(CH3)3); the R Y31 Each is independently controlled by 1, 2, or 3 Rs. Y32 Replace; the R Y32Each group is independently selected from -OH, -O-CH3, or pyridinyl groups; More preferably, each time R Y3 Each is independently selected from -H, -CH3, -CH2CH3, -CH2COOH, -CH2CH2COOH, -CH2COOC(CH3)3, -CH2CH2COOC(CH3)3, -CH2CH2OH, -CH2-C(=O)-NH(CH3), -CH2CH2-C(=O)-NH(CH3), -CH2CH2-C(=O)-NH(CH2CH3), -CH2CH2-C(=O)-NH(CH(CH3)2), -CH2CH2-C(=O)-NH(C(CH3)3), -C(=O)-CH3, , , , , , , , , or ; More preferably, R Y3 Selected from -CH2CH2COOH, -CH2CH2OH, -C(=O)-CH3, , , or .

[0057] 25. The compound of formula (I) or formula (I-2) as described in any one of 1-2, 15-21, and 24 above, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Selected from , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ; Preferably, Selected from , , , , , , , or .

[0058] 26. The compound of formula (I) or formula (I-2) as described in any one of 1-2 and 15-21 above, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Selected from , , , , , , or .

[0059] 27. The compound of formula (I) or formula (I-2) as described in any one of 1-2 and 15-21 above, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Selected from , , , , , , or .

[0060] 28. The compound of formula (I) or formula (I-2) as described in any one of 1-2 and 15-21 above, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R Y4 Selected from -H, -C 1-6 Alkyl group, -C(=O)(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), 3-7 membered carbocyclic group, 3-7 membered heterocyclic group, phenyl or 5-10 membered heteroaryl; said R Y4 Each is independently substituted by 1, 2, 3, 4, 5 or 6 substituents selected from the following: halogens, -C 1-3 Alkyl, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-4 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-4 Alkyl), -C(=O)N(C 1-3 Alkyl)2, -S(=O)NH2, -S(=O)NH(C 1-4 Alkyl), -S(=O)N(C 1-3 Alkyl)2, -S(=O)2NH2, -S(=O)2NH(C 1-4 Alkyl) or -S(=O)2N(C 1-3 Alkyl)2; Preferably, R Y4 Selected from -H, -C 1-3 Alkyl or halogenated C 1-3 alkyl; Preferably, R Y4 Selected from -H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CHFCH3 or -CF2CH3; Preferably, R Y4 It is -H; In some implementations, RY4 Selected from -H or -C 1-3 alkyl; Preferably, R Y4 Selected from -H, -CH3, -CH2CH3, -CH2CH2CH3, or -CH(CH3)2; Preferably, R Y4 Yes, it's -H.

[0061] 29. The compound of formula (I) or formula (I-2) as described in any one of 1-2, 15-21 and 28 above, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Selected from , , , , , , , , , , , , , , , , , , or ; Preferably, Selected from , , , , , , or .

[0062] 30. The compound of formula (I) or formula (I-2) as described in any one of 1-2, 15-21, and 28 above, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Selected from , , , , , , , , , , , , , , , , , , or ; Selected from , , , , , , or .

[0063] 31. The compound of formula (I) or formula (I-2) as described in any one of 1-2 and 15-30 above, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Selected from , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ; Preferably, Selected from , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or .

[0064] 32. A compound of formula (I), its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, Formula (I) in, R1 is independently selected from hydrogen, halogen, and -C. 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 Alkoxy, -C 2-3 alkenyl, -C 2-3 Alkyne group, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl), 3-7 membered cycloalkyl, 3-7 membered heterocyclic, 6-10 membered aryl, or 5-10 membered heteroaryl; wherein R1 may optionally be composed of 1, 2, 3, 4, 5, or 6 radicals selected from halogens, -C 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 Alkoxy, -C 2-3 alkenyl, -C 2-3 Alkyne group, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Substitution with alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups or 5-10 membered heteroaryl groups; R2 is independently selected from hydrogen, halogen, and -C. 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 Alkoxy, -C 2-3 alkenyl, -C2-3 Alkyne group, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl), 3-7 membered cycloalkyl, 3-7 membered heterocyclic, 6-10 membered aryl, or 5-10 membered heteroaryl; wherein R2 may optionally be composed of 1, 2, 3, 4, 5, or 6 radicals selected from halogens, -C 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 Alkoxy, -C 2-3 alkenyl, -C 2-3 Alkyne group, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Substitution with alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups or 5-10 membered heteroaryl groups; Among them, R4, R5, R6, R S1 R S2 The definitions of n1, n2, Y1 and ring B are the same as in 1.

[0065] 33. The compound of formula (I) mentioned in any one of 1 and 32 above, its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, R1 is independently selected from hydrogen, halogen, and -C. 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 Alkoxy, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl), 3-7 membered cycloalkyl, 3-7 membered heterocyclic, phenyl, or 5-10 membered heteroaryl; wherein R1 may optionally be composed of 1, 2, or 3 selected from halogen, -C 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 Alkoxy, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl), -NHS(=O)2(C 1-3 Alkyl groups or 3-7 membered cycloalkyl groups are substituted; Preferably, R1 is independently selected from hydrogen, halogen, -C 1-3 Alkyl, -CN, -C(=O)OH, -C(=O)(OC) 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2, -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2, -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl), phenyl, or a 5-6 membered heteroaryl group containing 1, 2, or 3 heteroatoms selected from N, O, or S; wherein R1 may optionally be substituted with 1, 2, or 3 substituents selected from -C 1-3 alkyl; More preferably, R1 is independently selected from hydrogen, halogen, -C 1-3 Alkyl, -CN, -COOH, -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-32. An alkyl group, or a 5-6 membered heteroaryl group containing one or two heteroatoms selected from N, O, or S; wherein the 5-6 membered heteroaryl group may optionally be substituted by one or two substituents selected from -C. 1-3 alkyl; More preferably, R1 is independently selected from -H, -F, -Cl, -Br, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CN, -COOH, -C(=O)NH2, -C(=O)NH(CH3), -C(=O)NH(CH2CH3), -C(=O)NH(CH2CH2CH3), -C(=O)NH(CH(CH3)2), -C(=O)N(CH3)2, -C(=O)N(CH2CH3)2, , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ; More preferably, R1 is independently selected from -CH3, -CN, -Br, -C(=O)-NH2, -COOH, , or .

[0066] 34. The compound of formula (I) mentioned in any one of 1 and 32-33 above, its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein R2 is independently selected from -H, halogen, -C 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3Alkoxy, -CN, -C(=O)OH, -NH2, -NH(C 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl groups or 3-7 membered cycloalkyl groups; More preferably, R2 is independently selected from -H, halogen, and -C. 1-3 Alkyl, Halogenated C 1-3 Alkyl or -CN; More preferably, R2 is independently selected from -H and -C. 1-3 Alkyl or -CN.

[0067] More preferably, R2 is independently selected from -H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2 or -CN; More preferably, R2 is independently selected from -H, -CH3, or -CN.

[0068] 35. The compound of formula (I) mentioned in any one of 1 and 32-34 above, its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein, Selected from , , , , , , , , , , , , or .

[0069] 36. The compound of formula (I) mentioned in any one of 12-35 above, its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein, Selected from , , , , , , , , , , , , , , , , , or .

[0070] 37. The compound of formula (I) mentioned in any one of 1 and 32-36 above, its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein, Selected from , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or .

[0071] 38. The stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives of any one of the preceding 1-37, wherein Y1 is selected from the absence of, -C(R Y1A )2-、-N(R Y1B -, -O-, -S-, -C(=O)-N(R) Y1B )- -S(=O)-N(R) Y1B )- -S(=O)2-N(R) Y1B )- -N(R) Y1B )-C(=O)- -N(R) Y1B )-S(=O)- or -N(R) Y1B )-S(=O)2- ; This represents the position where it connects to ring B; In some implementations, Y1 is selected from -C(R) Y1A )2-、-N(R Y1B -, -O-, -S-, -C(=O)-N(R) Y1B )- -S(=O)-N(R) Y1B )- -S(=O)2-N(R) Y1B )- -N(R) Y1B )-C(=O)- -N(R) Y1B )-S(=O)- or -N(R) Y1B )-S(=O)2- ; This represents the position where it connects to ring B; In some implementations, Y1 is selected from -N(R) Y1B )-、-N(R Y1B )-C(=O)- -N(R) Y1B )-S(=O)- or -N(R) Y1B )-S(=O)2- ; This represents the position where it connects to ring B; In some implementations, Y1 is selected from -N(R) Y1B - or -N(R) Y1B )-C(=O)- ; This represents the position where it connects to ring B; In some implementations, Y1 is selected from -N(R) Y1B )-C(=O)- ; This represents the position where it connects to ring B; In some implementations, Y1 is selected from -N(R) Y1B )-S(=O)- ; This represents the position where it connects to ring B; In some implementations, Y1 is selected from -N(R) Y1B )-S(=O)2- ; This represents the position where it connects to ring B; In some implementations, Y1 is selected from -N(R) Y1B )-.

[0072] The R Y1A and R Y1B The definition is the same as that in item 1 above.

[0073] 39. A compound of formula (I), (I-1), (I-1-1), or (I-2) from any of the preceding items 1-38, including its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein Y1 is selected from -N(R Y1B )2-; The R Y1B Same as the definition in 1.

[0074] 40. A compound of formula (I), (I-1), (I-1-1), or (I-2) from any of the preceding items 1-38, including its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein Y1 is selected from -N(R Y1B )-C(=O)- ; Indicates the connection point with ring B; the R Y1B Same as the definition in 1.

[0075] 41. A compound of formula (I), (I-1), (I-1-1), or (I-2) from any of the preceding items 1-38, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein Y1 is selected from -N(R Y1B )-S(=O)- ; Indicates the connection point with ring B; the R Y1B Same as the definition in 1.

[0076] 42. A compound of formula (I), (I-1), (I-1-1), or (I-2) from any of the preceding items 1-38, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein Y1 is selected from -N(R Y1B )-S(=O)2- ; Indicates the connection point with ring B; the R Y1B Same as the definition in 1.

[0077] 43. The compounds of formula (I), (I-1), (I-1-1), or (I-2) of any one of the preceding items 1-42, including their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of the stereoisomers, pharmaceutically acceptable salts of the tautomers, or pharmaceutically acceptable salts of the deuterated derivatives, wherein, R Y1A Selected from -H, halogen, -C 1-3 Alkyl or halogenated C 1-3 Alkyl; preferably, R Y1A Selected from -H or -C 1-3 Alkyl; more preferably, R Y1A Selected from -H, -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2; more preferably, R Y1A Selected from -H or -CH3; R Y1B Selected from -H or -C 1-3 Alkyl; more preferably, R Y1B Selected from -H, -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2; more preferably, R Y1B Selected from -H or -CH3.

[0078] 44. The stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of the stereoisomers, pharmaceutically acceptable salts of the tautomers, or pharmaceutically acceptable salts of the deuterated derivatives of any one of the preceding items 1-43, wherein Y1 is selected from the absence of, -O-, -S-, -CH2-, -CH(CH3)-, -CH(CH2CH3)-, -CH(CH2CH2CH3)-, -CH(CH(CH3)2)-, -C(CH3)2-, -NH2-, -NH(CH3)-, -NH(CH2CH3)-, -NH(CH2CH2CH3)-, -NH(CH(CH3)2)-, -NH-C(=O)- -N(CH3)-C(=O)- -N(CH2CH3)-C(=O)- -NH(CH2CH2CH3)-C(=O)- -NH(CH(CH3)2)-C(=O)- -NH-S(=O)- -N(CH3)-S(=O)- -N(CH2CH3)-S(=O)- -NH(CH2CH2CH3)-S(=O)- -NH(CH(CH3)2)-S(=O)- -NH-S(=O)2- -N(CH3)-S(=O)2- -N(CH2CH3)-S(=O)2- -NH(CH2CH2CH3)-S(=O)2- -NH(CH(CH3)2)-S(=O)2- -C(=O)-NH- -C(=O)-N(CH3)- -C(=O)-N(CH2CH3)- -C(=O)-NH(CH2CH2CH3)- -C(=O)-NH(CH(CH3)2)- -S(=O)-NH- -S(=O)-N(CH3)- -S(=O)-N(CH2CH3)- -S(=O)-NH(CH2CH2CH3)- -S(=O)-NH(CH(CH3)2)- -S(=O)2-NH- -S(=O)2-N(CH3)- -S(=O)2-N(CH2CH3)- -S(=O)2-NH(CH2CH2CH3)- or -S(=O)2-NH(CH(CH3)2)- ; In some embodiments, Y1 is selected from -NH2-, -NH(CH3)-, -NH(CH2CH3)-, -NH(CH2CH2CH3)-, -NH(CH(CH3)2)-, and -NH-C(=O)-. -N(CH3)-C(=O)- -N(CH2CH3)-C(=O)- -NH(CH2CH2CH3)-C(=O)- -NH(CH(CH3)2)-C(=O)- -NH-S(=O)- -N(CH3)-S(=O)- -N(CH2CH3)-S(=O)- -NH(CH2CH2CH3)-S(=O)- -NH(CH(CH3)2)-S(=O)- -NH-S(=O)2- -N(CH3)-S(=O)2- -N(CH2CH3)-S(=O)2- -NH(CH2CH2CH3)-S(=O)2- -NH(CH(CH3)2)-S(=O)2- ; Indicates the connection point with ring B; In some embodiments, Y1 is selected from -NH2-, -NH(CH3)-, and -NH-C(=O)-. or -N(CH3)-C(=O)- ; This indicates the connection point with ring B.

[0079] 45. A compound of formula (I), (I-1), (I-1-1) or (I-2) of any one of the preceding 1-44, wherein the stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer or pharmaceutically acceptable salt of the deuterated derivative, wherein Y1 is selected from -NH2-.

[0080] 46. ​​A compound of formula (I), (I-1), (I-1-1), or (I-2) from any of the preceding items 1-44, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein Y1 is selected from -NH-C(=O)- ; This indicates the connection point with ring B.

[0081] 47. A compound of formula (I), (I-1), (I-1-1), or (I-2) from any of the preceding items 1-44, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein Y1 is selected from -NH-S(=O)- ; This indicates the connection point with ring B.

[0082] 48. A compound of formula (I), (I-1), (I-1-1), or (I-2) from any one of the preceding items 1-44, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein Y1 is selected from -NH-S(=O)2- ; This indicates the connection point with ring B.

[0083] 49. A compound of formula (I), (I-1), (I-1-1), or (I-2) from any of the preceding items 1-48, wherein its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein, R4 groups are independently selected from -H, halogen, and -C. 1-3 Alkyl or halogenated C 1-3 alkyl.

[0084] In some implementations, R4 is independently selected from -H or -C. 1-3 alkyl.

[0085] In some implementations, R4 is independently selected from -H, -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2.

[0086] In some implementations, R4 is independently selected from -H or -CH3.

[0087] 50. A compound of formula (I), (I-1), (I-1-1) or (I-2) of any one of the preceding 1-49, wherein the stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer or pharmaceutically acceptable salt of the deuterated derivative, wherein R4 is independently selected from -H.

[0088] 51. A compound of formula (I), (I-1), (I-1-1) or (I-2) of any one of the preceding 1-50, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer or pharmaceutically acceptable salt of the deuterated derivative, wherein R4 is independently selected from -CH3.

[0089] 52. The compounds of formula (I), (I-1), (I-1-1), or (I-2) of any one of the preceding items 1-51, including their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of the stereoisomers, pharmaceutically acceptable salts of the tautomers, or pharmaceutically acceptable salts of the deuterated derivatives, wherein, R5 is independently selected from -H, halogen, and -C. 1-3 Alkyl or halogenated C 1-3 alkyl.

[0090] In some implementations, R5 is independently selected from -H or -C. 1-3 alkyl.

[0091] In some implementations, R5 is independently selected from -H, -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2.

[0092] In some implementations, R5 is independently selected from -H or -CH3.

[0093] 53. A compound of formula (I), (I-1), (I-1-1) or (I-2) of any one of the preceding 1-52, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer or pharmaceutically acceptable salt of the deuterated derivative, wherein R5 is independently selected from -H.

[0094] 54. A compound of formula (I), (I-1), (I-1-1) or (I-2) of any one of the preceding 1-52, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer or pharmaceutically acceptable salt of the deuterated derivative, wherein R5 is independently selected from -CH3.

[0095] 55. A compound of formula (I), (I-1), (I-1-1), or (I-2) of any one of the preceding terms 1-54, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein R4 is independently selected from -H or -C. 1-3 Alkyl groups, and each of the R5 groups is independently selected from -H or -C. 1-3 Alkyl group; preferably, each of R4 is independently selected from -H, -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2, and each of R5 is independently selected from -H, -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2; more preferably, each of R4 is independently selected from -H or -CH3, and each of R5 is independently selected from -H or -CH3; even more preferably, each of R4 is independently selected from -H, and each of R5 is independently selected from -H.

[0096] 56. A compound of formula (I) from any of the preceding 1-54, including its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of its stereoisomers, pharmaceutically acceptable salts of its tautomers, or pharmaceutically acceptable salts of its deuterated derivatives, wherein the compound is selected from any of the following structural formulas: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ; Among them, X1, X2, X3, X4, R1, R2, R4, R5, R6, R7, R8, R9, R 10 R Y2 R Y3 R Y4 Ring B, Y2, R S1 R S2 R S3 The definitions of n1, n2, n3, n4 and n5 are the same as those in 1-55 above.

[0097] 57. Compounds of formulas (I), (I-1), (I-1-1), or (I-2) of 1-56 above, including their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein, Each occurrence of R6 is independently selected from -H, halogen, and -C. 1-3 Alkyl, -OC 1-3 Alkyl or halogenated C 1-3 alkyl; In some embodiments, each occurrence of R6 is independently selected from -H, -OC. 1-3 Alkyl or halogenated C 1-3 alkyl; Preferably, each occurrence of R6 is independently selected from -H, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CHFCH3, or -CF2CH3; More preferably, each occurrence of R6 is independently selected from -H, -OCH3, or -CF3.

[0098] 58. The compounds of formula (I), (I-1), (I-1-1) or (I-2) of the preceding 1-57, wherein the stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of the stereoisomers, pharmaceutically acceptable salts of the tautomers or pharmaceutically acceptable salts of the deuterated derivatives, wherein each occurrence of R6 is independently selected from -H.

[0099] 59. The compounds of formula (I), (I-1), (I-1-1) or (I-2) of the preceding 1-57, wherein their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers or pharmaceutically acceptable salts of deuterated derivatives, wherein each occurrence of R6 is independently selected from -CF3.

[0100] 60. The compounds of formula (I), (I-1), (I-1-1) or (I-2) of the preceding 1-57, wherein their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers or pharmaceutically acceptable salts of deuterated derivatives, wherein each occurrence of R6 is independently selected from -OCH3.

[0101] 61. Compounds (I), (I-1), (I-1-1), or (I-2) mentioned in paragraphs 1-60, their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of the stereoisomers, pharmaceutically acceptable salts of the tautomers, or pharmaceutically acceptable salts of the deuterated derivatives, wherein, Selected from , or .

[0102] 62. Compounds of formulas (I), (I-1), (I-1-1), or (I-2) in paragraphs 1-61 above, including their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein, Selected from .

[0103] 63. The compounds of formula (I) of the preceding 1-62, including their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of their stereoisomers, pharmaceutically acceptable salts of their tautomers, or pharmaceutically acceptable salts of their deuterated derivatives, wherein the compound is selected from any one of the following formulas: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ; Among them, X1, X2, X3, X4, R1, R2, R4, R5, R7, R8, R9, R 10 R Y2 R Y3 R Y4 Ring B, Y2, R S1 R S2 R S3 The definitions of n1, n2, n3, n4 and n5 are the same as those in 1-62.

[0104] 64. The compounds of formula (I), (I-1), (I-1-1), or (I-2) of any one of the preceding items 1-63, including their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein, Selected from , , , , , , , , , , , , , , , , , , , , , , , , , 、 、 、 、 ， ， ， 、 、 ， 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 ， ， ， ， ， ， ， ， ， ， ， ， ， ， ， 、 、 、 、 or .

[0105] 65. The compounds of formula (I), (I-1), (I-1-1), or (I-2) of any one of the preceding items 1-64, including their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of the stereoisomers, pharmaceutically acceptable salts of the tautomers, or pharmaceutically acceptable salts of the deuterated derivatives, wherein, Ring B is selected from benzene rings or 5-10 membered heteroaromatic rings containing 1, 2, 3, 4, 5 or 6 heteroatoms selected from N, O or S; Preferably, ring B is selected from 5-6 membered heteroaromatic rings containing 1, 2, 3, 4, 5 or 6 heteroatoms selected from N, O or S; In some embodiments, ring B is selected from a 5-membered heteroaromatic ring containing 1, 2, or 3 heteroatoms selected from N, O, or S; a 6-membered heteroaromatic ring containing 1, 2, or 3 heteroatoms selected from N, O, or S; a 7-membered heteroaromatic ring containing 1, 2, or 3 heteroatoms selected from N, O, or S; an 8-membered heteroaromatic ring containing 1, 2, or 3 heteroatoms selected from N, O, or S; a 9-membered heteroaromatic ring containing 1, 2, or 3 heteroatoms selected from N, O, or S; or a 10-membered heteroaromatic ring containing 1, 2, or 3 heteroatoms selected from N, O, or S.

[0106] In some embodiments, ring B is selected from 5-6 membered heteroaromatic rings containing 1, 2 or 3 heteroatoms selected from N, O or S.

[0107] In some embodiments, ring B is selected from a 5-membered heteroaromatic ring containing 1, 2, or 3 heteroatoms selected from N, O, or S; or a 6-membered heteroaromatic ring containing 1, 2, or 3 heteroatoms selected from N, O, or S.

[0108] In some embodiments, ring B is selected from a 5-membered heteroaromatic ring containing 1, 2 or 3 heteroatoms selected from N, O or S.

[0109] In some embodiments, ring B is selected from a 6-membered heteroaromatic ring containing 1, 2 or 3 heteroatoms selected from N, O or S.

[0110] 66. A compound of formula (I), (I-1), (I-1-1), or (I-2) of any one of the preceding items 1-65, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein ring B is selected from... , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ; In some implementations, ring B is selected from... , , , , , , , , or ; In some implementations, ring B is selected from... , , , , , , or .

[0111] In some implementations, ring B is selected from... , , , , , or .

[0112] In some implementations, ring B is selected from... , , or .

[0113] In some implementations, ring B is selected from... , , , , , , or .

[0114] In some implementations, ring B is selected from... or .

[0115] In some implementations, ring B is selected from... .

[0116] 67. The compounds of formula (I), (I-1), (I-1-1), or (I-2) of any one of the preceding items 1-66, including their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of the stereoisomers, pharmaceutically acceptable salts of the tautomers, or pharmaceutically acceptable salts of the deuterated derivatives, wherein, R S2 Each time, they are independently selected from halogens and -C. 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 Alkoxy, halogenated C 2-3 Alkoxy, -C 2-3 alkenyl, -C 2-3 Alkyne group, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), oxo, -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl), 3-7 membered cycloalkyl, 3-7 membered heterocycloalkyl, 6-10 membered aryl or 5-10 membered heteroaryl; the R S2 It can be optionally selected by one or more halogens, -C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 1-3 Alkoxy, halogenated C 1-3 Alkyl, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -C(=O)(OC) 1-3 Alkyl) or -C (=O) (halogenated C) 1-3 Substitution of alkyl groups; Preferably, R S2 Each is independently selected from halogens and -C 1-3 Alkyl, -CN, oxo, -C(=O)OH, -C(=O)(OC) 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2, -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2, -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 Alkyl group, 2-3-7-membered cycloalkyl group, 3-7-membered heterocycloalkyl group, phenyl group, or 5-6-membered heteroaryl group; wherein the heterocycloalkyl group contains 1, 2, or 3 heteroatoms selected from N, O, or S; wherein the heteroaryl group contains 1, 2, or 3 heteroatoms selected from N, O, or S; More preferably, R S2 Each is independently selected from -C 1-3 Alkyl, oxo, -CN; More preferably, R S2Each is independently selected from -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CN, or oxo; More preferably, R S2 Each is independently selected from -CH3, -CH2CH3, -CH(CH3)2, -CN, or oxo.

[0117] 68. A compound of formula (I), (I-1), (I-1-1), or (I-2) of any one of the preceding 1-67, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein n2 is selected from 0, 1, 2, 3, 4, 5, or 6; preferably, n2 is selected from 0, 1, 2, 3, or 4; more preferably, n2 is selected from 0, 1, 2, or 3; and even more preferably, n2 is selected from 0, 1, or 2.

[0118] 69. A compound of formula (I), (I-1), (I-1-1), or (I-2), wherein its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein, Selected from , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or .

[0119] In some implementations... Selected from , , , , , , , , , , , , , , , , , , , , , , , , or ; In some implementations... Selected from , , , , , , , , , , , , , or .

[0120] In some implementations... Selected from , , , , , , , , , or .

[0121] In some implementations... Selected from , , , , or .

[0122] In some implementations... Selected from , , , , , , , , , , , , , or .

[0123] In some implementations... Selected from or .

[0124] In some implementations... Selected from .

[0125] 70. A compound of formula (I) of any one of the preceding 1-69, including its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein the compound is selected from any one of the following formulas: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ; Among them, X1, X2, X3, X4, R1, R2, R4, R5, R7, R8, R9, R 10 R Y2 R Y3 R Y4 Y2, R S1 R S3 The definitions of n1, n3, n4 and n5 are the same as those in 1-69.

[0126] 71. Compounds of formula (II), their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives: Formula (II) in, X1 is selected from N or CR7; X3 is selected from N or CR9; X4 is selected from N or CR 10 ; R7 is selected from hydrogen, halogens, and -C. 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 1-3 Alkoxy, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C)1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl groups, 3-7 membered carbon rings, 3-7 membered heterocycles, phenyl groups, or 5-10 membered heteroaryl groups; R8 is selected from -H, -NHC(=O)(R 81 -NHS(=O)(R) 81 -NHS(=O)2(R) 81 -C(=O)N(R) 81 )2、-C(=O)NH(R 81 -S(=O)N(R) 81 )2、-S(=O)NH(R 81 -S(=O)2N(R) 81 )2 or -S(=O)2NH(R 81 ); The R 81 Each is independently selected from 3-10 membered carbon rings, 3-10 membered heterocycles, phenyl or 5-10 membered heteroaryl groups; the R 81 Can be selected from halogens, -C 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, oxo, -CN, -OH, -SH, -NH2, -NH(C) 1-3 alkyl), -N(C)1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl group, 3-7 membered carbon ring, 3-7 membered heterocyclic ring, phenyl or 5-10 membered heteroaryl group, one or more substituents; R9 is selected from -H, -(C 0-3 (alkylene)-R 91 -C(=O)-N(R) 92 )2、-S(=O)-N(R 92 )2、-S(=O)2-N(R 92 )2、-C(=O)(R 93 -S(=O)(R) 93 ) or -S(=O)2(R 93 ); The R 91 Each independently selected from -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 2-3 Alkoxy, halogenated C 2-3 Alkoxy, oxo, -CN, -OH, -SH, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3Alkyl), -C(=O)(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl groups, 3-7 membered carbon rings, 3-7 membered heterocycles, phenyl groups, or 5-10 membered heteroaryl groups; The R 92 Each is independently selected from 3-7 membered carbon rings, 3-7 membered heterocycles, phenyl or 5-6 membered heteroaryl groups; the R 92 Can be selected from halogens, -C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 Alkyne, oxo, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl group, 3-7 membered carbon ring, 3-7 membered heterocyclic ring, phenyl or 5-10 membered heteroaryl group, one or more substituents; The R 93 Each halogen is selected independently each time; When X2 is CR8 and X3 is CR9, only one of R8 and R9 is hydrogen; R 10 Selected from hydrogen, halogens, -C 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 1-3 Alkoxy, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl groups, 3-7 membered carbon rings, 3-7 membered heterocycles, phenyl groups, or 5-10 membered heteroaryl groups; Y1 is selected from -N(R) Y1B -, -O-, -S-, -C(=O)-N(R) Y1B )- -S(=O)-N(R) Y1B )- -S(=O)2-N(R) Y1B )- -N(R) Y1B )-C(=O)- -N(R) Y1B )-S(=O)- or -N(R) Y1B )-S(=O)2- ; Indicates the connection point with ring B; R Y1B Selected from -H or -C 1-3 Alkyl; more preferably, R Y1B Selected from -H, -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2; more preferably, R Y1B Selected from -H or -CH3; R6 is selected from -H, halogen, -C 1-3 Alkyl or halogenated C 1-3 alkyl; R4 and R5 are each independently selected from -H or -C. 1-3 alkyl; Ring B is selected from phenyl or 5-10 membered heteroaromatic rings containing 1, 2, 3, 4, 5 or 6 heteroatoms selected from N, O or S; R S2 Each is independently selected from halogens, -C 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 Alkoxy, halogenated C 2-3 Alkoxy, -C 2-3 alkenyl, -C 2-3 Alkyne group, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), oxo, -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl), 3-7 membered cycloalkyl, 3-7 membered heterocyclic, 6-10 membered aryl or 5-10 membered heteroaryl; the R S2 Can be selected from halogens, -C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 1-3 Alkoxy, halogenated C 1-3 Alkyl, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -C(=O)(OC) 1-3 Alkyl) or -C (=O) (halogenated C) 1-3 One or more substituents of alkyl group are used; n2 is selected from 0, 1, 2, 3, 4, 5 or 6; R S1 n1 has the same definition as 1.

[0127] 72. The compound of formula (II) of the preceding 71, its stereoisomers, its tautomers, its deuterated derivatives, its pharmaceutically acceptable salts, its pharmaceutically acceptable salts, its pharmaceutically acceptable salts, or its deuterated derivatives thereof, wherein X1 is selected from N.

[0128] 73. The compound of formula (II) of the preceding 71, its stereoisomers, its tautomers, its deuterated derivatives, its pharmaceutically acceptable salts, its pharmaceutically acceptable salts, its pharmaceutically acceptable salts, or its deuterated derivatives thereof, wherein X1 is selected from CR7; R7 has the same definition as any of 12.

[0129] 74. A compound of formula (II) of any one of the preceding items 71-73, its stereoisomer, its tautomer, its deuterated derivative, its pharmaceutically acceptable salt, its pharmaceutically acceptable salt, its pharmaceutically acceptable salt, or a pharmaceutically acceptable salt of its deuterated derivative, wherein X3 is selected from N.

[0130] 75. A compound of formula (II) of any one of the preceding items 71-73, its stereoisomer, its tautomer, its deuterated derivative, its pharmaceutically acceptable salt, its pharmaceutically acceptable salt, its pharmaceutically acceptable salt, or a pharmaceutically acceptable salt of its deuterated derivative, wherein X3 is selected from CR9; R9 has the same definition as any one of items 10-11.

[0131] 76. A compound of formula (II) of any one of the preceding items 71-75, its stereoisomer, its tautomer, its deuterated derivative, its pharmaceutically acceptable salt, its pharmaceutically acceptable salt, its pharmaceutically acceptable salt, or a pharmaceutically acceptable salt of its deuterated derivative, wherein X4 is selected from N.

[0132] 77. A compound of formula (II) of any one of the preceding items 71-75, its stereoisomer, its tautomer, its deuterated derivative, its pharmaceutically acceptable salt, a pharmaceutically acceptable salt of its stereoisomer, a pharmaceutically acceptable salt of its tautomer, or a pharmaceutically acceptable salt of its deuterated derivative, wherein X4 is selected from CR 10 ;R 10 It has the same definition as 13.

[0133] 78. A compound of formula (II) of any one of the preceding items 71-77, its stereoisomer, its tautomer, its deuterated derivative, its pharmaceutically acceptable salt, a pharmaceutically acceptable salt of its stereoisomer, a pharmaceutically acceptable salt of its tautomer, or a pharmaceutically acceptable salt of its deuterated derivative, wherein, X1 is selected from N or CR7; X3 is selected from N or CR9; X4 is selected from N or CR 10 And no more than two of X1, X3, and X4 are N; or X1 is selected from N or CR7; X2 is selected from N or CR8; X3 is selected from N or CR9; X4 is selected from N or CR 10 And no more than one of X1, X3 and X4 is N.

[0134] 79. A compound of formula (II) of any one of the preceding items 71-78, its stereoisomer, its tautomer, its deuterated derivative, its pharmaceutically acceptable salt, a pharmaceutically acceptable salt of its stereoisomer, a pharmaceutically acceptable salt of its tautomer, or a pharmaceutically acceptable salt of its deuterated derivative, wherein, X1 is selected from N, X3 is selected from CR9 and X4 is selected from CR 10 ;or X1 is selected from N, X3 is selected from N and X4 is selected from CR 10 ;or X1 is selected from N, X3 is selected from CR9, and X4 is selected from N; or X1 is selected from CR7, X3 is selected from N, and X4 is selected from CR. 10 ;or X1 is selected from CR7, X3 is selected from CR9, and X4 is selected from N; or X1 is selected from CR7, X3 is selected from N, and X4 is selected from N; or X1 is selected from CR7, X3 is selected from CR9, and X4 is selected from CR7. 10 .

[0135] 80. A compound of formula (II) of any one of the preceding 71-79, its stereoisomer, its tautomer, its deuterated derivative, its pharmaceutically acceptable salt, a pharmaceutically acceptable salt of its stereoisomer, a pharmaceutically acceptable salt of its tautomer, or a pharmaceutically acceptable salt of its deuterated derivative, wherein the compound is selected from any one of the following formulas: , , , , , or .

[0136] 81. A compound of formula (I-1-1), its stereoisomers, its tautomers, its deuterated derivatives, its pharmaceutically acceptable salts, pharmaceutically acceptable salts of its stereoisomers, pharmaceutically acceptable salts of its tautomers, or pharmaceutically acceptable salts of their deuterated derivatives: Formula (I-1-1) in, R4 and R5 are each independently selected from -H or -C. 1-3 alkyl; R6 is selected from -H, halogen, -C 1-3 Alkyl or halogenated C 1-3 alkyl; R7 is selected from hydrogen, halogens, and -C. 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 1-3 Alkoxy, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl groups, 3-7 membered carbon rings, 3-7 membered heterocycles, phenyl groups, or 5-10 membered heteroaryl groups; R8 is selected from -H, -NHC(=O)(R 81 -NHS(=O)(R) 81 -NHS(=O)2(R) 81 -C(=O)N(R) 81 )2、-C(=O)NH(R 81 -S(=O)N(R) 81 )2、-S(=O)NH(R 81 -S(=O)2N(R) 81 )2 or -S(=O)2NH(R 81 ); The R 81 Each is independently selected from 3-10 membered carbon rings, 3-10 membered heterocycles, phenyl or 5-10 membered heteroaryl groups; the R 81 Can be selected from halogens, -C 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, oxo, -CN, -OH, -SH, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)(C 1-3Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl group, 3-7 membered carbon ring, 3-7 membered heterocyclic ring, phenyl or 5-10 membered heteroaryl group, one or more substituents; R9 is selected from -H, -(C 0-3 (alkylene)-R 91 -C(=O)-N(R) 92 )2、-S(=O)-N(R 92 )2、-S(=O)2-N(R 92 )2、-C(=O)(R 93 -S(=O)(R) 93 ) or -S(=O)2(R 93 ); The R 91 Each independently selected from -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 2-3 Alkoxy, halogenated C 2-3 Alkoxy, oxo, -CN, -OH, -SH, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl groups, 3-7 membered carbon rings, 3-7 membered heterocycles, phenyl groups, or 5-10 membered heteroaryl groups; The R 92 Each is independently selected from 3-7 membered carbon rings, 3-7 membered heterocycles, phenyl or 5-6 membered heteroaryl groups; the R 92 Can be selected from halogens, -C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 Alkyne, oxo, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl group, 3-7 membered carbon ring, 3-7 membered heterocyclic ring, phenyl or 5-10 membered heteroaryl group, one or more substituents; The R 93 Each is independently selected from halogens; When X2 is CR8 and X3 is CR9, only one of R8 and R9 is hydrogen; R 10 Selected from hydrogen, halogens, -C 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 1-3 Alkoxy, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl groups, 3-7 membered carbon rings, 3-7 membered heterocycles, phenyl groups, or 5-10 membered heteroaryl groups; Y1 is selected from -N(R) Y1B -, -O-, -S-, -C(=O)-N(R) Y1B )- -S(=O)-N(R) Y1B )- -S(=O)2-N(R) Y1B )- -N(R) Y1B )-C(=O)- -N(R) Y1B )-S(=O)- or -N(R) Y1B )-S(=O)2- ; Indicates the connection point with ring B; R Y1B Selected from -H or -C 1-3 Alkyl; more preferably, R Y1B Selected from -H, -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2; more preferably, R Y1B Selected from -H or -CH3; Ring B is selected from phenyl or 5-10 membered heteroaromatic rings containing 1, 2, 3, 4, 5 or 6 heteroatoms selected from N, O or S; R S2 Each time, they are independently selected from halogens and -C. 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 Alkoxy, halogenated C 2-3 Alkoxy, -C 2-3 alkenyl, -C 2-3 Alkyne group, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), oxo, -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl), 3-7 membered cycloalkyl, 3-7 membered heterocyclic, 6-10 membered aryl or 5-10 membered heteroaryl; the R S2 Can be selected from halogens, -C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 1-3Alkoxy, halogenated C 1-3 Alkyl, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -C(=O)(OC) 1-3 Alkyl) or -C (=O) (halogenated C) 1-3 One or more substituents of alkyl group are used; n2 is selected from 0, 1, 2, 3, 4, 5 or 6; R S1 n1 has the same definition as 1.

[0137] 82. The compound of formula (I-1-1) of the preceding 80, its stereoisomers, its tautomers, its deuterated derivatives, its pharmaceutically acceptable salts, its pharmaceutically acceptable salts, its pharmaceutically acceptable salts, or its deuterated derivatives thereof, wherein R7 has the same definition as in 12.

[0138] 83. A compound of formula (I-1-1) of any one of the preceding items 81-82, its stereoisomers, its tautomers, its deuterated derivatives, its pharmaceutically acceptable salts, its pharmaceutically acceptable salts, its pharmaceutically acceptable salts, or its deuterated derivatives thereof, wherein R8 has the same definition as any one of items 8-9.

[0139] 84. A compound of formula (I-1-1) of any one of the preceding items 80-83, its stereoisomers, its tautomers, its deuterated derivatives, its pharmaceutically acceptable salts, its pharmaceutically acceptable salts, its pharmaceutically acceptable salts, or its deuterated derivatives thereof, wherein R9 has the same definition as any one of items 10-11.

[0140] 85. A compound of formula (I-1-1) of any one of the preceding items 81-84, its stereoisomers, its tautomers, its deuterated derivatives, its pharmaceutically acceptable salts, pharmaceutically acceptable salts of its stereoisomers, pharmaceutically acceptable salts of its tautomers, or pharmaceutically acceptable salts of its deuterated derivatives, wherein R 10 It has the same definition as 13.

[0141] 86. A compound of formula (I-1-1) of any one of the preceding items 81-85, its stereoisomers, its tautomers, its deuterated derivatives, its pharmaceutically acceptable salts, its pharmaceutically acceptable salts, its pharmaceutically acceptable salts, or its deuterated derivatives thereof, wherein R4 and R5 have the same definitions as in any one of items 49-55.

[0142] 87. A compound of formula (I-1-1) of any one of the preceding items 81-86, its stereoisomers, its tautomers, its deuterated derivatives, its pharmaceutically acceptable salts, its pharmaceutically acceptable salts, its pharmaceutically acceptable salts, or its deuterated derivatives thereof, wherein R6 has the same definition as in any one of items 57-60.

[0143] 88. A compound of formula (I-1-1) of any one of the preceding items 81-87, its stereoisomers, its tautomers, its deuterated derivatives, its pharmaceutically acceptable salts, its pharmaceutically acceptable salts, its pharmaceutically acceptable salts, or its deuterated derivatives thereof, wherein Y1 has the same definition as any one of items 38-48.

[0144] 89. A compound of formula (I-1-1) of any one of the preceding items 80-89, its stereoisomer, its tautomer, its deuterated derivative, its pharmaceutically acceptable salt, a pharmaceutically acceptable salt of its stereoisomer, a pharmaceutically acceptable salt of its tautomer, or a pharmaceutically acceptable salt of its deuterated derivative, wherein, Selected from , , , , , , , , , , , , , , , , , , , , , , , , , or ; Preferably, Selected from , , , .

[0145] 90. A compound of formula (I-1-1) of any one of the preceding items 81-89, its stereoisomers, its tautomers, its deuterated derivatives, its pharmaceutically acceptable salts, its pharmaceutically acceptable salts, its pharmaceutically acceptable salts, or its deuterated derivatives thereof, wherein ring B has the same definition as in any one of items 65-66.

[0146] 91. A compound of formula (I-1-1) of any one of the preceding items 81-90, its stereoisomers, its tautomers, its deuterated derivatives, its pharmaceutically acceptable salts, pharmaceutically acceptable salts of its stereoisomers, pharmaceutically acceptable salts of its tautomers, or pharmaceutically acceptable salts of its deuterated derivatives, R S2 The definition of n is the same as in section 67 above; the definition of n2 is the same as in section 68 above.

[0147] 92. A compound of formula (I-1-1) of any one of the preceding items 81-91, its stereoisomers, its tautomers, its deuterated derivatives, its pharmaceutically acceptable salts, pharmaceutically acceptable salts of its stereoisomers, pharmaceutically acceptable salts of its tautomers, or pharmaceutically acceptable salts of its deuterated derivatives. The definition is the same as in section 69 above.

[0148] 93. A compound of formula (I-1-1) of any one of the preceding claims 81-92, its stereoisomers, its tautomers, its deuterated derivatives, its pharmaceutically acceptable salts, pharmaceutically acceptable salts of its stereoisomers, pharmaceutically acceptable salts of its tautomers, or pharmaceutically acceptable salts of their deuterated derivatives, wherein the compound has any of the following structures: , , , , , , , , , , , , , , , , , , , , , , , , , or .

[0149] 94. Compounds of formula (I-2), their stereoisomers, their tautomers, their deuterated derivatives, their pharmaceutically acceptable salts, pharmaceutically acceptable salts of their stereoisomers, pharmaceutically acceptable salts of their tautomers, or pharmaceutically acceptable salts of their deuterated derivatives: Formula (I-2) in, Y2 is selected from -C(RY2)2-, -O-, -NRY3-, -S-, -C(=O)NRY4-、 -NRY4C(=O)-、 -S(=O)NRY4-、 -NRY4S(=O)-、 -S(=O)2NRY4- or -NRY4S(=O)2-; indicates a AND operation with... Partial connection points; R Y2 Selected from hydrogen, halogens, -C 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 1-3 Alkoxy, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl groups, 3-7 membered carbon rings, 3-7 membered heterocycles, phenyl groups, or 5-10 membered heteroaryl groups; R Y3 Selected from -H, -C 1-6 Alkyl group, -C(=O)(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), 3-7 membered carbon rings, 3-7 membered heterocycles, phenyl or 5-10 membered heteroaryl; the R Y3 It can be independently controlled by 1, 2, 3, 4, 5 or 6 R's. Y31 replace; The R Y31 Each is independently selected from halogens, -C 1-3 Alkyl, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-4 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-4 Alkyl), -C(=O)N(C 1-3 Alkyl)2, -S(=O)NH2, -S(=O)NH(C 1-4 Alkyl), -S(=O)N(C 1-3 Alkyl)2, -S(=O)2NH2, -S(=O)2NH(C 1-4 Alkyl) or -S(=O)2N(C 1-3 Alkyl)2; the R Y31 It can be independently controlled by 1, 2, 3, 4, 5 or 6 RYs 32 Replace; the R Y32 Each independently selected from -C 2-3 Alkoxy, -NH2, -NH(C) 1-3alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl groups or 5-10 heteroaryl groups; R Y4 Selected from -H, -C 1-6 Alkyl group, -C(=O)(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), 3-7 membered carbon rings, 3-7 membered heterocycles, phenyl or 5-10 membered heteroaryl; the R Y4 It can be independently substituted by 1, 2, 3, 4, 5 or 6 substituents, said substituents being selected from halogens, -C 1-3 Alkyl, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-4 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-4 Alkyl), -C(=O)N(C 1-3 Alkyl)2, -S(=O)NH2, -S(=O)NH(C 1-4 Alkyl), -S(=O)N(C 1-3 Alkyl)2, -S(=O)2NH2, -S(=O)2NH(C 1-4 Alkyl) or -S(=O)2N(C 1-3 Alkyl)2; n4 is selected from 0, 1, 2, 3 or 4; n5 is selected from 0, 1, 2, 3 or 4; Y1 is selected from -N(R) Y1B -, -O-, -S-, -C(=O)-N(R) Y1B )- -S(=O)-N(R) Y1B )- -S(=O)2-N(R) Y1B )- -N(R) Y1B )-C(=O)- -N(R) Y1B )-S(=O)- or -N(R) Y1B)-S(=O)2- ; Indicates the connection point with ring B; R Y1B Selected from -H or -C 1-3 Alkyl; more preferably, R Y1B Selected from -H, -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2; more preferably, R Y1B Selected from -H or -CH3; R6 is selected from -H, halogen, -C 1-3 Alkyl or halogenated C 1-3 alkyl; R4 and R5 are each independently selected from -H or -C. 1-3 alkyl; Ring B is selected from phenyl or 5-10 membered heteroaromatic rings containing 1, 2, 3, 4, 5 or 6 heteroatoms selected from N, O or S; R S2 Each is independently selected from halogens, -C 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 Alkoxy, halogenated C 2-3 Alkoxy, -C 2-3 alkenyl, -C 2-3 Alkyne group, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), oxo, -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C1-3 Alkyl), 3-7 membered cycloalkyl, 3-7 membered heterocyclic, 6-10 membered aryl or 5-10 membered heteroaryl; the R S2 Can be selected from halogens, -C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 1-3 Alkoxy, halogenated C 1-3 Alkyl, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -C(=O)(OC) 1-3 Alkyl) or -C (=O) (halogenated C) 1-3 One or more substituents of alkyl group are used; n2 is selected from 0, 1, 2, 3, 4, 5 or 6; R S1 n1, R S3 n3 and n3 have the same definition as 1.

[0150] 95. A compound of formula (I-2-1), its stereoisomers, its tautomers, its deuterated derivatives, its pharmaceutically acceptable salts, pharmaceutically acceptable salts of its stereoisomers, pharmaceutically acceptable salts of its tautomers, or pharmaceutically acceptable salts of their deuterated derivatives: Formula (I-2-1) Among them, R4, R5, R6, RS1, RS2, RS3, n1, n2, n3, n4, n5, RY2, Y1 and ring B have the same definition as 94.

[0151] 96. A compound of formula (I-2-1), its stereoisomers, its tautomers, its deuterated derivatives, its pharmaceutically acceptable salts, pharmaceutically acceptable salts of its stereoisomers, pharmaceutically acceptable salts of its tautomers, or pharmaceutically acceptable salts of their deuterated derivatives, wherein RY2 is selected from -H, halogens, -C 1-3 Alkyl or halogenated C 1-3 Alkyl group; preferably, RY2 is selected from -H, -Cl, -F, -Br, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CHFCH3 or -CF2CH3; more preferably, RY2 is -H; in some embodiments, RY2 is selected from -H or -C 1-3Alkyl group; preferably, RY2 is selected from -H, -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2; more preferably, RY2 is -H.

[0152] 97. A compound of formula (I-2-2), its stereoisomers, its tautomers, its deuterated derivatives, its pharmaceutically acceptable salts, pharmaceutically acceptable salts of its stereoisomers, pharmaceutically acceptable salts of its tautomers, or pharmaceutically acceptable salts of their deuterated derivatives: Formula (I-2-2) Among them, R4, R5, R6, R S1 R S2 R S3 n1, n2, n3, n4, n5, R Y3 Y1 and ring B have the same definitions as 94.

[0153] 98. A compound of formula (I-2-1), its stereoisomers, its tautomers, its deuterated derivatives, its pharmaceutically acceptable salts, pharmaceutically acceptable salts of its stereoisomers, pharmaceutically acceptable salts of its tautomers, or pharmaceutically acceptable salts of their deuterated derivatives, wherein R Y3 Selected from -H, -C 1-3 Alkyl group, -C(=O)(C 1-3 Alkyl group), 3-7 membered carbon ring or 3-7 membered heterocycle; the R Y3 It can be independently controlled by 1, 2 or 3 Rs. Y31 Replace; the R Y31 Each time, each is selected independently from -C 1-3 Alkyl, -OH, -O(C) 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-4 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-4 Alkyl) or -C(=O)N(C 1-3 Alkyl)2; the R Y31 It can be independently controlled by 1, 2, 3, 4, 5 or 6 R's. Y32 Replace; the R Y32 Each independently selected from -C 2-3 Alkoxy, -OH, -O(C) 1-3 Alkyl groups or 5-10 heteroaryl groups.

[0154] Preferably, R Y3Selected from -H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C(=O)(CH3), -C(=O)(CH2CH3), -C(=O)(CH2CH2CH3), -C(=O)(CH(CH3)2), , , , , , , , , , or The R Y3 Each is independently controlled by 1, 2, or 3 Rs. Y31 Replace; the R Y31 Each time, they are independently selected from -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -OH, -O-CH3, -O-CH2CH3, -O-CH2CH2CH3, -O-CH(CH3)2, -C(=O)CH3, -C(=O)(CH2CH3), -C(=O)-CH(CH3)2, -C(=O)OH, -C(=O)(OCH3), -C(=O)(OCH2CH3), -C(=O)(OCH2CH2 CH3), -C(=O)(OCH(CH3)2), -C(=O)(OC(CH3)3), -C(=O)NH2, -C(=O)NH2, -C(=O)NH(CH3), -C(=O)NH(CH2CH3), -C(=O)NH(CH2CH2CH3), -C(=O)NH(CH(CH3)2), -C(=O)NH(C(CH3)3), -C(=O)N(CH3)2 or -C(=O)N(CH2CH3)2; the R Y31 Each is independently controlled by 1, 2, 3, 4, 5, or 6 R's. Y32 Replace; the R Y32 Each is independently selected from -CH3-O-CH3, -CH2CH3-O-CH3, -CH2-O-CH2CH3, -CH(CH3)-O-CH3, -OH, -O-CH3, -O-CH2CH3, -O-CH(CH3)2, thiophene, furanyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrroleyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, or isoxazolyl; More preferably, R Y3 Selected from -H, -CH3, -CH2CH3, -C(=O)(CH3), , , or The R Y3 Each is independently controlled by 1, 2, or 3 Rs. Y31 Replace; the R Y31 Each is independently selected from -CH3, -CH2CH3, -OH, -C(=O)CH3, -C(=O)OH, -C(=O)(OC(CH3)3), -C(=O)NH2, -C(=O)NH(CH3), -C(=O)NH(CH2CH3), -C(=O)NH(CH(CH3)2) or -C(=O)NH(C(CH3)3); the R Y31 Each is independently controlled by 1, 2, or 3 Rs. Y32 Replace; the R Y32 Each group is independently selected from -OH, -O-CH3, or pyridinyl groups; More preferably, R Y3 Selected from -H, -CH3, -CH2CH3, -CH2COOH, -CH2CH2COOH, -CH2COOC(CH3)3, -CH2CH2COOC(CH3)3, -CH2CH2OH, -CH2-C(=O)-NH(CH3), -CH2C H2-C(=O)-NH(CH3), -CH2CH2-C(=O)-NH(CH2CH3), -CH2CH2-C(=O)-NH(CH(CH3)2), -CH2CH2-C(=O)-NH(C(CH3)3), -C(=O)-CH3, , , , , , , , , or ; More preferably, R Y3 Selected from -CH2CH2COOH, -CH2CH2OH, -C(=O)-CH3, , , or .

[0155] 99. Compounds of formula (I-2-3), their stereoisomers, their tautomers, their deuterated derivatives, their pharmaceutically acceptable salts, pharmaceutically acceptable salts of their stereoisomers, pharmaceutically acceptable salts of their tautomers, or pharmaceutically acceptable salts of their deuterated derivatives: Formula (I-2-3) Among them, R4, R5, R6, RS1, RS2, RS3, n1, n2, n3, n4, n5, Y1 and ring B have the same definition as 94.

[0156] 100. Compounds of formula (I-2-4), their stereoisomers, their tautomers, their deuterated derivatives, their pharmaceutically acceptable salts, pharmaceutically acceptable salts of their stereoisomers, pharmaceutically acceptable salts of their tautomers, or pharmaceutically acceptable salts of their deuterated derivatives: Formula (I-2-4) Among them, R4, R5, R6, RS1, RS2, RS3, n1, n2, n3, n4, n5, Y1 and ring B have the same definition as 94.

[0157] 101. Compounds of formula (I-2-5), their stereoisomers, their tautomers, their deuterated derivatives, their pharmaceutically acceptable salts, pharmaceutically acceptable salts of their stereoisomers, pharmaceutically acceptable salts of their tautomers, or pharmaceutically acceptable salts of their deuterated derivatives: Formula (I-2-5) Among them, R4, R5, R6, RS1, RS2, RS3, n1, n2, n3, n4, n5, R Y4 Y1 and ring B have the same definitions as 94.

[0158] 102. Compounds of formula (I-2-6), their stereoisomers, their tautomers, their deuterated derivatives, their pharmaceutically acceptable salts, pharmaceutically acceptable salts of their stereoisomers, pharmaceutically acceptable salts of their tautomers, or pharmaceutically acceptable salts of their deuterated derivatives: Formula (I-2-6) Among them, R4, R5, R6, R S1 R S2 R S3 n1, n2, n3, n4, n5, R Y4 Y1 and ring B have the same definitions as 94.

[0159] 103. Compounds of formulas (I-2-5) and (I-2-6), their stereoisomers, their tautomers, their deuterated derivatives, their pharmaceutically acceptable salts, pharmaceutically acceptable salts of their stereoisomers, pharmaceutically acceptable salts of their tautomers, or pharmaceutically acceptable salts of their deuterated derivatives, wherein R Y4 Selected from -H, -C 1-3 Alkyl or halogenated C 1-3 Alkyl; preferably, R Y4Selected from -H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CHFCH3 or -CF2CH3; more preferably, R Y4 -H; in some embodiments, R Y4 Selected from -H or -C 1-3 Alkyl; preferably, R Y4 Selected from -H, -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2; more preferably, R Y4 It is -H.

[0160] 104. Compounds of formula (I-2), formula (I-2-1), formula (I-2-2), formula (I-2-3), formula (I-2-4), formula (I-2-5) and formula (I-6), their stereoisomers, their tautomers, their deuterated derivatives, their pharmaceutically acceptable salts, their pharmaceutically acceptable salts, their pharmaceutically acceptable salts, their pharmaceutically acceptable salts, or their pharmaceutically acceptable salts of deuterated derivatives thereof, wherein n4 and n5 have the same definition as in any of 18-21.

[0161] 105. Compounds of formula (I-2), (I-2-1), (I-2-2), (I-2-3), (I-2-4), (I-2-5) and (I-6), their stereoisomers, their tautomers, their deuterated derivatives, their pharmaceutically acceptable salts, their pharmaceutically acceptable salts, their pharmaceutically acceptable salts, their pharmaceutically acceptable salts, or their pharmaceutically acceptable salts of deuterated derivatives thereof, wherein R4 and R5 have the same definition as in any of 49-55.

[0162] 106. Compounds of formula (I-2), formula (I-2-1), formula (I-2-2), formula (I-2-3), formula (I-2-4), formula (I-2-5) and formula (I-6), their stereoisomers, their tautomers, their deuterated derivatives, their pharmaceutically acceptable salts, their pharmaceutically acceptable salts, their pharmaceutically acceptable salts, their pharmaceutically acceptable salts, or their pharmaceutically acceptable salts of deuterated derivatives thereof, wherein R6 has the same definition as in any of 57-60.

[0163] 107. Compounds of formula (I-2), formula (I-2-1), formula (I-2-2), formula (I-2-3), formula (I-2-4), formula (I-2-5) and formula (I-6), their stereoisomers, their tautomers, their deuterated derivatives, their pharmaceutically acceptable salts, their pharmaceutically acceptable salts, their pharmaceutically acceptable salts, their pharmaceutically acceptable salts, or their pharmaceutically acceptable salts of deuterated derivatives thereof, wherein Y1 has the same definition as any of 38-48.

[0164] 108. Compounds of formula (I-2) and formula (I-2-1) of any one of the preceding items 94-96 and 104-107, their stereoisomers, their tautomers, their deuterated derivatives, their pharmaceutically acceptable salts, their pharmaceutically acceptable salts, their pharmaceutically acceptable salts, or their pharmaceutically acceptable salts of deuterated derivatives, wherein, Selected from or .

[0165] 109. Compounds of formula (I-2) and formula (I-2-2), their stereoisomers, their tautomers, their deuterated derivatives, their pharmaceutically acceptable salts, pharmaceutically acceptable salts of their stereoisomers, pharmaceutically acceptable salts of their tautomers, or pharmaceutically acceptable salts of their deuterated derivatives, wherein, Selected from , , , , , , , , , , , , , , , , , , , , , , , , , or ; Preferably, Selected from , , , , , , , .

[0166] 110. Compounds of formula (I-2) and (I-2-3), their stereoisomers, their tautomers, their deuterated derivatives, their pharmaceutically acceptable salts, pharmaceutically acceptable salts of their stereoisomers, pharmaceutically acceptable salts of their tautomers, or pharmaceutically acceptable salts of their deuterated derivatives, wherein, Selected from , , , , or Preferably, Selected from .

[0167] 111. Compounds of formula (I-2) and (I-2-4), their stereoisomers, their tautomers, their deuterated derivatives, their pharmaceutically acceptable salts, pharmaceutically acceptable salts of their stereoisomers, pharmaceutically acceptable salts of their tautomers, or pharmaceutically acceptable salts of their deuterated derivatives, wherein, Selected from , , , , or Preferably, Selected from .

[0168] 112. Compounds of formula (I-2) and formula (I-2-6) of any one of items 94, 101, and 103-107, their stereoisomers, their tautomers, their deuterated derivatives, their pharmaceutically acceptable salts, pharmaceutically acceptable salts of their stereoisomers, pharmaceutically acceptable salts of their tautomers, or pharmaceutically acceptable salts of their deuterated derivatives, wherein, Selected from , , or .

[0169] 113. Compounds of formula (I-2) and formula (I-2-6) of any one of items 94, 101, and 103-107, their stereoisomers, their tautomers, their deuterated derivatives, their pharmaceutically acceptable salts, pharmaceutically acceptable salts of their stereoisomers, pharmaceutically acceptable salts of their tautomers, or pharmaceutically acceptable salts of their deuterated derivatives, wherein, Selected from , , or .

[0170] 114. Compounds of formulas (I-2-1), (I-2-2), (I-2-3), (I-2-4), (I-2-5), and (I-2-6) of any one of items 94-113, their stereoisomers, their tautomers, their deuterated derivatives, their pharmaceutically acceptable salts, pharmaceutically acceptable salts of their stereoisomers, pharmaceutically acceptable salts of their tautomers, or pharmaceutically acceptable salts of their deuterated derivatives, wherein, Selected from , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or .

[0171] 115. Any of the compounds of formulas (I-2), (I-2-1), (I-2-2), (I-2-3), (I-2-4), (I-2-5), and (I-6) in any of the preceding terms 94-115, including their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein the definition of ring B is the same as in any of 65-66.

[0172] 116. Any compound of formulas (I-2), (I-2-1), (I-2-2), (I-2-3), (I-2-4), (I-2-5), and (I-6) of any one of the preceding terms 94-115, including its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein R S2 The definition of n is the same as in 67; the definition of n2 is the same as in 68.

[0173] 117. Any compound of formulas (I-2), (I-2-1), (I-2-2), (I-2-3), (I-2-4), (I-2-5), and (I-6) of any one of the preceding terms 94-116, wherein, , The definition is the same as in 69.

[0174] 118. Any of the compounds of formulas (I-2), (I-2-1), (I-2-2), (I-2-3), (I-2-4), (I-2-5), and (I-6) of any one of the preceding terms 94-117, including their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein the compound is any one of the following formulas: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or .

[0175] 119. A compound of formula (I), its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives: Formula (I) in, R1 is independently selected from hydrogen, halogen, and -C. 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 Alkoxy, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl), 3-7 membered cycloalkyl, 3-7 membered heterocycloalkyl, phenyl, or 5-10 membered heteroaryl; wherein R1 may optionally be substituted with 1, 2, or 3 substituents, the substituents being selected from halogens, -C 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 Alkoxy, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -NHS(=O)(C 1-3Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl), -NHS(=O)2(C 1-3 Alkyl groups or 3-7 membered cycloalkyl groups; R2 is independently selected from -H, halogen, and -C. 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 Alkoxy, -CN, -C(=O)OH, -NH2, -NH(C 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl groups or 3-7 membered cycloalkyl groups; R4 and R5 are independently selected from -H or -C 1-3 alkyl; R6 is selected from -H, halogen, -C 1-3 Alkyl or halogenated C 1-3 alkyl; Y1 is selected from -N(R) Y1B -, -O-, -S-, -C(=O)-N(R) Y1B )- -S(=O)-N(R) Y1B )- -S(=O)2-N(R) Y1B )- -N(R) Y1B )-C(=O)- -N(R) Y1B )-S(=O)- or -N(R) Y1B )-S(=O)2- ; Indicates the connection point with ring B; R Y1B Selected from -H or -C 1-3 Alkyl; more preferably, R Y1B Selected from -H, -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2; more preferably, RY1B Selected from -H or -CH3; Ring B is selected from phenyl or 5-10 membered heteroaromatic rings containing 1, 2, 3, 4, 5 or 6 heteroatoms selected from N, O or S; R S2 Independently selected from halogens, -C 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 Alkoxy, halogenated C 2-3 Alkoxy, -C 2-3 alkenyl, -C 2-3 Alkyne group, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), oxo, -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl), 3-7 membered cycloalkyl, 3-7 membered heterocycloalkyl, 6-10 membered aryl or 5-10 membered heteroaryl; the R S2 It may optionally be substituted with one or more substituents selected from halogens, -C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 1-3 Alkoxy, halogenated C 1-3 Alkyl, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -C(=O)(C1-3 Alkyl), -C(=O)(OC) 1-3 Alkyl) or -C (=O) (halogenated C) 1-3 alkyl); n2 is selected from 0, 1, 2, 3, 4, 5 or 6; R S1 The definitions of n1 and n1 are the same as in 1.

[0176] 120. A compound of formula (I-1) of any one of 1, 32-69, or 119 above, wherein its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein, R1 is independently selected from hydrogen, halogen, and -C. 1-3 Alkyl, -CN, -C(=O)OH, -C(=O)(OC) 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2, -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2, -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl), phenyl, or a 5-6 membered heteroaryl group containing 1, 2, or 3 heteroatoms selected from N, O, or S; wherein R1 may optionally be surrounded by 1, 2, or 3 heteroatoms selected from -C 1-3 Alkyl substituents; More preferably, each R1 is independently selected from hydrogen, halogen, -C 1-3 Alkyl, -CN, -COOH, -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl group 2, or containing one or two heteroatoms selected from N, O or S. 5-6 The 5-6 heteroaryl group may optionally be selected from 1 or 2 groups chosen from -C 1-3 Alkyl substituents; More preferably, R1 is independently selected from -H, -F, -Cl, -Br, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CN, -COOH, -C(=O)NH2, -C(=O)NH(CH3), -C(=O)NH(CH2CH3), -C(=O)NH(CH2CH2CH3), -C(=O)NH(CH(CH3)2), -C(=O)N(CH3)2, -C(=O)N(CH2CH3)2, , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ; More preferably, R1 is selected from -CH3, -CN, -Br, -C(=O)-NH2, -COOH, , or .

[0177] 121. The compound of formula (I-1) of any one of the preceding items 1, 32-69, and 119-120, wherein its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein, R2 is independently selected from -H, halogen, and -C. 1-3 Alkyl, Halogenated C 1-3 Alkyl or -CN; Preferably, R2 is independently selected from -H and -C. 1-3 Alkyl or -CN; More preferably, R2 is independently selected from -H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2 or -CN; More preferably, R2 is selected from -H, -CH3, or -CN.

[0178] 122. The compound of formula (I-1) of any one of the preceding 1, 32-69, 119-121, including its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein R4 and R5 are defined in the same way as any one of 62-66.

[0179] 123. The compound of formula (I-1) of any one of the preceding 1, 32-69, 119-122, including its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein R6 is defined as in any one of 62-66.

[0180] 124. The compound of formula (I-1) of any one of the preceding 1, 32-69, 119-123, including its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein the definition of Y1 is the same as that of any one of 62-66.

[0181] 125. The compound of formula (I-1) of any one of the preceding 1, 32-69, 119-124, and its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives.

[0182] Selected from , , , , , , , , , , , , , , , or .

[0183] 126. The compound of formula (I-1) of any one of the preceding 1, 32-69, 119-125, including its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein the definition of ring B is the same as in any one of 65-66.

[0184] 127. The compound of formula (I-1) of any one of the preceding items 1, 32-69, and 119-126, wherein its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein, The definition of RS2 is the same as in 67; The definition of n2 is the same as that in 68.

[0185] 128. The compound of formula (I-1) of any one of the preceding items 1, 32-69, and 119-127, wherein its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein, The definition of the group is the same as in 69.

[0186] 129. A compound of formula (I-1), its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, wherein the compound is any one of the following formulas: , , , , , , , , , , , , , , , or .

[0187] 130. The compounds of formula (I-1) described in 1-129 above, including their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of the stereoisomers, pharmaceutically acceptable salts of the tautomers, or pharmaceutically acceptable salts of the deuterated derivatives, wherein the compound is any one of the following formulas: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or .

[0188] 131. An intermediate, selected from any of the following formulas: , , , , , , , ; Wherein, R4, R5, R6, R7, R9, R... 10 RY2, Y1, ring B, R S1 R S2 R S3 The definitions of n1, n2, n3, n4, or n5 are the same as any one of 1 to 130; In each formula, LG6 is a leaving group, selected from halogens (such as -Cl, -Br or -I), -OMs, -OTs or -OTf; In each formula, Y4 is -C(=O)-, -S(=O)-, or -S(=O)2-; In each formula, LG2 is a leaving group or a group that can be converted into a leaving group; the leaving group is selected from halogens (such as -Cl, -Br or -I), -OMs, -OTs or -OTf; the group that can be converted into a leaving group is selected from -OH, which can be converted into leaving groups including but not limited to -Cl, -Br, -I, -OMs, -OTs or -OTf. Poc2 is a protecting group for nitrogen atoms, including but not limited to tert-butoxycarbonyl; Preferably, the intermediate is selected from: , , , , , , , , , , , , , , , .

[0189] 132. A method for preparing a compound of formula (I-1-1), wherein the stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, includes either scheme 1 or scheme 2: In each formula, R4, R5, R6, R7, R8, R9, R 10 R 81 Y1, ring B, R S1 R S2 The definitions of n1 or n2 are the same as any one of 1 to 130; The LG3 in LG4 in LG5, (LG1-Y3-R) 81 LG1 in (or LG2 in formula (I-1-1E')) is a leaving group or a group that can be converted into a leaving group; in some embodiments, the leaving group is selected from halogens (such as -Cl, -Br or -I), -OMs, -OTs or -OTf; in some embodiments, the group that can be converted into a leaving group is selected from -OH, which can be converted into a leaving group including but not limited to -Cl, -Br, -I, -OMs, -OTs or -OTf; In formulas (I-1-1A'), (I-1-1B'), and (I-1-1C'), LG6 is a leaving group selected from halogens (such as -Cl, -Br, or -I), -OMs, -OTs, or -OTf; LG7 is a leaving group, such as benzyl or methyl, that can be removed from formula (I-1-1D') in subsequent reactions; (LG1-Y3-R) 81 Y3 in the formula (Y4 in formula (I-1-1E')) is selected from -C(=O)-, -S(=O)- or -S(=O)2-; Y5 is -C(=O)-, -S(=O)-, or -S(=O)2-; Y6 is -S- or -CH2-; when -Y6- is -CH2-, it is oxidized to form Y4 (-C(=O)-) in formula (I-1-1E'); when -Y6- is -S-, it is oxidized to form Y4 (-S(=O)- or -S(=O)2-) in formula (I-1-1E').

[0190] 133. A method for preparing a compound of formula (I-2-1), wherein the stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, includes scheme 3 below: In each formula, R4, R5, R6, RY2, Y1, ring B, R S1 R S2R S3 The definitions of n1, n2, n3, n4, or n5 are the same as any one of 1 to 130; The LG3 in LG4 and LG5 in the figure is a leaving group or a group that can be converted into a leaving group; in some embodiments, the leaving group is selected from halogens (such as -Cl, -Br or -I), -OMs, -OTs or -OTf; in some embodiments, the group that can be converted into a leaving group is selected from -OH, which can be converted into leaving groups including but not limited to -Cl, -Br, -I, -OMs, -OTs or -OTf. The Poc1 is a -NH2 protecting group, preferably, Poc1 is... ; Y5 is -C(=O)-, -S(=O)-, or -S(=O)2-.

[0191] 134. A method for preparing a compound of formula (I-2-2), wherein the stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, includes scheme 4 below: In each formula, R4, R5, R6, R Y3 Y1, ring B, R S1 R S2 R S3 The definitions of n1, n2, n3, n4, or n5 are the same as any one of 1 to 130; The LG3 in LG4 and LG5 in the figure is a leaving group or a group that can be converted into a leaving group; in some embodiments, the leaving group is selected from halogens (such as -Cl, -Br or -I), -OMs, -OTs or -OTf; in some embodiments, the group that can be converted into a leaving group is selected from -OH, which can be converted into leaving groups including but not limited to -Cl, -Br, -I, -OMs, -OTs or -OTf. Y5 is -C(=O)-, -S(=O)-, or -S(=O)2-; The Poc1 is a -NH2 protecting group, preferably, Poc1 is... ; Poc2 is a protecting group for the nitrogen atom; preferably, Poc2 is a tert-butyloxycarbonyl group.

[0192] 135. A pharmaceutical composition comprising any one of the compounds of any one of 1-130, their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers or pharmaceutically acceptable salts of deuterated derivatives, and at least one pharmaceutically acceptable excipient.

[0193] 136. A method of treating a subject with cancer associated with Fascin overexpression, comprising administering to the subject a therapeutically effective amount of any one of the compounds described in any one of 1-130, their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, or the pharmaceutical composition described in 135; preferably, the cancer is selected from breast cancer, central nervous system cancer, endometrial cancer, kidney cancer, colorectal cancer, lung cancer, esophageal cancer, tongue cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, mesothelioma, melanoma, fibrosarcoma, bladder cancer, rectal cancer, lymphoma, cervical cancer, head and neck cancer, upper respiratory tract and digestive tract cancer, colorectal cancer, urinary system cancer, or colon cancer; more preferably, each cancer is independently selected from adenocarcinoma. Cancer, squamous cell carcinoma, mixed adenosquamous carcinoma, undifferentiated carcinoma; more preferably, ovarian cancer includes high-grade ovarian serous adenocarcinoma, ovarian mucinous cystadenocarcinoma, or malignant Brenner's tumor of the ovary; renal cancer includes clear cell renal cell carcinoma; tongue cancer includes squamous cell carcinoma of the tongue; lung cancer includes lung adenocarcinoma, lung adenosquamous carcinoma, squamous cell lung cancer, large cell lung cancer, small cell lung cancer, papillary lung cancer, or non-small cell lung cancer; pancreatic cancer includes pancreatic adenocarcinoma or pancreatic ductal adenocarcinoma; esophageal cancer includes esophageal squamous cell carcinoma; mesothelioma includes biphasic mesothelioma; central nervous system cancers include glioma, glioblastoma, or glioblastoma multiforme; gastric cancer includes gastric adenocarcinoma; breast cancer includes ductal carcinoma, adenocarcinoma, or HR+ breast cancer; bladder cancer includes bladder squamous cell carcinoma; melanoma includes malignant melanoma; colon cancer includes colonic adenocarcinoma; head and neck cancer includes small squamous cell carcinoma of the head and neck.

[0194] 137. The use of any one of the compounds described in any one of claims 1-130 above, their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, or the use of the pharmaceutical composition described in claim 135 in the preparation of a medicament for treating cancers associated with Fascin overexpression; preferably, the cancer is selected from breast cancer, central nervous system cancer, endometrial cancer, kidney cancer, colorectal cancer, lung cancer, esophageal cancer, tongue cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, mesothelioma, melanoma, fibrosarcoma, bladder cancer, rectal cancer, lymphoma, cervical cancer, head and neck cancer, upper respiratory tract and digestive tract cancer, colorectal cancer, urinary system cancer, or colon cancer; more preferably, each cancer is independently selected from adenocarcinoma, squamous cell carcinoma. Mixed adenosquamous carcinoma, undifferentiated carcinoma; more preferably, ovarian cancer includes high-grade ovarian serous adenocarcinoma, ovarian mucinous cystadenocarcinoma, or malignant ovarian Brenner's tumor; renal cancer includes clear cell renal cell carcinoma; tongue cancer includes squamous cell carcinoma of the tongue; lung cancer includes lung adenocarcinoma, lung adenosquamous carcinoma, squamous cell lung cancer, large cell lung cancer, small cell lung cancer, papillary lung cancer, or non-small cell lung cancer; pancreatic cancer includes pancreatic adenocarcinoma or pancreatic ductal adenocarcinoma; esophageal cancer includes esophageal squamous cell carcinoma; mesothelioma includes biphasic mesothelioma; central nervous system cancers include glioma, glioblastoma, or glioblastoma multiforme; gastric cancer includes gastric adenocarcinoma; breast cancer includes ductal carcinoma, adenocarcinoma, or HR+ breast cancer; bladder cancer includes bladder squamous cell carcinoma; melanoma includes malignant melanoma; colon cancer includes colonic adenocarcinoma; head and neck cancer includes small squamous cell carcinoma of the head and neck.

[0195] 138. The compound of any one of claims 1-130 above, its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, or the pharmaceutical composition described in claim 135, for the treatment of cancers associated with Fascin overexpression; preferably, the cancer is selected from breast cancer, central nervous system cancer, endometrial cancer, kidney cancer, colorectal cancer, lung cancer, esophageal cancer, tongue cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, mesothelioma, melanoma, fibrosarcoma, bladder cancer, rectal cancer, lymphoma, cervical cancer, head and neck cancer, upper respiratory tract and digestive tract cancer, colorectal cancer, urinary system cancer, or colon cancer; more preferably, each cancer is independently selected from adenocarcinoma, squamous cell carcinoma, mixed carcinoma, etc. Adenosquamous carcinoma, undifferentiated carcinoma; more preferably, ovarian cancer includes high-grade ovarian serous adenocarcinoma, ovarian mucinous cystadenocarcinoma, or malignant Brenner's tumor of the ovary; renal cancer includes clear cell renal cell carcinoma; tongue cancer includes squamous cell carcinoma of the tongue; lung cancer includes lung adenocarcinoma, lung adenosquamous carcinoma, squamous cell lung cancer, large cell lung cancer, small cell lung cancer, papillary adenocarcinoma of the lung, or non-small cell lung cancer; pancreatic cancer includes pancreatic adenocarcinoma or pancreatic ductal adenocarcinoma; esophageal cancer includes esophageal squamous cell carcinoma; mesothelioma includes biphasic mesothelioma; central nervous system cancers include glioma, glioblastoma, or glioblastoma multiforme; gastric cancer includes gastric adenocarcinoma; breast cancer includes ductal carcinoma, adenocarcinoma, or HR+ breast cancer; bladder cancer includes bladder squamous cell carcinoma; melanoma includes malignant melanoma; colon cancer includes colonic adenocarcinoma; head and neck cancer includes small squamous cell carcinoma of the head and neck.

[0196] definition Unless otherwise stated, the terms “halogen” or “halogenated” used interchangeably herein refer to fluorine, chlorine, bromine, or iodine. Preferred halogen groups include -F, -Cl, and -Br.

[0197] Unless otherwise stated, the term "alkyl" as used herein includes saturated monovalent hydrocarbon groups having a straight chain or branched chains. For example, alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 3-(2-methyl)butyl, 2-pentyl, 2-methylbutyl, neopentyl, n-hexyl, 2-hexyl, and 2-methylpentyl. 1-6 C in alkyl 1-6 It is defined as a group that identifies a straight or branched arrangement of 1, 2, 3, 4, 5 or 6 carbon atoms.

[0198] Unless otherwise stated, the term "haloalkyl" as used herein refers to the alkyl group described above that is substituted with one or more (1, 2, 3, 4, 5, or 6) halogens (-F, -Cl, or -Br). In some embodiments, the haloalkyl group is an interchangeable haloC. 1-6 Alkyl or halogenated C1-6 Alkyl, wherein -C 1-6 Halogenated alkyl or halogenated C 1-6 C in alkyl 1-6 This indicates that the total number of carbon atoms in the alkyl group is 1 to 6. In some embodiments, the halogenated C 1-6 Alkyl groups are halogenated C 1-3 Alkyl group. In some embodiments, the halogenated C 1-3 The alkyl group is substituted with 1, 2, 3, 4, 5, or 6 F atoms (methyl, ethyl, propyl, or isopropyl); preferably, the C atoms are halogenated. 1-3 The alkyl group is -CF3.

[0199] The term "alkylene" refers to a bifunctional group obtained by removing an additional hydrogen atom from an alkyl group as defined above. Examples include methylene (i.e., -CH2-), ethylene (i.e., -CH2-CH2- or -CH(CH3)-), and propylene (i.e., -CH2-CH2-CH2-, -CH(-CH2-CH3)-, or -CH2-CH(CH3)-).

[0200] The term "alkenyl" refers to a straight-chain or branched hydrocarbon group containing one or more double bonds, and typically has a length of 2 to 20 carbon atoms. For example, "-C 2-6 "Alkenyl" contains 2 to 6 carbon atoms. Alkenyl groups include, but are not limited to, vinyl, propenyl, butenyl, 2-methyl-2-buten-1-yl, heptenyl, octenyl, etc.

[0201] The term "alkynyl" refers to a straight-chain or branched hydrocarbon group containing one or more triple bonds, and typically has a length of 2 to 20 carbon atoms. For example, "C 2-6 The "alkynyl" group contains 2 to 6 carbon atoms. Representative alkynyl groups include, but are not limited to, ethynyl, 1-propynyl, 1-butynylheptynyl, octyynyl, etc.

[0202] The term "alkoxy" refers to an oxygen ether formed from the aforementioned alkyl group. Alkoxy refers to an alkyl group substituted with -O-alkyl or a -OH group substituted with an alkyl group. For example, alkoxy refers to an alkyl group substituted with -O-alkyl, including but not limited to -CH2-O-CH3, -CH2CH2-O-CH3, -CH2-O-CH2CH3, -CH2(CH3)-O-CH3 and -CH2CH2-O-CH2CH2; alkoxy refers to an alkyl group substituted with a hydroxyl group (-OH), including but not limited to -O-CH3, -O-CH2CH3 and -O-CH(CH3)2.

[0203] In this invention, it is affected by one or more -O(C) 1-6 alkyl) substituted -O(C 1-6Alkyl groups, for example -CH2-O-CH3-O-CH3, -CH2CH2-O-CH2-O-CH3, -CH2CH2-O-CH2CH2-O-CH2CH3.

[0204] Unless otherwise stated, the term "haloalkoxy" as used herein refers to the aforementioned alkoxy group substituted with one or more (1, 2, 3, 4, 5, or 6) halogens (-F, -Cl, or -Br). In some embodiments, the haloalkoxy group is interchangeably -C 1-6 Halogenated alkoxy or halogenated C 1-6 alkoxy group, where -C 1-6 Halogenated alkoxy or halogenated C 1-6 C in alkoxy 1-6 This indicates that the total number of carbon atoms in the alkoxy group is 1 to 6. In some embodiments, -C 1-6 Halogenated alkoxy groups are -C 1-3 Halogenated alkoxy groups. In some embodiments, -C 1-3 The haloalkoxy group is substituted with 1, 2, 3, 4, 5, or 6 F atoms (methoxy, ethoxy, propoxy, or isopropoxy); preferably, the -C 1-3 Haloalkoxy groups include, but are not limited to, -OCF3, -CH2-O-CF3 and -CHF-O-CH3.

[0205] Unless otherwise stated, the term "aryl" as used herein refers to an unsubstituted or substituted monocyclic or polycyclic aromatic ring system containing a carbon ring atom. Preferred aryl groups are 6-10 membered aromatic ring systems, either monocyclic or bicyclic. Phenyl and naphthyl are preferred aryl groups.

[0206] Unless otherwise stated, the term "heterocyclic group" or "heterocycle" as used herein refers to an unsubstituted or substituted monocyclic or polycyclic non-aromatic ring system containing one or more heteroatoms, including monocyclic heterocyclic groups, bicyclic heterocyclic groups, bridged heterocyclic groups (including non-aromatic groups fused with aromatic ring systems), fused heterocyclic groups, and spirocyclic groups. Preferred heteroatoms include N, O, and S, including N-oxides, sulfur oxides, and dioxides. Preferably, the ring is tri- to deca-membered and is fully saturated or has one or more degrees of unsaturation. The current definition includes multiple degrees of substitution (preferably one, two, or three degrees of substitution). Examples of such heterocyclic groups include, but are not limited to, aziridine, pyrrolidine, piperidinyl, piperazine, oxoperazinyl, oxoperridinyl, oxadiazine, oxadiazine, oxadiazine, oxadiazine, heptyl, aziridine, tetrahydrofuranyl, dioxopentyl, tetrahydroimidazolyl, tetrahydrothiazolyl, pyrrolidine, tetrahydrooxazolyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone, and oxadiazolyl.

[0207] Unless otherwise stated, the term "heteroaryl" as used herein refers to an aromatic ring system containing carbon and at least one heteroatom. Heteroaryls can be monocyclic or polycyclic, substituted or unsubstituted. Monocyclic heteroaryls may have 1 to 4 heteroatoms in the ring, while polycyclic heteroaryls may contain 1 to 10 heteroatoms. Polycyclic heteroaryl rings may contain fused rings, spiro rings, or bridged rings; for example, bicyclic heteroaryls are polycyclic heteroaryls. Bicyclic heteroaryl rings may contain 8 to 12 member atoms. Monocyclic heteroaryl rings may contain 5 to 8 member atoms (carbon and heteroatoms). Examples of heteroaryl groups include, but are not limited to, thienyl, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl, pyrroleyl, thiazolyl, thiadiazolyl, triazolyl, pyridinyl, pyridazinyl, indolyl, azaindolyl, indolyl, benzimidazolyl, benzofuranyl, benzothiophenyl, benzoisoxazolyl, benzoxazolyl, benzopyrazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl, adenine, quinolinyl, or isoquinolinyl.

[0208] In pyridyl groups, tautomers can exist when the carbon atom adjacent to the N heteroatom is substituted with -OH or -NH2, for example... In this invention, when ring B is a pyridine ring ( Furthermore, when the carbon atom adjacent to the N heteroatom is replaced by -OH, tautomers can exist. .

[0209] The term "carbocyclic" refers to a substituted or unsubstituted monocyclic, bicyclic, bridged, fused, or spirocyclic non-aromatic ring system containing only carbon atoms. Preferably, the ring is tri- to ten-membered and is either fully saturated or has one or more degrees of unsaturation. Multiple degrees of substitution, preferably one, two, or three, are included within this definition. Carbocyclic groups include, but are not limited to, cycloalkyl, cycloalkenyl, and cycloynyl groups. Exemplary "cycloalkyl" groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl groups.

[0210] The term "one or more" refers to one or more. In some embodiments, "one or more" refers to 1, 2, 3, 4, 5, or 6. In some embodiments, "one or more" refers to 1, 2, 3, or 4. In some embodiments, "one or more" refers to 1, 2, or 3. In some embodiments, "one or more" refers to 1 or 2. In some embodiments, "one or more" refers to 1. In some embodiments, "one or more" refers to 2. In some embodiments, "one or more" refers to 3. In some embodiments, "one or more" refers to 4. In some embodiments, "one or more" refers to 5. In some embodiments, "one or more" refers to up to 6.

[0211] In this invention, when a ring is substituted by one or more substituents, this means that each substituent can independently substitute for each ring atom of the ring, including but not limited to ring carbon atoms or ring amine atoms. Furthermore, when the ring is a polycyclic ring, such as a fused ring, bridged ring, or spirocyclic ring, each substituent can independently substitute for each ring atom of the polycyclic ring.

[0212] The term "oxo" refers to the formation of a functional group by an oxygen atom and the carbon atom bonded to it. .

[0213] In this invention, the term "composition" is intended to cover a product containing a specific amount of a specific ingredient, as well as any product produced directly or indirectly from a combination of specific amounts of the specific ingredients. Therefore, pharmaceutical compositions containing compounds of this invention as active ingredients, and methods for preparing the compounds of this invention, are also part of this invention. Furthermore, some crystalline forms of the compounds may exist in polycrystalline form and are therefore intended to be included in this invention. Additionally, some compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also included within the scope of this invention.

[0214] The term "pharmaceutically acceptable salt" refers to a salt prepared from a pharmaceutically acceptable non-toxic alkali or acid. When the compounds of the present invention are acidic, their corresponding salts can be readily prepared from pharmaceutically acceptable non-toxic alkalis, including inorganic and organic bases. When the compounds of the present invention are basic, their corresponding salts can be readily prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Since the compounds of the present invention are intended for pharmaceutical use, they are preferably provided in substantially pure form, for example at least 60% pure, more preferably at least 75% pure, and especially at least 98% pure (% by weight).

[0215] This invention includes, within its scope, prodrugs of the compounds of this invention. Typically, such prodrugs are functional derivatives of compounds that readily convert in vivo to the desired compound. Therefore, in the therapeutic methods of this invention, the term "administration" should encompass treating various conditions with a specifically disclosed compound or with a compound that may not be specifically disclosed but is converted in vivo to the specific compound after administration to an individual. Conventional methods for selecting and preparing suitable prodrug derivatives are described, for example, in "Design of Prodrugs," ed. H. Bundgaard, Elsevier, 1985.

[0216] The definition of any substituent or variable at a specific position in a molecule is intended to be independent of the definition of substituents or variables at other positions in the molecule. It should be understood that those skilled in the art can select the substituents and substitution patterns on the compounds of the present invention to provide chemically stable compounds that can be readily synthesized using techniques known in the art and the methods set forth herein.

[0217] The compounds of this invention may contain one or more asymmetric centers, and thus may produce diastereomers and optical isomers. This invention includes all such possible diastereomers and their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and their pharmaceutically acceptable salts.

[0218] This invention includes all stereoisomers of compounds and their pharmaceutically acceptable salts. It also includes mixtures of stereoisomers and isolated specific stereoisomers. The products of these steps, either during the synthetic steps used to prepare these compounds or during the use of racemic or epimerization methods known to those skilled in the art, can be mixtures of stereoisomers.

[0219] As used in this invention, "stereoisomer" refers to isomers in a molecule that have the same order of interconnection of atoms or groups of atoms but different spatial arrangements. Stereoisomers include configurational isomers and conformational isomers. Configurational isomers include geometrical isomers and optical isomers, and optical isomers mainly include enantiomers and diastereomers. This invention encompasses all possible stereoisomers of the compound.

[0220] Some of the compounds presented in this article can exist as trans-isomers, which are conformational stereoisomers (that occur when rotation around a single bond in the molecule is prevented or greatly slowed due to steric interactions with other parts of the molecule). The compounds presented in this article include all trans-isomers, including pure, individual trans-isomers, individually enriched preparations, or mixtures of their respective nonspecificities. Separation of trans-isomers can be allowed if the rotational barrier around the single bond is high enough and the interconversion between conformations is slow enough.

[0221] This invention aims to include all isotopes of atoms present in the compounds of this invention. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and not limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of hydrogen can be represented as... 1 H (hydrogen), 2 H (deuterium) and 3 H (tritium). They are also commonly represented as D (deuterium) and T (tritium). In this application, CD3 represents methyl, where all hydrogen atoms are deuterium. Carbon isotopes include 13 C and 14 C. The isotopically labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by methods similar to those described herein, using appropriate isotopically labeled reagents instead of unlabeled reagents.

[0222] Unless otherwise stated, the term "deuterated derivative" as used herein refers to a compound having the same chemical structure as the reference compound, but in which one or more hydrogen atoms are replaced by deuterium atoms ("D"). It will be appreciated that variations in the natural isotopic abundance can occur in synthetic compounds depending on the source of the chemical materials used in the synthesis. The concentration of naturally abundant stable hydrogen isotopes is small and insignificant compared to the degree of stable isotopic substitution in the deuterated derivatives described herein. Therefore, unless otherwise stated, when referring to the "deuterated derivative" of the compounds disclosed herein, at least one hydrogen atom is substituted with deuterium at a level well above its natural isotopic abundance (typically about 0.015%). In some embodiments, the deuterated derivatives disclosed in this invention have an isotope enrichment factor of at least 3500 for each deuterium atom (containing 52.5% deuterium in each specified deuterium), at least 4500 (containing 67.5% deuterium), at least 5000 (containing 75% deuterium), at least 5500 (containing 82.5% deuterium), at least 6000 (containing 90% deuterium), at least 6333.3 (containing 95% deuterium), at least 6466.7 (containing 97% deuterium), or at least 6600 (containing 99% deuterium).

[0223] When the compounds of the present invention have tautomers, the present invention includes any possible tautomers and their pharmaceutically acceptable salts and mixtures thereof, unless otherwise specifically stated.

[0224] The pharmaceutical compositions of the present invention comprise, as an active ingredient, a compound of the present invention (or a pharmaceutically acceptable salt thereof), a pharmaceutically acceptable carrier, and optionally other therapeutic ingredients or excipients. Although the most suitable route of administration in any given case will depend on the specific host and the nature and severity of the condition (for which the active ingredient is being administered), the compositions include those suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration. The pharmaceutical compositions can be conveniently present in unit dosage forms and prepared by any method well known in the pharmaceutical field.

[0225] In practice, according to conventional pharmaceutical formulation techniques, the compounds of the present invention, or their prodrugs, metabolites, or pharmaceutically acceptable salts, can be combined as active ingredients with a pharmaceutical carrier to form a close mixture. Depending on the desired route of administration, the carrier can take various forms, such as oral or parenteral (including intravenous). Therefore, the pharmaceutical compositions of the present invention can exist as discrete units suitable for oral administration, such as capsules, pouches, or tablets, each containing a predetermined amount of the active ingredient. Furthermore, the compositions can exist as powders, granules, solutions, suspensions in aqueous liquids, non-aqueous liquids, oil-in-water emulsions, or water-in-oil emulsions. In addition to the common dosage forms described above, the compounds represented by Formula I, or their pharmaceutically acceptable salts, can also be administered via controlled-release methods and / or delivery devices. The composition can be prepared by any pharmaceutical method. Typically, such methods involve the step of combining the active ingredient with a carrier constituting one or more essential components. Typically, the composition is prepared by uniformly and closely mixing the active ingredient with a liquid carrier or a finely chopped solid carrier, or both. The product can then be conveniently shaped into the desired form.

[0226] Therefore, the pharmaceutical compositions of the present invention may include pharmaceutically acceptable carriers and compounds or pharmaceutically acceptable salts. Compounds of Formula I or pharmaceutically acceptable salts thereof may also be included in the pharmaceutical composition in combination with one or more other therapeutically active compounds.

[0227] The drug carrier used can be, for example, solid, liquid, or gas. Examples of solid carriers include lactose, gypsum powder, sucrose, talc, gelatin, agar, pectin, gum arabic, magnesium stearate, and stearic acid. Examples of liquid carriers are syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen. In preparing compositions for oral dosage forms, any convenient drug medium can be used. For example, water, ethylene glycol, oil, alcohol, flavoring agents, preservatives, coloring agents, etc., can be used to form oral liquid dosage forms such as suspensions, elixirs, and solutions; while carriers such as starch, sugar, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrants, etc., can be used to form oral solid dosage forms such as powders, capsules, and tablets. Tablets and capsules are preferred oral dosage units that use solid drug carriers due to ease of administration. Optionally, tablets can be coated using standard aqueous or non-aqueous techniques.

[0228] Tablets containing the compositions of the present invention can be prepared by compression or molding, and optionally contain one or more excipients or auxiliary ingredients. Compressed tablets can be prepared by compressing the active ingredient, such as powder or granules, in a suitable machine, optionally mixed with a binder, lubricant, inert diluent, surfactant, or dispersant. Molded tablets can be prepared by molding a mixture of powdered compounds wetted with an inert liquid diluent in a suitable machine. Each tablet preferably contains about 0.05 mg to about 5 g of the active ingredient, and each capsule or pouch preferably contains about 0.05 mg to about 5 g of the active ingredient. For example, formulations for oral administration to humans may contain about 0.5 mg to about 5 g of the active ingredient mixed with a suitable and convenient amount of a carrier substance, the carrier substance comprising about 0.05% to about 95% of the total composition. Unit dosage forms typically contain approximately 0.01 mg to approximately 2 g of the active ingredient, usually in doses of 0.01 mg, 0.02 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, 1000 mg, 1500 mg, or 2000 mg.

[0229] The pharmaceutical compositions of the present invention suitable for parenteral administration can be prepared as solutions or suspensions of the active compound in water. Suitable surfactants, such as hydroxypropyl cellulose, may be included. The dispersions can also be prepared in glycerol, liquid polyethylene glycol, and mixtures thereof in oil. Furthermore, preservatives may be included to prevent harmful microbial growth.

[0230] The pharmaceutical compositions of the present invention suitable for injectable use comprise sterile aqueous solutions or dispersions. Alternatively, the composition may be in the form of a sterile powder for the ad hoc preparation of such sterile injectable solutions or dispersions. In all cases, the final injectable form must be sterile and must be effectively flowable for injection. The pharmaceutical composition must be stable under the conditions of manufacture and storage; therefore, it is best to preserve it to prevent contamination by microorganisms such as bacteria and fungi. The carrier may be, for example, a solvent or dispersion medium containing water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.

[0231] The pharmaceutical compositions of the present invention can be in forms suitable for topical application, such as aerosols, creams, ointments, lotions, powders, etc. Furthermore, the compositions can be in forms suitable for transdermal devices. These formulations can be prepared using conventional processing methods, utilizing compounds of Formula I of the present invention or pharmaceutically acceptable salts thereof. For example, creams or ointments can be prepared by mixing a hydrophilic material and water with about 0.05 wt% to about 10 wt% of the compound to produce a cream or ointment with the desired consistency.

[0232] The pharmaceutical compositions of the present invention can be in a form suitable for rectal administration, wherein the carrier is solid. Preferably, the mixture is formed into a unit-dose suppository. Suitable carriers include cocoa butter and other materials commonly used in the art. Suppositories can be conveniently formed by first mixing the composition with a softened or melted carrier, then cooling and molding it in a mold.

[0233] In addition to the carrier components described above, the pharmaceutical formulations may suitably contain one or more other carrier components, such as diluents, buffers, flavoring agents, binders, surfactants, thickeners, lubricants, preservatives (including antioxidants), etc. Furthermore, other excipients may be included to make the formulation isotonic with the blood of the intended recipient. Compositions containing compounds of Formula I or pharmaceutically acceptable salts thereof may also be prepared in powder or liquid concentrate form.

[0234] Typically, dosage levels of approximately 0.001 mg / kg to approximately 150 mg / kg body weight per day are used to treat the above-mentioned conditions, or approximately 0.05 mg to approximately 7 g per patient per day. For example, administering the compound at approximately 0.001 to 50 mg per kilogram of body weight per patient per day, or administering the compound at approximately 0.05 mg to approximately 3.5 g per patient per day, can be effective in treating inflammation, cancer, psoriasis, allergies / asthma, immune system disorders and conditions, and central nervous system (CNS) disorders and conditions.

[0235] However, it should be understood that the specific dosage level for any particular patient will depend on a variety of factors, including age, weight, general health condition, sex, diet, timing of administration, route of administration, excretion rate, combination of drugs, and the severity of the specific disease being treated.

[0236] Unless the context otherwise indicates, when a value is expressed as “about” X or “approximately” X, the value of X will be understood to be accurate to ±10%, preferably ±5% or ±2%.

[0237] These and other aspects will become apparent from the following written description of the invention.

[0238] Preparation method The compounds of this invention can be synthesized from commercially available reagents using the synthetic methods and reaction routes described herein. Examples of specific synthetic routes are provided, along with the following general routes, intended to guide synthetic chemists in the art. They will readily understand that solvents, concentrations, reagents, protecting groups, the order of synthetic steps, time, temperature, etc., can be modified as needed within the skill and judgment of a person skilled in the art.

[0239] Example The following examples are provided to better illustrate the invention. All ingredients and percentages are by weight, and all temperatures are in degrees Celsius unless otherwise explicitly stated. The following abbreviations are used in the examples:

[0240] General Synthesis Method In this invention, R4, R5, R6, R7, R8, R9, R 10 R 81 R Y2 Y1, ring B, R S1 R S2 R S3 The definition of n1, n2, n3, n4, or n5 in each occurrence of equation (I-1-1), equation (I-1-1A), equation (I-1-1B), equation (I-1-1C), equation (I-1-1D), equation (I-1-1A'), equation (I-1-1B'), equation (I-1-1C'), equation (I-1-1D'), equation (I-1-1E'), equation (I-2-1), equation (I-2-1A), equation (I-2-1B), equation (I-2-1C), equation (I-2-1D), equation (I-2-1E), equation (I-2-2), equation (I-2-2A), equation (I-2-2B), equation (I-2-2C), equation (I-2-2D), equation (I-2-2E), or equation (I-2-2G).

[0241] Preparation of formula (I-1-1) The compound of formula (I-1-1) can be prepared according to step A or step B or other methods described herein.

[0242] or The above in LG1-Y3-R 81LG1 in the formula (I-1-1E') or LG2 in the formula is a leaving group or a group that can be converted into a leaving group; in some embodiments, the leaving group is selected from halogens (such as -Cl, -Br or -I), -OMs, -OTs or -OTf; in some embodiments, the group that can be converted into a leaving group is selected from -OH and can be converted into leaving groups including but not limited to -Cl, -Br, -I, -OMs, -OTs or -OTf. The above in LG1-Y3-R 81 Y3 in the formula (I-1-1E') or Y4 in the formula is -C(=O)-, -S(=O)- or -S(=O)2-.

[0243] Preparation of formula (I-1-1D) The compounds of formula (I-1-1D) are obtained from the compounds of formula (I-1-1A) according to the Scheme 1 reaction described herein or by other methods.

[0244] The compound of formula (I-1-1B) can be reacted with the compound of formula (I-1-1A) It is prepared by substitution reaction between them.

[0245] Compounds of formula (I-1-1C) can react with compounds of formula (I-1-1B). Y5 is prepared by a condensation reaction between two substances, wherein Y5 is -C(=O)-, -S(=O)-, or -S(=O)2-; or a compound of formula (I-1-1C) can be prepared by a condensation reaction between a compound of formula (I-1-1B) and a compound of formula (I-1-1C). The compound is prepared by substitution reaction between the two compounds; or the compound of formula (I-1-1C) can be prepared by reaction of the compound of formula (I-1-1B) with the compound of formula (I-1-1B). Preparation by coupling reaction in the presence of a catalyst; the catalyst includes, but is not limited to, monovalent copper catalyst, palladium (0) catalyst or palladium (2) catalyst; the monovalent copper catalyst includes, but is not limited to, CuI; the palladium (0) catalyst includes, but is not limited to, Pd(PPh)4, Pd2(dba)3 or Pd(dba)2; the palladium (2) catalyst includes, but is not limited to, Pd(TFA)2, Pd(OAc)2, PdCl2, Pd(PPh)3Cl2 or Pd(OTf)2.

[0246] The compound of formula (I-1-1D) can be prepared by a reduction reaction between the compound of formula (I-1-1C) and a reducing agent; the reducing agent includes, but is not limited to, palladium on carbon (Pd / C) and hydrogen, or iron powder.

[0247] The LG3 is in In the middle, LG4 is In China, and LG5 in The group is a leaving group or a group that can be converted into a leaving group; in some embodiments, the leaving group is selected from halogens (such as -Cl, -Br or -I), -OMs, -OTs or -OTf; in some embodiments, the group that can be converted into a leaving group is selected from -OH and can be converted into leaving groups including but not limited to -Cl, -Br, -I, -OMs, -OTs or -OTf.

[0248] Preparation of formula (I-1-1E') Compounds of formula (I-1-1E') can be prepared from compounds of formula (I-1-1A') according to scheme 2 or other methods described herein.

[0249] Compounds of formula (I-1-1B') can react with compounds of formula (I-1-1A'). It is prepared by substitution reaction between them.

[0250] Compounds of formula (I-1-1C') can react with compounds of formula (I-1-1B'). Y5 is prepared by a condensation reaction between two substances, wherein Y5 is -C(=O)-, -S(=O)-, or -S(=O)2-; or a compound of formula (I-1-1C') can be prepared by a condensation reaction between a compound of formula (I-1-1B') and a compound of formula (I-1-1B'). The compound is prepared by substitution reaction between the two compounds; or the compound of formula (I-1-1C') can be prepared by reaction with the compound of formula (I-1-1B'). Preparation by coupling reaction in the presence of a catalyst; the catalyst includes, but is not limited to, monovalent copper catalyst, palladium (0) catalyst or palladium (2) catalyst; the monovalent copper catalyst includes, but is not limited to, CuI; the palladium (0) catalyst includes, but is not limited to, Pd(PPh)4, Pd2(dba)3 or Pd(dba)2; the palladium (2) catalyst includes, but is not limited to, Pd(TFA)2, Pd(OAc)2, PdCl2, Pd(PPh)3Cl2 or Pd(OTf)2.

[0251] In formulas (I-1-1A'), (I-1-1B'), and (I-1-1C'), LG6 is a leaving group selected from halogens (such as -Cl, -Br, or -I), -OMs, -OTs, or -OTf.

[0252] The compound of formula (I-1-1D') can be prepared by coupling the compound of formula (I-1-1C') with H-Y6-LG7 in the presence of a palladium (O) catalyst; the palladium (O) catalyst includes, but is not limited to, Pd(PPh)4, Pd2(dba)3 or Pd(dba)2; preferably, the palladium (O) catalyst is Pd2(dba)3. Y6 is -S- or -CH2-; LG7 is a leaving group that can be removed from formula (I-1-1D') in subsequent oxidation reactions, such as benzyl or methyl; The compound of formula (I-1-1E') is obtained by oxidizing the compound of formula (I-1-1D') in the presence of an oxidizing agent, including but not limited to NCS or 1,3-dichloro-5,5-dimethylhydantoin, and also providing a leaving group -LG2 in the oxidation reaction; when -Y6- is -CH2-, it is oxidized to form -C(=O)-; when -Y6- is -S-, it is oxidized to form -S(=O)- or -S(=O)2-.

[0253] The LG3 is in In the middle, LG4 is In China, and LG5 in The group is a leaving group or a group that can be converted into a leaving group; in some embodiments, the leaving group is selected from halogens (such as -Cl, -Br or -I), -OMs, -OTs or -OTf; in some embodiments, the group that can be converted into a leaving group is selected from -OH and can be converted into leaving groups including but not limited to -Cl, -Br, -I, -OMs, -OTs or -OTf.

[0254] Preparation of formula (I-2-1) Compounds of formula (I-2-1) can be prepared from compounds of formula (I-2-1A) according to scheme 3 or other methods described herein.

[0255] The compound of formula (I-2-1) can be reacted with the compound of formula (I-2-1E) The compound is prepared by a condensation reaction between the two compounds; Y5 is -C(=O)-, -S(=O)-, or -S(=O)2-; or the compound of formula (I-2-1) can be prepared by a condensation reaction between the compound of formula (I-2-1E) and the compound of formula (I-2-1E). The compound is prepared by substitution reaction between the two compounds; or the compound of formula (I-2-1) can be prepared by reaction of the compound of formula (I-2-1E) with the compound of formula (I-2-1E). Preparation by coupling reaction in the presence of a catalyst; the catalyst includes, but is not limited to, monovalent copper catalyst, palladium (0) catalyst or palladium (2) catalyst; the monovalent copper catalyst includes, but is not limited to, CuI; the palladium (0) catalyst includes, but is not limited to, Pd(PPh)4, Pd2(dba)3 or Pd(dba)2; the palladium (2) catalyst includes, but is not limited to, Pd(TFA)2, Pd(OAc)2, PdCl2, Pd(PPh)3Cl2 or Pd(OTf)2.

[0256] The compound of formula (I-2-1E) is obtained by deprotection reaction of the compound of formula (I-2-1D).

[0257] Compounds of formula (I-2-1D) can react with compounds of formula (I-2-1C). It is prepared by substitution reaction between them.

[0258] The compound of formula (I-2-1C) is obtained from the compound of formula (I-2-1B) in the presence of an amino protecting agent; said amino protecting agent is a protecting agent for a primary or secondary amine; preferably, said amino protecting agent is a primary amine protecting agent, including but not limited to... The Poc1 is a -NH2 protecting group, preferably, Poc1 is... .

[0259] The compound of formula (I-2-1B) can be prepared by reacting the compound of formula (I-2-1A) with hydrazine.

[0260] The LG3 is in In the middle, LG4 is In China, and LG5 in The group is a leaving group or a group that can be converted into a leaving group; in some embodiments, the leaving group is selected from halogens (such as -Cl, -Br or -I), -OMs, -OTs or -OTf; in some embodiments, the group that can be converted into a leaving group is selected from -OH and can be converted into leaving groups including but not limited to -Cl, -Br, -I, -OMs, -OTs or -OTf.

[0261] Preparation of formula (I-2-2) The compound of formula (I-2-2) can be prepared from the compound of formula (I-2-2G) according to step C or other methods described herein.

[0262] The compound of formula (I-2-2) can react with R through the compound of formula (I-2-2G). Y3Preparation by substitution / condensation / alkylation / arylation reactions between -X; wherein X includes, but is not limited to, halogens (such as -Cl, -Br, -I), -OH, -OMs, -OTs or -OTf.

[0263] Compounds of formula (I-2-2G) can be prepared from compounds of formula (I-2-2A) according to scheme 4 or other methods described herein.

[0264] The compound of formula (I-2-2G) is obtained by the deprotection reaction of Poc2 in formula (I-2-2F).

[0265] Compounds of formula (I-2-2F) can react with compounds of formula (I-2-2E). The compound is prepared by a condensation reaction between two substances; Y5 is -C(=O)-, -S(=O)-, or -S(=O)2-; or a compound of formula (I-2-2F) can be prepared by a condensation reaction between a compound of formula (I-2-2E) and... The compound is prepared by substitution reaction between the two compounds; or the compound of formula (I-2-2F) can be prepared by reaction of the compound of formula (I-2-2E) with the compound of formula (I-2-2E). Preparation by coupling reaction in the presence of a catalyst; the catalyst includes, but is not limited to, monovalent copper catalyst, palladium (0) catalyst or palladium (2) catalyst; the monovalent copper catalyst includes, but is not limited to, CuI; the palladium (0) catalyst includes, but is not limited to, Pd(PPh)4, Pd2(dba)3 or Pd(dba)2; the palladium (2) catalyst includes, but is not limited to, Pd(TFA)2, Pd(OAc)2, PdCl2, Pd(PPh)3Cl2 or Pd(OTf)2.

[0266] The compound of formula (I-2-2E) is obtained by deprotection reaction of Poc1 in formula (I-2-2D).

[0267] Compounds of formula (I-2-2D) can react with compounds of formula (I-2-2C). It is prepared by substitution reaction between them.

[0268] The compound of formula (I-2-2C) is obtained from the compound of formula (I-2-2B) in the presence of an amino protecting agent; said amino protecting agent is a protecting agent for a primary or secondary amine; preferably, said amino protecting agent is a primary amine protecting agent, including but not limited to... The Poc1 is a -NH2 protecting group, preferably, Poc1 is... .

[0269] The compound of formula (I-2-2B) can be prepared by reacting the compound of formula (I-2-2A) with hydrazine.

[0270] In formulas (I-2-2A), (I-2-2B), (I-2-2C), (I-2-2D), (I-2-2E), and (I-2-2F), Poc2 includes, but is not limited to, tert-butyloxycarbonyl, which is a protecting group for the nitrogen atom.

[0271] The LG3 is in In the middle, LG4 is In China, and LG5 in The group is a leaving group or a group that can be converted into a leaving group; in some embodiments, the leaving group is selected from halogens (such as -Cl, -Br or -I), -OMs, -OTs or -OTf; in some embodiments, the group that can be converted into a leaving group is selected from -OH and can be converted into leaving groups including but not limited to -Cl, -Br, -I, -OMs, -OTs or -OTf.

[0272] Intermediate 1 (INT 1) Potassium hydroxide (KOH, 5.04 g, 2.00 equivalents) was added to a solution of 5-nitro-1H-indazole-3-amine (8.00 g, 1.00 equivalents) in dimethyl sulfoxide (DMSO, 80.0 mL) at 20 °C. After stirring for 10 minutes, 1-(bromomethyl)-4-(trifluoromethyl)benzene (11.3 g, 1.05 equivalents) was added dropwise to DMSO (8.00 mL). The reaction mixture was stirred at 20 °C for 1 hour, diluted with H2O (100 mL), and extracted with ethyl acetate (EA, 200 mL). The combined organic layers were washed with saturated brine (50 mL), dried over sodium sulfate (Na2SO4), and concentrated under reduced pressure to give a residue, which was purified by silica gel column chromatography (eluting with petroleum ether / ethyl acetate) to give INT1-1 (4.77 g) solid. LCMS: m / z = 337.1 [M+1] + .

[0273] INT1-1 (4.70 g, 1.00 equivalent) was dissolved in pyridine (28.2 mL), and EDCI (4.02 g, 1.50 equivalent) and 2-methylfuran-3-carboxylic acid (1.94 g, 1.10 equivalent) were added. The reaction mixture was stirred at 20 °C for 12 h, diluted with H2O (100 mL), and then extracted with ethyl acetate (100 mL). The combined organic layers were concentrated under reduced pressure to obtain a residue, which was purified by silica gel column chromatography (eluting with petroleum ether / ethyl acetate) to give INT1-2 (5.10 g) as a solid. LCMS: m / z = 445.1 [M+1] + .

[0274] INT1-2 (1.00 g, 1.00 equivalent) was dissolved in ethanol (EtOH, 10.0 mL) and H2O (10.0 mL), and ammonium chloride (NH4Cl, 963 mg, 8.00 equivalent) and iron powder (628 mg, 5.00 equivalent) were added. The reaction mixture was stirred at 80 °C for 2 hours, diluted with H2O (50 mL), and then extracted with ethyl acetate (80 mL). The combined organic layers were washed with saturated brine (50 mL), dried over sodium sulfate (Na2SO4), and concentrated under reduced pressure to give INT1 (800 mg, 85.9% yield) as a solid. LCMS: m / z = 415.1 [M+1] + . 1 HNMR (400 MHz, DMSO- d6 ): δ 10.15 (s, 1H), 7.69 (d, J = 8.4 Hz, 2H), 7.59 (d, J = 1.6 Hz, 1H), 7.46 - 7.36 (m, 3H), 7.13 (s, 1H), 6.86 (dd, J = 8.8Hz, J = 1.6 Hz, 1H), 6.78 (s, 1H), 5.60 (s, 2H), 5.44 (s, 2H), 2.56 (s, 3H). Intermediate 2 (INT2) 2-O-cyclopentane-1-carboxynitrile (4.00 g, 1.0 equivalent) was dissolved in a mixture of H₂O (8.00 mL) and ethanol (EtOH, 80.0 mL), and hydrazine hydrochloride (5.02 g, 2.0 equivalent) was added. The reaction mixture was stirred at 80 °C for 2 hours, and then concentrated under reduced pressure to give a crude product of INT₂-₁ (7.20 g), which was used directly in the next reaction without further purification. LCMS: m / z = 124.2 [M+1] + .

[0275] The crude product of INT2-1 (3.00 g) was dissolved in 1,4-dioxane (30.0 mL), and molecular sieves (0.5 g) and isobenzofuran-1,3-dione (5.05 g, 1.4 equivalents) were added. The reaction mixture was stirred at 100 °C for 10 hours, and then concentrated under reduced pressure to give INT2-2 (5.00 g, 81.1% yield) as a solid. LCMS: m / z = 254.2 [M+1] + .

[0276] INT2-2 (2.00 g, 1.0 equivalent) and potassium carbonate (K2CO3, 2.18 g, 2.0 equivalent) were dissolved in acetonitrile (ACN, 20.0 mL), and 1-(bromomethyl)-4-(trifluoromethyl)benzene (4.72 g, 2.5 equivalent) was added. The reaction mixture was stirred at 50 °C for 18 hours and then filtered. The filtrate was concentrated under reduced pressure to give crude INT2-3 (3.50 g), which was used directly in the next reaction without further purification. LCMS: m / z = 412.1 [M+1] + .

[0277] The crude product of INT2-3 (3.50 g) was dissolved in ethanol (20.0 mL), and hydrazine hydrate (NH2-NH2·H2O, 3.68 g, 9.0 equivalents) was added. The mixture was stirred at 80 °C for 10 hours and then filtered. The filtrate was concentrated under reduced pressure to obtain a residue, which was purified by silica gel column chromatography (eluting with petroleum ether / ethyl acetate) to give INT2 (300 mg, 13.5% yield) as a solid. LCMS: m / z = 282.1 [M+1] + .

[0278] 1 HNMR (400 MHz, MeOH- d 4 ): δ 7.62 (d, J = 8.4 Hz, 2H), 7.31 (d, J= 8.0 Hz, 2H), 5.07 (s, 2H), 2.58 - 2.55 (m, 2H), 2.53 - 2.49 (m, 4H). The intermediates in the table below can be synthesized using the corresponding starting materials through the INT2 synthesis process or its modified process.

[0279] Intermediate 8 (INT8) INT8-1 (50.0 g, 237 mmol) was dissolved in ethanol (EtOH, 1.00 L), and hydrazine hydrochloride (NH2NH2·HCl, 16.7 g, 237 mmol) was added. The reaction mixture was reacted at 15 °C. The reaction mixture was stirred at 60 °C for 5 hours, and then concentrated under reduced pressure to obtain a residue. The residue was dissolved in an aqueous sodium bicarbonate solution (aq. NaHCO3, 300 mL) and extracted with ethyl acetate (EtOAc, 300 mL × 3). The combined organic layers were washed with saturated brine (100 mL), dried over sodium sulfate (Na2SO4), and then concentrated under reduced pressure to give crude INT8-2 (40.0 g), which was used directly in the next reaction without further purification. LCMS: m / z = 225.1 [M+1] + . 1 HNMR: (400 MHz, DMSO-d6) δ 5.92 - 5.14 (m, 3H), 4.31 (d, J = 16.5 Hz, 2H), 4.21 (d, J = 11.1 Hz (2H), 1.43 (s, 9H) At 15 °C, DMF-DMA (42.5 g, 357 mmol, 47.4 mL, 2.00 equivalents) was added to a mixture of INT8-2 (40.0 g, 178 mmol) in toluene (400 mL). The reaction mixture was stirred at 110 °C for 2 hours, and then concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (eluting gradient PE / EA = 100 / 1 to 0 / 1) to give INT8-3 (20.0 g, 67.6 mmol, 37.9% yield) as a brown oil. LCMS: m / z = 280.3 [M+1] + . 1 HNMR(400 MHz, DMSO-d6) δ 11.91 (s, 1H), 7.77 (d, J= 5.5 Hz, 1H), 4.37(d, J = 3.2 Hz, 2H), 4.20 (d, J = 10.7 Hz, 2H), 3.03 (s, 3H), 2.90 (s, 3H), 1.46(d, J = 2.7 Hz, 9H). INT8-3 (20.0 g, 71.6 mmol) was dissolved in acetonitrile (MeCN, 400 mL), and potassium carbonate (K₂CO₃, 24.7 g, 179 mmol) and 4-(trifluoromethyl)benzyl bromide (25.6 g, 107 mmol, 16.6 mL) were added. The reaction mixture was stirred at 80 °C for 12 hours and then filtered. The filtrate was concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (eluting gradient EA / MeOH = 100 / 1 to 0 / 1) to give INT8-4 (20.0 g, 40.7 mmol, 56.8% yield) as a pale yellow solid. LCMS: m / z = 438.2 [M+1] + .

[0280] INT8-4 (18.0 g, 41.2 mmol) was dissolved in acetonitrile (MeCN, 180 mL), and hydrazine hydrate (NH2NH2·H2O, 20.6 g, 329 mmol, 19.9 mL, 80% purity, 8.00 equivalents) was added. The reaction mixture was stirred at 60 °C for 16 hours, and then concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (eluting gradient PE / EA = 100 / 1 to 0 / 1) to give INT8 (13.0 g, 33.3 mmol, 80.97% yield) as a white solid. LCMS: m / z = 383.1 [M+1] + .

[0281] 1 HNMR(400 MHz, CDCl3) δ 7.58 - 7.48 (m, 2H), 7.23 (d, J = 8.0 Hz, 2H), 4.98 (d, J = 3.3 Hz, 2H), 4.26 - 4.07 (m, 4H), 1.40 (d, J = 6.1 Hz, 9H). Intermediate 9 (INT9) 5-Bromo-1H-indazole-3-amine (2.00 g, 9.43 mmol) was dissolved in dimethyl sulfoxide (DMSO, 20.0 mL) at 20 °C, potassium hydroxide (KOH, 1.06 g, 18.8 mmol) was added, followed by dropwise addition of 1-(bromomethyl)-4-(trifluoromethyl)benzene (2.37 g, 9.90 mmol, 1.53 mL). The reaction mixture was stirred at 20 °C for 2 hours, diluted with H₂O (20 mL), and extracted with dichloromethane (DCM, 50 mL). The combined organic layers were washed with saturated brine (10 mL), dried over sodium sulfate (Na₂SO₄), and concentrated under reduced pressure to obtain a residue, which was purified by silica gel column chromatography (eluting with petroleum ether / ethyl acetate) to give INT9-1 (3.00 g, 8.10 mmol) as a solid. LCMS: m / z = 370.1 / 372.1 [M+1] + .

[0282] INT9-1 (3.00 g, 8.10 mmol) was dissolved in pyridine (15.0 mL), and EDCI (2.33 g, 12.1 mmol, 1.50 equivalent) and 2-methylfuran-3-carboxylic acid (1.12 g, 8.91 mmol, 1.10 equivalent) were added. The reaction mixture was stirred at 20 °C for 12 hours. The reaction mixture was diluted with H2O (100 mL) and extracted with dichloromethane (DCM, 200 mL). The combined organic layers were washed with saturated brine (100 mL), dried over sodium sulfate (Na2SO4), and concentrated under reduced pressure to obtain a residue, which was purified by silica gel column chromatography (eluting with petroleum ether / ethyl acetate) to give INT9-2 (2.50 g, 5.23 mmol) as a solid. LCMS: m / z = 500.0 / 502.0 [M+1] + .

[0283] INT9-2 (1.50 g, 3.14 mmol) was dissolved in dioxane (15.0 mL), and diisopropylethylamine (DIEA, 810 mg, 6.27 mmol, 1.09 mL, 2.00 equivalents), xantphos (181 mg, 313 μmol, 0.10 equivalents), benzylthiophenol (BnSH, 0.73 g, 5.88 mmol, 688 μL, 1.87 equivalents) and dichlorodiphenylphosphine palladium (Pd2(dba)3, 143 mg, 156 μmol, 0.05 equivalents) were added. The reaction mixture was stirred at 90 °C for 4 hours, diluted with H2O (20 mL), and then extracted with dichloromethane (DCM, 50 mL). The combined organic layers were washed with saturated brine (10 mL), dried over sodium sulfate, and then concentrated under reduced pressure to obtain a residue. This residue was purified by silica gel column chromatography (eluting with petroleum ether / ethyl acetate) to give INT9-3 (1.20 g, 2.30 mmol) as an oil. LCMS: m / z = 522.1 [M+1] + .

[0284] 1 HNMR(400 MHz, CDCl3) δ 8.17 (s, 1H), 7.57 (s, 1H), 7.56 (d, J = 8.0 Hz,2H), 7.26-7.34 (m, 5H), 7.13-7.16 (m, 4H), 6.58 (d, J = 2.0 Hz, 1H), 5.50 (s, 2H), 4.13 (s, 2H), 2.69 (s, 3H). DCDMH (113 mg, 575 μmol) was added to INT9-3 (200 mg, 383.47 μmol, 1.00 equivalent) dissolved in a mixed solvent of acetonitrile (ACN, 4.00 mL), H2O (0.50 mL), and acetic acid (AcOH, 0.80 mL). The mixture was stirred at 0 °C for 1 hour, diluted with H2O (8 mL), and then extracted with ethyl acetate (EA, 10 mL × 3). The combined organic layers were washed with an aqueous solution of sodium bicarbonate (aq. NaHCO3, 10 mL), dried over sodium sulfate, and concentrated under reduced pressure to give INT9 (250 mg), which was used directly in the next reaction without further purification.

[0285] Intermediate 10 (INT10) Potassium hydroxide (KOH, 2.65 g, 47.1 mmol) was added to a solution of 6-bromo-1H-indazole-3-amine (5.00 g, 23.5 mmol, 1.00 equivalent) in dimethyl sulfoxide (DMSO, 100 mL) at 20 °C. After stirring for 10 min, 1-(bromomethyl)-4-(trifluoromethyl)benzene (5.92 g, 24.7 mmol, 3.82 mL) was added dropwise. The reaction mixture was stirred at 20 °C for 2 h, diluted with H₂O (50 mL), and then extracted with ethyl acetate (EA, 200 mL). The combined organic layers were washed with saturated brine (50 mL), dried over sodium sulfate (Na₂SO₄), and concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (eluting gradient PE / EA = 10 / 1 to 0 / 1) to give INT10-1 (4.00 g, 10.8 mmol, 45.8% yield) as a yellow solid. 1 HNMR (400 MHz, DMSO- d 6 ) δ 7.82 (s, 1H), 7.64-7.82 (m, 3H), 7.35 (d, J = 8.0 Hz, 2H), 7.06 (dd, J = 8.4 Hz, J = 1.6 Hz, 1H), 5.67 (s, 2H), 5.42 (s, 2H). INT10-1 (4.00 g, 10.8 mmol, 1.00 equivalent) was dissolved in pyridine (24.0 mL), and EDCI (3.11 g, 16.2 mmol, 1.50 equivalent) and 2-methylfuran-3-carboxylic acid (1.50 g, 11.8 mmol, 1.10 equivalent) were added. The reaction mixture was stirred at 20 °C for 12 h, diluted with H2O (50 mL), and extracted with ethyl acetate (EA, 200 mL). The combined organic layers were washed with saturated brine (50 mL), dried over sodium sulfate (Na2SO4), and concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (eluting gradient PE / EA = 10 / 1 to 0 / 1) to give INT10-2 (3.00 g, 6.27 mmol, 58.0% yield) as a yellow solid.

[0286] Under a nitrogen atmosphere, palladium chloride (Pd(dppf)Cl2, 458 mg, 627 μmol, 0.1 equivalent) and triethylamine (TEA, 1.90 g, 18.8 mmol, 3.00 equivalent) were added to a solution of INT10-2 (3.00 g, 6.27 mmol) in methanol (MeOH, 18.0 mL). The reaction mixture was washed repeatedly with carbon monoxide (CO), then stirred at 70 °C for 12 hours under a CO atmosphere (50 psi), and then filtered. The filtrate was concentrated under reduced pressure to obtain a residue, which was purified by silica gel column chromatography (eluting gradient PE / EA = 10 / 1 to 0 / 1) to give INT10-3 (1.40 g, 46.3% yield) as a yellow solid. 1 HNMR(400 MHz, CDCl3)δ 8.21 (d, J = 8.8 Hz, 1H), 8.08 (s, 1H), 8.04 (s, 1H), 7.82 (d, J = 8.8 Hz, 1H), 7.57 (d, J = 8.4 Hz, 2H), 7.28-7.34 (m, 3H), 6.59 (d, J = 2.0 Hz, 1H), 5.59 (s, 2H), 3.96 (s, 3H), 2.68 (s, 3H). INT10-3 (0.80 g, 1.75 mmol, 1.00 equivalent) was dissolved in tetrahydrofuran (THF, 16.0 mL), and lithium aluminum hydride (LAH, 331 mg, 8.75 mmol, 5.00 equivalent) was added. The reaction mixture was stirred at 0 °C for 2 h, quenched with H2O (5 mL) at 0 °C, and then extracted with ethyl acetate (EA, 100 mL). The combined organic layers were washed with saturated brine (10 mL), dried over sodium sulfate, and concentrated under reduced pressure to give crude INT10-4 (0.52 g), which was used directly in the next reaction without further purification. 1 HNMR (400 MHz, DMSO- d 6 ) δ .10.39 (s, 1H), 7.69-7.72 (m, 3H), 7.60(d, J = 2.8 Hz, 2H), 7.40 (d, J = 8.0 Hz, 2H), 7.16 (s, 1H), 7.08-7.09 (m, 1H),5.70 (s, 2H), 5.31 (t, J = 5.6 Hz, 1H), 4.62 (d,J = 5.6 Hz, 2H), 2.57 (s, 3H). INT10-4 (0.30 g, 698 μmol, 1.00 equivalent) was dissolved in dichloromethane (DCM, 3.00 mL), and N-bromosuccinimide (NBS, 248 mg, 1.40 mmol, 2.00 equivalent) and triphenylphosphine (PPh3, 274 mg, 1.05 mmol, 1.50 equivalent) were added. The reaction mixture was stirred at 20 °C for 3 hours, and then concentrated under reduced pressure to obtain a residue. The residue was purified by preparative thin-layer chromatography (prep-TLC, SiO2, eluent gradient PE / EA = 3 / 1) to give INT10-5 (200 mg, 406 μmol, 58.1% yield) as a yellow oil.

[0287] INT10-5 (200 mg, 406 μmol, 1.00 equivalent) was dissolved in acetonitrile (ACN, 2.00 mL), and trimethylsilyl cyanide (TMSCN, 80.6 mg, 812 μmol, 101 μL, 2.00 equivalent) and potassium carbonate (140 mg, 1.02 mmol, 2.50 equivalent) were added. The reaction mixture was stirred at 80 °C for 12 h, diluted with H2O (5 mL), and extracted with ethyl acetate (EA, 20 mL). The combined organic layers were washed with saturated brine (5 mL), dried over sodium sulfate, and concentrated under reduced pressure to obtain a residue, which was purified by preparative thin-layer chromatography (prep-TLC, SiO2, eluent gradient PE / EA = 3 / 1) to give INT10 (120 mg, 273 μmol, 67.3% yield) as a yellow oil.

[0288] Intermediate 11 (INT11) INT8 (780 mg, 2.04 mmol, 1.00 equivalent) was dissolved in pyridine (8 mL), and EDCI (626 mg, 3.26 mmol, 1.60 equivalent) and 2-methylfuran-3-carboxylic acid (334.42 mg, 2.65 mmol, 1.3 equivalent) were added. The reaction mixture was stirred at 20 °C for 12 hours, poured into H2O (20.0 mL), and then extracted with ethyl acetate (EtOAc, 30.0 mL × 3). The combined organic layers were washed with saturated brine (20.0 mL), dried over sodium sulfate, and concentrated under reduced pressure to obtain a residue, which was purified by silica gel column chromatography (eluting gradient PE / EA = 50 / 1 to 1 / 1) to give INT11-1 (780 mg, 1.27 mmol, 62.4% yield) as a yellow solid.

[0289] INT11-1 (730 mg, 1.49 mmol, 1.00 equivalent) was dissolved in dichloromethane (DCM, 4.0 mL), and trifluoroacetic acid (TFA, 1.54 g, 13.5 mmol, 1.00 mL, 9.07 equivalent) was added. The reaction mixture was stirred at 20 °C for 12 hours, and then concentrated under reduced pressure to give INT11 (1.00 g) as a yellow solid.

[0290] Intermediate 12 (INT12) INT11 (100 mg, 256 μmol) and tert-butyl-3-oxoazacyclobutane-1-carboxylic acid ester (65.7 mg, 384 μmol) were dissolved in methanol (MeOH, 1.00 mL), and acetic acid (AcOH, 1.54 mg, 25.6 μmol, 1.47 μL, 0.100 equivalent) and sodium borohydride (NaBH3CN, 40.2 mg, 640 μmol, 2.50 equivalent) were added and reacted at 20 °C. The reaction mixture was stirred at 50 °C for 12 hours and then concentrated under reduced pressure to obtain a residue, which was purified by preparative thin-layer chromatography (prep-TLC, SiO2, eluent gradient DCM / MeOH = 10 / 1) to give INT12-1 (70.0 mg, 128 μmol, 50.09% yield) as a yellow solid.

[0291] INT12-1 (70.0 mg, 128 μmol, 1.00 equivalent) was dispersed in HCl / dioxane (700 μL) and stirred at 20 °C for 1 hour, then concentrated under reduced pressure to obtain a residue. The residue was purified by preparative high performance liquid chromatography (prep-HPLC, column: Phenomenex Luna C18 100 × 30 mm × 3 μm; mobile phase: H2O (0.04% HCl) / ACN; mobile phase gradient: 5%-40% ACN; flow rate: 8.0 min) to obtain INT12 hydrochloride (35.59 mg, 77.1 μmol, 60.1% yield) as a white solid.

[0292] 1 HNMR (400 MHz, DMSO- d 6 ) δ 10.71 (s, 1H), 9.67 (d, J = 2.3 Hz, 1H), 9.24- 9.08 (m, 1H), 7.75 (d, J = 8.2 Hz, 2H), 7.56 (d, J = 2.0 Hz, 1H), 7.49 (d, J=7.9 Hz, 2H), 7.16 (d, J = 2.0 Hz, 1H), 5.34 (s, 2H), 4.80 - 4.32 (m, 7H), 4.26- 4.17 (m, 2H), 2.54 (s, 3H). Intermediate 13 (INT13) Sodium tert-butoxide (377 mg, 3.92 mmol, 3.00 equivalent) was added to a solution of INT8 (500 mg, 1.31 mmol) and 3-bromo-5-methylpyridine (269 mg, 1.57 mmol) in dioxane (5.00 mL) at 20 °C. Then, BrettPhos Pd G3 (118 mg, 130 μmol, 0.100 equivalent) was added under a nitrogen atmosphere. The reaction mixture was stirred at 100 °C for 12 hours and then filtered. The filtrate was concentrated under reduced pressure to obtain a residue, which was purified by silica gel column chromatography (eluting gradient of DCM / MeOH = 100 / 1 to 10 / 1) to give INT13-1 (210 mg, 443 μmol, 33.9% yield) as a brown oil. 1 HNMR(400 MHz, CDCl3) δ 8.18 - 8.08 (m, 1H), 7.92 (br s, 1H), 7.62 - 7.49 (m,3H), 7.29 (d, J = 7.9 Hz, 2H), 7.23 (d, J = 8.1 Hz, 1H), 5.10 (d, J = 3.1 Hz, 2H),4.26 - 4.17 (m, 4H), 2.23 (d, J = 4.0 Hz, 3H), 1.39 (s, 9H) INT13-1 (50.0 mg, 105 μmol, 1.00 equivalent) was dissolved in HCl / 1,4-dioxane (4 M, 500 μL), stirred at 20 °C for 1 hour, and then concentrated under reduced pressure to obtain a residue. The residue was purified by preparative high performance liquid chromatography (prep-HPLC, column: Waters Xbridge Prep OBD C18 150×40 mm×10 μm; mobile phase: H2O (0.05% NH3H2O ​​+ 10 mM NH4HCO3) / ACN; mobile phase gradient: 10%-40% ACN; flow rate: 8.0 min) to obtain INT13 (13.79 mg, 36.9 μmol, 34.9% yield) as a white solid.

[0293] 1 HNMR (400 MHz, DMSO- d 6 ) δ 8.70-8.47 (m, 1H), 8.37-8.24 (m, 1H), 7.83-7.71 (m, 3H), 7.59-7.42 (m, 3H), 5.31-5.18 (m, 2H), 4.38-4.21 (m, 1H), 3.76(d, J = 14.7 Hz, 3H), 2.24-2.18 (m, 3H).

[0294] Example 1 INT9 (0.150 g, 301 μmol) was dissolved in tetrahydrofuran (THF, 1.00 mL), and triethylamine (183 mg, 1.81 mmol, 252 μL, 6.00 equivalence) and cyclopropylamine (25.8 mg, 452 μmol, 31.3 μL, 1.50 equivalence) were added. The reaction mixture was stirred at -30 °C for 1 h, diluted with H2O (10 mL), and extracted with ethyl acetate (EA, 15 mL). The combined organic layers were washed with saturated brine (10 mL), dried over sodium sulfate, and concentrated under reduced pressure to obtain a residue, which was purified by preparative high-performance liquid chromatography (C18 column, eluted with H2O / CH3CN) to give compound 1 (45.0 mg, 28.5% yield) as a solid. LCMS: m / z = 519.1 [M+1] + . 1 HNMR (400 MHz, DMSO- d 6 ): δ 10.67 (s, 1H), 8.40 (d, J = 1.2 Hz, 1H), 7.97 (d, J = 8.8 Hz, 1H), 7.86 (d, J = 2.4 Hz, 1H), 7.80 (dd, J = 8.8 Hz, J = 1.6 Hz, 1H), 7.72 (d, J = 8.0 Hz, 2H), 7.61 (d, J = 2.0 Hz, 1H), 7.46 (d, J = 8.0 Hz, 2H), 7.16 (d, J= 2.0 Hz, 1H), 5.78 (s, 2H), 2.58 (s, 3H), 2.05-2.12 (m, 1H), 0.44-0.46 (m, 2H), 0.35-0.39 (m, 2H).

[0295] Example 2 INT9 (0.150 g, 301 μmol, 1.00 equivalent) was dissolved in tetrahydrofuran (THF, 1.00 mL), and triethylamine (183 mg, 1.81 mmol, 252 μL, 6.00 equivalent) and cyclohexylamine (44.8 mg, 452 μmol, 1.50 equivalent) were added. The mixture was stirred at -30 °C for 1 hour, diluted with H2O (10 mL), and then extracted with ethyl acetate (EA, 15 mL). The combined organic layers were washed with saturated brine (10 mL), dried over sodium sulfate (Na2SO4), and concentrated under reduced pressure to obtain a residue. This residue was purified by preparative high-performance liquid chromatography (column: Waters Xbridge Prep OBD C18 150×40 mm×10 μm; mobile phase: H2O (NH4HCO3 (10 mM)) / ACN; mobile phase gradient: 45%-75%ACN; flow rate: 8.0 min) to give compound 3 (39.0 mg, 66.8 μmol, 22.2% yield) as a pink solid.

[0296] 1 HNMR (400 MHz, DMSO- d 6 ) δ 10.65 (s, 1H), 8.36 (s, 1H), 7.94 (d, J = 9.2Hz, 1H), 7.81 (dd, J = 8.8 Hz, J = 1.2 Hz, 1H), 7.72 (d, J = 8.0 Hz, 2H), 7.56-7.63(m, 2H), 7.46 (d, J = 8.0 Hz, 2H), 7.18 (d, J = 1.6 Hz, 1 H), 5.77 (s, 2H), 2.94(d, J = 1.6 Hz, 1H), 2.59 (s, 3H), 1.50-1.64 (m, 4H), 1.42 (d, J= 11.2 Hz, 1H), 0.98-1.18 (m, 5H).

[0297] The compounds in the table below can be synthesized using the corresponding starting materials and the corresponding intermediate INT9 through the synthetic procedures of compound 1 or compound 3 or their modifications.

[0298] Example 3 INT1 (50.0 mg, 1.00 equivalent) and 3-methylisoxazole-4-carboxylic acid (16.9 mg, 1.10 equivalent) were dissolved in pyridine (0.5 mL), and EDCI (37.0 mg, 1.60 equivalent) was added. The mixture was stirred at 20 °C for 2 hours, and then concentrated under reduced pressure to obtain a residue, which was purified by preparative high-performance liquid chromatography (C18 column, eluted with H2O / CH3CN) to give compound 13 (31.6 mg, 50.03% yield) as a solid. LCMS: m / z = 524.2 [M+1] + . 1 HNMR (400 MHz, MeOH- d 4 ): δ 10.40 (s, 1H), 10.27 (s, 1H), 9.44 (s,1H), 7.99 (s, 1H), 7.74 - 7.68 (m, 4H), 7.61 (d, J = 2.0 Hz, 1H), 7.44 (d, J =8.0 Hz, 2H), 7.15 (d, J = 1.6 Hz, 1H), 5.71 (s, 2H), 2.57 (s, 3H), 2.42 (s, 3H).

[0299] The compounds in the table below can be synthesized using the corresponding starting materials and the corresponding intermediate INT1 through the synthesis procedure of compound 13 or its modified procedure.

[0300] Example 4 INT1 (40.0 mg, 1.00 equivalent) was dissolved in pyridine (0.8 mL), and 1,3-thiazolyl-5-sulfonyl chloride (53.2 mg, 3.00 equivalent) was added. The mixture was stirred at 25 °C for 8 hours, diluted with H2O (5.0 mL), and then extracted with ethyl acetate (EA, 50 mL). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure to obtain a residue, which was purified by preparative high-performance liquid chromatography (C18 column, eluted with H2O / CH3CN) to give compound 18 (7.52 mg, 13.9% yield) as a solid. LCMS: m / z = 562.9 [M+1] + . 1 HNMR (400 MHz, MeOH- d 4 ): δ 9.11 (s, 1H), 8.13 (s, 1H), 7.61 - 7.57(m, 3H), 7.47 (d, J = 9.2 Hz, 1H), 7.44 (d, J = 2.0 Hz, 1H), 7.39 (d, J = 8.0 Hz, 2H), 7.24 (dd, J = 2.0 Hz, J = 8.8 Hz, 1H), 6.91 (s, 1H), 5.64 (s, 2H), 2.60 (s, 3H).

[0301] The compounds in the table below can be synthesized using the corresponding starting materials and the corresponding intermediate INT1 through the synthesis procedure of compound 18 or its modified procedure.

[0302] Example 5 INT2 (99.3 mg, 1.0 equivalent) and 2-methylfuran-3-carboxylic acid (48.97 mg, 1.1 equivalent) were dissolved in pyridine (2.50 mL), and EDCI (81.2 mg, 1.2 equivalent) was added. The mixture was stirred at 80 °C for 10 hours, and then concentrated under reduced pressure to obtain a residue, which was purified by preparative high-performance liquid chromatography (C18 column, eluted with H2O / CH3CN) to give compound 22 (15.0 mg, 10.9% yield) as a solid. LCMS: m / z = 390.1 [M+1] + . 1 HNMR (400MHz, MeOH-d 4 ) δ 7.64 (d, J = 8.0 Hz, 2H), 7.38 (d, J = 8.0 Hz,2H), 7.39 (s, 1H), 6.81 (d, J = 3.2 Hz, 1H), 5.24 (s, 2H), 2.78 - 2.75 (m, 2H), 2.68 - 2.64 (m, 2H), 2.56 (s, 3H), 2.58 - 2.51 (m, 2H).

[0303] The compounds in the table below can be synthesized using the corresponding starting materials and intermediates through the synthesis process of compound 22 or its modifications.

[0304] Example 6 At 20 °C, INT11 (300 mg, 1.00 equivalent) and formaldehyde (37.0% purity, 3.12 g, 2.86 mL, 50.0 equivalent) were dissolved in methanol (5.00 mL), and acetic acid (110 mg, 105 μL, 2.40 equivalent) and sodium borohydride (72.4 mg, 1.50 equivalent) were added. The mixture was stirred at 20 °C for 1 hour, and then concentrated under reduced pressure to obtain a residue, which was purified by preparative high-performance liquid chromatography (C18 column, eluted with H2O / CH3CN) to give compound 43 (120 mg, 38.7% yield) as a solid. LCMS: m / z = 405.2 [M+1] + . 1 HNMR (400 MHz, MeOH- d 4 ) δ 7.67 (d, J = 8.1 Hz, 2H), 7.43 (d, J = 8.0 Hz, 2H), 7.40 (d, J = 2.1 Hz, 1H), 6.83 (d, J = 2.0 Hz, 1H), 5.28 (s, 2H), 3.98 (s,2H), 3.74 (t, J= 1.7 Hz, 2H), 2.59 (s, 3H), 2.57 (s, 3H).

[0305] Example 7 INT11 (133 mg, 0.34 mmol, 1.00 equivalent) and (1-ethoxycyclopropoxy)trimethylsilane (356 mg, 2.041 mmol, 6 equivalent) were dissolved in methanol (MeOH, 5 mL), and acetic acid (200 μL, 3.4 mmol, 10 equivalent) was added. After stirring for 0.5 hours, NaBH3CN (107 mg, 1.7 mmol, 5 equivalent) was added. The reaction mixture was stirred at 50 °C for 12 hours, diluted with H2O (100 mL), and then extracted with ethyl acetate (100 mL × 3). The combined organic layers were washed with saturated brine (100 mL), dried over sodium sulfate, and concentrated under reduced pressure to obtain a residue, which was purified by preparative high performance liquid chromatography (C18 column, eluted with H2O / CH3CN) to give compound 63 (59.8 mg, 0.139 mmol, 40.8% yield) as a white solid. LCMS: m / z = 431.5 [M+H] + . 1 HNMR (400 MHz, DMSO- d 6 ) δ 10.30 (s, 1H), 7.74 (d, J = 8.0 Hz, 2H), 7.52(d, J = 2.1 Hz, 1H), 7.42 (d, J = 7.9 Hz, 2H), 7.14 (d, J = 2.1 Hz, 1H), 5.25 (s,2H), 3.89 (d, J = 38.5 Hz, 4H), 2.52 (s, 3H), 2.16 (s, 1H), 0.40 (m, 4H).

[0306] Example 8 At 0 °C, triethylamine (TEA, 51.8 mg, 512 μmol, 2.50 equivalents) and acetyl chloride (24.1 mg, 307 μmol, 1.50 equivalents) were added to a solution of INT11 (80.0 mg, 205 μmol, 1.00 equivalents) in dichloromethane (DCM, 0.80 mL). The reaction mixture was stirred at 25 °C for 12 h and then concentrated under reduced pressure to obtain a residue, which was purified by preparative high performance liquid chromatography (column: Waters Xbridge BEH C18 100×30 mm×10 μm; mobile phase: H2O (NH4HCO3 (10 mM)) / ACN; mobile phase gradient: 15%-45% ACN; flow rate: 8.0 min) to give compound 64 (32 mg, 74.00 μmol, 28.8% yield) as a white solid.

[0307] 1 HNMR (400 MHz, DMSO- d 6 ) δ 10.58-10.51 (m, 1H), 7.80 (d, J = 8.2 Hz, 2H),7.61-7.57 (m, 1H), 7.52 (d, J = 8.1 Hz, 2H), 7.21 (s, 1H), 5.41-5.33 (m, 2H), 4.75 (br s, 2H), 4.59-4.46 (m, 2H), 2.60 (s, 3H), 2.11-2.04 (m, 3H).

[0308] Example 9 Potassium carbonate (70.8 mg, 512 μmol) was added to a solution of INT11 (100 mg, 256 μmol) and 2-(2-bromoethoxy)tetrahydro-2H-pyran (58.9 mg, 281 μmol, 42.5 μL) in acetonitrile (1.00 mL) at 20 °C. The reaction mixture was stirred at 50 °C for 12 hours and then filtered. The filtrate was concentrated under reduced pressure to obtain a residue, which was purified by preparative high performance liquid chromatography (column: Waters Xbridge BEH C18 100×30 mm×10 μm; mobile phase: H2O (NH4HCO3 (10 mM)) / ACN; mobile phase gradient: 45%-75% ACN; flow rate: 8.0 min) to give compound 66-1 (40.0 mg, 77.1 μmol, 30.1% yield) as a white solid.

[0309] Compound 66-1 (40.0 mg, 77.1 μmol, 1.00 equivalent) was dissolved in HCl / dioxane (4.00 M, 5.19 equivalent) and stirred at 25 °C for 16 hours. The solution was then concentrated under reduced pressure to obtain a residue. This residue was purified by preparative high performance liquid chromatography (column: Waters Xbridge BEH C18 100×30 mm×10 μm; mobile phase: H2O (NH4HCO3 (10 mM)) / ACN; mobile phase gradient: 25%-60% ACN; flow rate: 8.0 min) to obtain compound 66 (23.4 mg, 54.0 μmol, 70.0% yield) as a white solid.

[0310] 1 H NMR: (400 MHz, DMSO- d 6 ) d 10.28 (s, 1H), 7.74 (d, J = 8.1 Hz, 2H), 7.52(d, J = 2.0 Hz, 1H), 7.42 (d, J = 8.0 Hz, 2H), 7.13 (d, J = 1.9 Hz, 1H), 5.25 (s,2H), 4.52-4.46 (m, 1H), 3.86 (s, 2H), 3.77 (s, 2H), 3.50 (q, J = 6.0 Hz, 2H), 2.77 (t, J = 6.2 Hz, 2H), 2.52 (s, 3H).

[0311] Example 10 INT11 (50.0 mg, 128 μmol, 1.00 equivalent) and 1-methylazacyclobutane-3-one (16.4 mg, 192 μmol, 1.50 equivalent) were dissolved in methanol (MeOH, 500 μL), and acetic acid (AcOH, 769 μg, 12.81 μmol, 0.10 equivalent) was added. After stirring for 0.5 hours, NaBH3CN (20.1 mg, 320 μmol, 2.50 equivalent) was added. The reaction mixture was stirred at 50°C for 12 hours and then concentrated under reduced pressure to obtain a residue, which was purified by preparative high performance liquid chromatography (column: Waters XbridgePrep OBD C18 150×40mm×10um; mobile phase: H2O (0.05% NH3H2O ​​+ NH4HCO3 (10mM)) / ACN; mobile phase gradient: 10%-55% ACN; flow rate: 8.0 min) to give compound 67 (25.0 mg, 54.41 μmol, 42.48% yield) as a white solid.

[0312] 1 HNMR (400 MHz, DMSO- d 6 ) δ 7.68 (d, J = 8.1 Hz, 2H), 7.46-7.38 (m, 3H), 6.84 (d, J = 2.0 Hz, 1H), 5.28 (s, 2H), 3.96 (s, 2H), 3.74 (s, 2H), 3.67-3.58(m, 3H), 3.18-3.11 (m, 2H), 2.57 (s, 3H), 2.42 (s, 3H).

[0313] Example 11 At 20°C, methyl formaldehyde (MeCHO, 31.6 mg, 560 μmol, 40% purity, 3.00 equivalents), acetic acid (AcOH, 1.12 mg, 18.6 μmol, 0.10 equivalents) and NaBH3CN (, 29.3 mg, 466 μmol, 2.50 equivalents) were added to a solution of INT12 (90.0 mg, 186 μmol, 1.00 equivalents) in methanol (2.70 mL). The reaction mixture was stirred at 50 °C for 12 hours and then concentrated under reduced pressure to obtain a residue, which was purified by preparative high performance liquid chromatography (column: Waters XbridgePrep OBD C18 150×40mm×10um; mobile phase: H2O (0.05% NH3H2O ​​+ NH4HCO3 (10mM)) / ACN; mobile phase gradient: 15%-45% ACN; flow rate: 8.0 min) to give compound 70 (34.3 mg, 72.5 μmol, 38.8% yield) as a white solid.

[0314] 1 HNMR (400 MHz, DMSO- d 6 ) δ 10.32 (s, 1H), 7.75 (d, J = 8.1 Hz, 2H), 7.53(d, J = 2.0 Hz, 1H), 7.42 (d, J = 8.1 Hz, 2H), 7.14 (d, J = 2.0 Hz, 1H), 5.26 (s,2H), 3.84-3.72 (m, 4H), 3.52 (t, J = 6.3 Hz, 1H), 3.39 (d, J = 6.8 Hz, 4H), 2.93(br s, 2H), 2.49-2.35 (m, 3H), 0.88 (t, J = 7.2 Hz, 3H). Example 12 At 20°C, acetic acid (1.25 mg, 20.7 μmol, 1.19 μL, 0.100 equivalent) and NaBH3CN (32.6 mg, 518 μmol, 2.50 equivalent) were sequentially added to a solution of INT12 (100 mg, 207 μmol, 1.00 equivalent) and (tert-butyldimethylsiloxy)acetaldehyde (54.2 mg, 311 μmol, 59.3 μL, 1.50 equivalent) in methanol (MeOH, 3.00 mL). After stirring for 12 hours, hydrochloric acid (aq.HCl, 12 M, 1.00 mL) was added. The reaction mixture was stirred at 20°C for 1 hour, and then concentrated under reduced pressure to obtain a residue, which was purified by preparative high performance liquid chromatography (column: Waters Xbridge Prep OBD C18 150×40mm×10um; mobile phase: H2O (0.05% NH3H2O ​​+ NH4HCO3 (10mM)) / ACN; mobile phase gradient: 15%-45% ACN; flow rate: 8.0min) to give compound 71 (43.37mg, 88.6μmol, 42.7% yield) as a yellow solid.

[0315] 1 HNMR (400 MHz, DMSO- d 6 ) δ 10.32 (s, 1H), 7.75 (d, J = 8.1 Hz, 2H), 7.53(d, J = 2.0 Hz, 1H), 7.43 (d, J = 7.9 Hz, 2H), 7.14 (d, J = 1.8 Hz, 1H), 5.26 (s,2H), 4.36 (t, J = 5.3 Hz, 1H), 3.80 (br s, 2H), 3.74 (br s, 2H), 3.51 (t, J = 6.3Hz, 2H), 3.39 (t, J = 7.0 Hz, 4H), 2.94 (t, J = 6.8 Hz, 2H), 2.49 - 2.44 (m, 3H).

[0316] The compounds in the table below can be synthesized using the corresponding starting materials and intermediates through the synthetic procedures of compounds 5 to 10 or their modifications.

[0317] Example 13 INT11 (1.00 g, 1.00 equivalent) was dissolved in acetonitrile (20.0 mL), and diisopropylethylamine (662 mg, 892 μL, 2.00 equivalent) was added at 20 °C. Then, a solution of tert-butyl-2-bromoacetate (549 mg, 416 μL, 1.10 equivalent) in acetonitrile (1.00 mL) was added dropwise. The reaction mixture was stirred at 0 °C for 4 hours, poured into H2O (50.0 mL), and extracted with ethyl acetate (15.0 mL × 4). The combined organic layers were washed with saturated brine (20.0 mL), dried over sodium sulfate, and concentrated under reduced pressure to give a crude product. This crude product was purified by silica gel column chromatography (eluent: PE / EA) to give compound 73 (700 mg, 54.2% yield) as a solid. LCMS: m / z = 505.2 [M+1] + . 1 HNMR (400 MHz, CDCl3) δ 7.93(s, 1H), 7.52 (d, J = 8.1 Hz, 2H), 7.23 - 7.18 (m, 3H), 6.41 (d, J = 1.9 Hz, 1H), 5.04 (s, 2H), 4.21 (br s, 2H), 3.86 (br s, 2H), 3.44 (s, 2H), 2.53 (s, 3H), 1.38 (s, 9H).

[0318] Compound 73 (700 mg, 1.00 equivalent) was dissolved in dichloromethane (DCM, 7.00 mL), and HCl / dioxane (4 M, 1.75 mL, 5.05 equivalent) was added. The reaction mixture was stirred at 25 °C for 16 hours, and then concentrated under reduced pressure to give compound 74 (650 mg) as a solid. LCMS: m / z = 449.1 [M+1] + .

[0319] Compound 74 (100 mg, 1.00 equivalent) was dissolved in dimethylformamide (DMF, 2.00 mL), and HATU (127 mg, 1.50 equivalent), diisopropylethylamine (DIEA, 86.4 mg, 116 μL, 3.00 equivalent), and pyridine-3-amine (104 mg, 5.00 equivalent) were added. The reaction mixture was stirred at 20 °C for 16 hours, and then purified by preparative high-performance liquid chromatography (prep-HPLC, C18 column, eluting with H2O / CH3CN) to give compound 75 (43.0 mg, 36.8% yield) as a solid. LCMS: m / z = 525.2 [M+1] + . 1 HNMR (400 MHz, CDCl3) d 9.15 (s, 1H), 8.62 (d, J = 2.4 Hz, 1H), 8.39 (dd, J = 1.4, 4.7 Hz, 1H), 8.29 - 8.22 (m, 1H), 7.89 (s, 1H), 7.66 (d, J = 8.1 Hz,2H), 7.38 - 7.29 (m, 4H), 6.51 (d, J = 2.0 Hz, 1H), 5.18 (s, 2H), 4.32 (s, 2H), 3.91 (s, 2H), 3.62 (s, 2H), 2.63 (s, 3H).

[0320] The compounds in the table below can be synthesized using the corresponding starting materials and the corresponding intermediate INT11 through the synthesis procedure of compound 75 or its modified procedure.

[0321] Example 14 At 20 °C, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 2.34 g, 2.50 equivalent) and isopropyl 2-methylprop-2-enoate (1.18 g, 1.50 equivalent) were added to a solution of INT11 (2.4 g, 1.00 equivalent) in methanol (25.00 mL). The reaction mixture was stirred at 20 °C for 12 hours, poured into H2O (100 mL), and then extracted with ethyl acetate (120 mL × 4). The combined organic layers were washed with saturated brine (100 mL), dried over sodium sulfate, and concentrated under reduced pressure to obtain a residue, which was purified by preparative thin-layer chromatography (eluent: PE / EA) to give compound 77 (320.0 mg) as a solid. LCMS: m / z = 519.2 [M+1] + .

[0322] Compound 77 (320 mg, 1.00 equivalent) was dissolved in dichloromethane (DCM, 1.60 mL), and trifluoroacetic acid (494 mg, 0.320 mL) was added. The reaction mixture was stirred at 20 °C for 2 hours, and then concentrated under reduced pressure to obtain a crude product. This crude product was purified by preparative high-performance liquid chromatography (C18 column, eluted with H2O / CH3CN) to give compound 78 (100 mg, 34.9% yield) as a solid. LCMS: m / z = 463.2 [M+1] + . 1 HNMR (400 MHz, MeOH- d 4 ): d 7.68 (d, J = 8.4 Hz, 2H), 7.47 (d, J = 8.0 Hz, 2H), 7.39 (d, J = 2.0 Hz, 1H), 6.83 (d, J = 2.0 Hz, 1H), 5.31 (s, 2H), 4.56 (s,2H), 4.35 (s, 2H), 3.46 (t, J = 6.4 Hz, 2H), 2.58-2.59 (m, 2H), 2.56 (s, 3H) Compound 78 (100 mg, 1.00 equivalent) and 2-methylpropyl-2-amine (15.8 mg, 1.05 equivalent) were dissolved in dimethylformamide (DMF, 1.00 mL), and 1-methylimidazole (NMI, 35.5 mg, 2.00 equivalent) and N,N,N',N'-tetramethylchloroformamide hexafluorophosphate (72.8 mg, 259 μmol, 1.20 equivalent) were added. The reaction mixture was stirred at 25 °C for 2 hours, and then purified by preparative high-performance liquid chromatography (C18 column, eluted with H2O / CH3CN) to give compound 79 (34.1 mg, 30.5% yield) as a solid. LCMS: m / z = 518.1 [M+1] + . 1 HNMR (400 MHz, DMSO- d 6 ) d 10.31 (s, 1H), 7.74 (d, J = 8.0 Hz, 2H), 7.57(s, 1H), 7.53 (d, J = 2.0 Hz, 1H), 7.41 (d, J = 7.9 Hz, 2H), 7.15 (d, J = 1.9 Hz,1H), 5.26 (s, 2H), 3.83 (s, 2H), 3.73 (s, 2H), 2.87 (t, J = 6.9 Hz, 2H), 2.53(s, 3H), 2.22 (t, J = 7.2 Hz, 2H), 1.23 (s, 9H).

[0323] The compounds in the table below can be synthesized using the corresponding starting materials and the corresponding intermediate INT11 through the synthesis procedure of compound 79 or its modified procedure.

[0324] Example 15 Sodium tert-butoxide (377 mg, 3.00 equivalent) was added to a solution of INT8 (500 mg, 1.00 equivalent) and 5-bromo-3-methylpyridine (269 mg, 1.20 equivalent) in dioxane (5.00 mL) at 20 °C, followed by the addition of BrettPhos Pd G3 (118 mg, 0.100 equivalent) under a nitrogen atmosphere. The reaction mixture was stirred at 100 °C for 12 hours and then filtered. The filtrate was concentrated under reduced pressure to obtain a residue, which was purified by silica gel column chromatography (eluting gradient of DCM / MeOH = 100 / 1 to 0 / 1) to give compound 83-1 (210 mg) as an oil. LCMS: m / z = 474.2 [M+1] + . 1 HNMR (400MHz, CDCl3) δ 8.18-8.08 (m, 1H), 7.92 (br s, 1H), 7.62 - 7.49 (m, 3H), 7.29(d, J = 7.9 Hz, 2H), 7.23 (d, J = 8.1 Hz, 1H), 5.10 (d, J = 3.1 Hz, 2H), 4.26-4.17(m, 4H), 2.23 (d, J = 4.0 Hz, 3H), 1.39 (s, 9H). Compound 83-1 (50.0 mg, 1.00 equivalent) was dissolved in HCl / dioxane (500 μL) and stirred at 20 °C for 1 hour. The solution was then concentrated under reduced pressure to obtain a residue. This residue was purified by preparative high-performance liquid chromatography (HPLC) (column: Waters Xbridge Prep OBD C18 150 × 40 mm × 10 μm; mobile phase: H2O (0.05% NH3H2O ​​+ NH4HCO3 (10 mM)) / ACN; mobile phase gradient: 10%-40% ACN; flow rate: 8.0 min) to obtain compound 83 (13.79 mg, 34.9% yield) as a solid. LCMS: m / z = 374.1 [M+1] + . 1 H NMR (400 MHz, DMSO- d 6): δ 8.70-8.47 (m, 1H), 8.37-8.24 (m, 1H), 7.83-7.71 (m, 3H), 7.59 - 7.42 (m, 3H), 5.31-5.18 (m, 2H), 4.38-4.21 (m, 1H), 3.76 (br d, J = 14.7 Hz, 3H), 2.24-2.18 (m, 3H).

[0325] Formaldehyde (22.8 mg, 20.9 μL, 37% purity, 1.50 equivalent), acetic acid (AcOH, 1.13 mg, 1.07 μL, 0.100 equivalent), and NaBH3CN (29.4 mg, 2.50 equivalent) were sequentially added to a solution of compound 83 (70.0 mg, 1.00 equivalent) in methanol (MeOH, 1.40 mL) at 20 °C. The reaction mixture was stirred at 50 °C for 12 hours and then concentrated under reduced pressure to obtain a residue. The residue was purified by preparative high-performance liquid chromatography (column: Phenomenex Gemini-NX 80 × 40 mm × 3 μm; mobile phase: H2O (NH4HCO3 (10 mM)) / ACN; mobile phase gradient: 30%-50% ACN; flow rate: 8.0 min) to give compound 84 (18.8 mg, 25.9% yield) as a solid. LCMS: m / z = 388.2 [M+1] + . 1 H NMR (400 MHz, DMSO- d 6 ): δ 8.52 (s, 1H), 8.29 (d, J = 2.3 Hz, 1H),7.78 (s, 1H), 7.74 (d, J = 8.1 Hz, 2H), 7.46 (d, J = 5.6 Hz, 2H), 7.44 (s, 1H), 5.23 (s, 2H), 3.65 (s, 2H), 3.58 (s, 2H), 2.47 (s, 3H), 2.21 (s, 3H).

[0326] Example 16 At 0 °C, NaBH3CN (29.4 mg, 468 μmol, 2.50 equivalents) and acetic acid (1.13 mg, 18.7 μmol, 1.07 μL, 0.100 equivalents) were added to a solution of INT13 (70.0 mg, 187 μmol, 1.00 equivalents) in methanol (700 μL), and then 1-ethoxy-1-(trimethylsiloxy)cyclopropane (49.0 mg, 281 μmol, 56.5 μL, 1.50 equivalents) was added dropwise. The reaction mixture was stirred at 65°C for 12 hours and then concentrated under reduced pressure to obtain a residue, which was purified by preparative high performance liquid chromatography (column: Waters Xbridge BEH C18100×30mm×10um; mobile phase: H2O(NH4HCO3(10mM)) / ACN; mobile phase gradient: 25%-70%ACN; flow rate: 8.0min) to give compound 85 (16.36mg, 39.5μmol, 21.1% yield) as a white solid.

[0327] 1 HNMR: (400 MHz, DMSO- d 6 ) δ 8.51 (s, 1H), 8.29 (d, J = 2.4 Hz, 1H), 7.78(s, 1H), 7.74 (d, J = 8.0 Hz, 2H), 7.47 (d, J = 4.1 Hz, 2H), 7.44 (s, 1H), 5.23(s, 2H), 3.80 (s, 2H), 3.71 (s, 2H), 2.20 (s, 3H), 2.19-2.14 (m, 1H), 0.47-0.41 (m, 2H), 0.38 (d, J = 2.8 Hz, 2H) The compounds in the table below can be synthesized using the corresponding starting materials and intermediates through the synthetic procedures of compound 84 or compound 85 or their modifications.

[0328] Example 17 INT10 (40.0 mg, 91.2 μmol, 1.00 equivalent) was dissolved in methanol (MeOH, 0.4 mL) and H2O (0.1 mL), and potassium hydroxide (KOH, 15.4 mg, 274 μmol, 3.00 equivalent) was added. The mixture was stirred at 100 °C for 3 hours, the pH was adjusted to 4 with 2 M HCl, and then extracted with dichloromethane (DCM, 20 mL). The combined organic layers were washed with saturated brine (2 mL), dried over sodium sulfate, and concentrated under reduced pressure to obtain a residue. This residue was purified by preparative high-performance liquid chromatography (Phenomenex C18 75×30 mm×3 μm; mobile phase: H2O (NH4HCO3 (10 mM)) / ACN; mobile phase gradient: 5%-35% ACN; flow rate: 8.0 min) to give compound 119 (5.95 mg, 12.7 μmol, 13.9% yield) as a white solid and compound 120 (5.77 mg, 12.6 μmol, 13.8% yield) as a white solid.

[0329] The compounds in the table below were synthesized using the process described above or a modified version thereof.

[0330] Pharmacological experiments 1. Fascin and F-actin binding experiment The materials and reagents used in the F-actin binding experiment are shown in Table 1.

[0331] Table 1

[0332] Each compound to be tested in this invention was redissolved in DMSO to a concentration of 10 mM, and then diluted with DMSO to concentrations of 3 mM, 120 μM, and 12 μM.

[0333] Actin binding activity was measured by low-speed centrifugation.

[0334] 1 μM rabbit G-actin polymerization was induced in F-actin buffer (20 mM Tris-HCl, pH 8.0, 1 mM ATP, 1 mM DTT, 2 mM MgCl2, and 100 mM KCl) at 25 °C. Each compound to be tested was diluted with F-actin buffer to concentrations of 120 μM, 12 μM, 1.2 μM, and 0 μM, respectively, and then 0.25 μM recombinant Fascin protein was added to obtain final concentrations of 30 μM, 3 μM, 0.3 μM, and 0 μM. The solutions of each compound were incubated at 25 °C for 30 min, and then centrifuged at 10,000 g for 30 min in an Eppendorf 5810 benchtop centrifuge. The supernatant and precipitate were dissolved in an equal volume of SDS sample buffer, and the Fascin content was determined by SDS-PAGE. Images of Kumasi-stained gels were captured using a multi-functional imaging system, and the image grayscale values ​​of each compound at each concentration were analyzed using ImageJ. The relative actin binding activity (P) was then calculated.

[0335] The inhibition rate (%) is calculated according to the following formula: Inhibition rate (%) = 100 - P(30 μM) P(30 μM) represents the inhibition rate at a concentration of 30 μM.

[0336] Table 2 Inhibition rate of compound (30 μM)

[0337] As can be seen from Table 2, the representative compounds of this invention have a good inhibitory effect on actin binding.

[0338] 2. Boyden-chamber cell migration assay The Boyden chamber cell migration assay can be used to confirm that the compounds described in this invention inhibit the migration activity of tumor cells (such as breast tumor cells).

[0339] The materials, reagents, plates, and instruments used in the Boyden-chamber cell migration assay are shown in Table 3. Table 3

[0340] 4T1 cell lines were incubated in DMEM medium containing 10% fetal bovine serum and 1% penicillin-streptomycin until cell confluence reached 60-80%. The medium was removed, and the cells were washed with PBS. The 4T1 cells were then incubated overnight in serum-free DMEM medium at 37°C under a 5% CO2 atmosphere. The next day, the cells were treated with trypsin and resuspended in serum-free medium. Cells were counted and diluted to 2 × 10⁶ cells / mL with serum-free medium. 5 A density of cells / mL was achieved. Cell suspension (200 μL) was seeded into the insert in the upper chamber, resulting in a final cell density of 4 × 10⁻⁶ cells / mL. 4 Cells / well. Redissolve each compound to be tested in DMSO to a concentration of 9 mM. Dilute each compound to be tested to a concentration of 90 μM in serum-free DMEM medium, or to a concentration of 30 μM in DMEM medium containing 10% FBS, to obtain the test medium. Add 100 μL of FBS-free test medium to the upper chamber of the Transwell and 600 μL of FBS-containing test medium to the lower chamber. Incubate cells at 37°C in a CO2 atmosphere (5%) for 6 hours. Wells containing the same percentage of DMSO serve as a carrier control. Transwell inserts were washed with 4% formaldehyde and fixed for 15 minutes. Migrating cells were stained with crystal violet for 10 minutes, and cells on the upper side of the insert were removed with a cotton swab. Five fields of view (10× objective) were randomly selected from the lower side of the insert for photographing, and the migrating cells were counted. The migration index represents the relative number of migrating cells in the presence of the compound versus in the absence of the compound (DMSO).

[0341] The migration index data from the Boyden-chamber cell migration assay are shown in Table 4 below: Table 4

[0342] As can be seen from Table 4, the representative compounds of this invention have a strong inhibitory effect on cell migration.

[0343] It should be understood that if any prior art publication is cited in this document, such citation does not constitute an admission that the publication constitutes part of the prior art of any country.

[0344] All publications, patents, patent applications, and published patent applications cited in this article are incorporated herein in their entirety through citation.

[0345] Although the invention has been described with reference to some embodiments and descriptions, it will be apparent to those skilled in the art that minor modifications can be made. Therefore, the descriptions and embodiments should not be construed as limiting the scope of the invention.

Claims

1. A compound of formula (I), including its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of its stereoisomers, pharmaceutically acceptable salts of its tautomers, or pharmaceutically acceptable salts of its deuterated derivatives: ， Formula (I) in, R1 is selected independently from hydrogen, halogen, and -C each time it appears. 1-6 Alkyl, Halogenated C 1-6 Alkyl, -C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, -NH2, -NH(C 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group, or 5-10 membered heteroaryl group; wherein, R1 can be independently selected from halogen, -C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, oxo, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group or 5-10 membered heteroaryl group substituted with 1, 2, 3, 4, 5 or 6 substituents; R2 is selected independently from hydrogen, halogen, and -C each time it appears. 1-6 Alkyl, Halogenated C 1-6 Alkyl, -C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, -NH2, -NH(C 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group, or 5-10 membered heteroaryl group; wherein, the R2 can be independently selected from halogen, -C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, oxo, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group or 5-10 membered heteroaryl group substituted with 1, 2, 3, 4, 5 or 6 substituents; Alternatively, R1 and R2, together with the atoms they are respectively connected to, make the equation (I) The following groups are formed: or ; when yes hour, X1 is selected from N or CR7; X2 is selected from N or CR8; X3 is selected from N or CR9; X4 is selected from N or CR 10 ; R7 is selected independently from hydrogen, halogen, and -C each time it appears. 1-6 Alkyl, Halogenated C 1-6 Alkyl, -C 2-6 Alkoxy, halogenated C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, -NH2, -NH(C 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group, or 5-10 membered heteroaryl group; wherein, the R7 can be independently selected from halogen, -C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, oxo, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group or 5-10 membered heteroaryl group substituted with 1, 2, 3, 4, 5 or 6 substituents; R8 is selected from hydrogen, -C(=O)N(R 81 )2、-NHC(=O)(R 81 -S(=O)N(R) 81 )2、-NHS(=O)(R 81 -S(=O)2N(R) 81 )2 or -NHS(=O)2(R 81 ); The R 81 Each occurrence is independently selected from 3-10 membered carbon rings, 3-10 membered heterocycles, phenyl, or 5-10 membered heteroaryl; the R 81 Can be selected from halogens, -C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, oxo, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 The alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group or 5-10 membered heteroaryl group are substituted with one or more substituents; R9 is selected from hydrogen, -(C 1-6 (alkylene)-R 91 -C(=O)(OR) 92 -S(=O)(OR) 92 -S(=O)2(OR) 92 -C(=O)-NHR 92 -S(=O)-NHR 92 -S(=O)2-NHR 92 -C(=O)(R) 93 -S(=O)(R) 93 -S(=O)2(R) 93 -OC(=O)(R) 93 -OS(=O)(R) 93 -OS(=O)2(R) 93 ), -NH-C(=O)(R 93 ), -NH-S(=O)(R 93 -NH-S(=O)2(R) 93 ); The R 91 Each time it appears, it is selected independently from -C. 2-6 Alkoxy, halogenated C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, -NH2, -NH(C 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl groups, 3-10 membered carbon rings, 3-10 membered heterocycles, 6-12 membered aryl groups, or 5-10 membered heteroaryl groups; The R 92 Each is independently selected from 3-10 membered carbon rings, 3-10 membered heterocycles, phenyl, or 5-10 membered heteroaryl; the R 92 Can be selected from halogens, -C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, oxo, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 The alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group or 5-10 membered heteroaryl group are substituted with one or more substituents; The R 93 Each occurrence is independently selected from halogens and -C. 2-6 Alkoxy, halogenated C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, -NH2, -NH(C 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl groups, 3-10 membered carbon rings, 3-10 membered heterocycles, 6-12 membered aryl groups, or 5-10 membered heteroaryl groups; X2 and X3 cannot both be N; When X2 is CR8 and X3 is CR9, only one of R8 and R9 is hydrogen; R 10 Each time it appears, it is independently selected from hydrogen, halogen, -C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, -C 2-6 Alkoxy, halogenated C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, -NH2, -NH(C 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl groups, 3-10 membered carbon rings, 3-10 membered heterocycles, 6-12 membered aryl groups, or 5-10 membered heteroaryl groups; wherein, the R group... 10 Independently selectable from halogens, -C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, oxo, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group or 5-10 membered heteroaryl group substituted with 1, 2, 3, 4, 5 or 6 substituents; When fragment for hour: n4 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; n5 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; Y2 is selected from -C(R) Y2 )2-、-R Y2 C=CR Y2 -、-C≡C-、-O-、-NR Y3 -, -S-, -C(=O)-, -S(=O)-, -S(=O)2-, -C(=O)O-、 -C(=O)NR Y4 -、 -NR Y4 C(=O)-、 -S(=O)NR Y4 -、 -NR Y4 S(=O)-、 -S(=O)2NR Y4 -or -NR Y4 S(=O)2-; Representation and fragment The connection point; R Y2 Each time it appears, it is independently selected from hydrogen, halogen, -C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, -C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, -NH2, -NH(C 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl groups, 3-10 membered carbon rings, 3-10 membered heterocycles, 6-12 membered aryl groups, or 5-10 membered heteroaryl groups; wherein, the R group... Y2 Independently selectable from halogens, -C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, oxo, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group or 5-10 membered heteroaryl group substituted with 1, 2, 3, 4, 5 or 6 substituents; R Y3 Each time it appears, it is independently selected from hydrogen and -C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, -C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl group, -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 alkyl) 2, 3-10 membered carbon rings, 3-10 membered heterocycles, 6-12 membered aryl or 5-10 membered heteroaryl; said R Y3 It can be independently represented by 1, 2, 3, 4, 5, or 6 R's. Y31 Replace; R Y31 Each occurrence is independently selected from halogens and -C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, -C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, -NH2, -NH(C 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl groups, 3-10 membered carbon rings, 3-10 membered heterocycles, 6-12 membered aryl groups, or 5-10 membered heteroaryl groups; The R Y31 It can be independently represented by 1, 2, 3, 4, 5, or 6 R's. Y32 replace; R Y32 Each occurrence is independently selected from halogens and -C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, oxo, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl groups, 3-10 membered carbon rings, 3-10 membered heterocycles, 6-12 membered aryl groups, or 5-10 membered heteroaryl groups; R Y4 Each time it appears, it is independently selected from hydrogen and -C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 alkynyl group, -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 alkyl) 2, 3-10 membered carbon rings, 3-10 membered heterocycles, 6-12 membered aryl or 5-10 membered heteroaryl; said R Y4 Independently selectable from halogens, -C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -N3, oxo, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group or 5-10 membered heteroaryl group substituted with 1, 2, 3, 4, 5 or 6 substituents; R4 is selected independently from -H, halogen, and -C each time it appears. 1-6 Alkyl or halogenated C 1-6 alkyl; R5 is selected independently from -H, halogen, and -C each time it appears. 1-6 Alkyl or halogenated C 1-6 alkyl; R6 is selected independently from -H, halogen, and -C each time it appears. 1-6 Alkyl, -OC 1-6 Alkyl or halogenated C 1-6 alkyl; Y1 is selected from non-existent, -C(R) Y1A )2-、-R Y1A C=CR Y1A -、-C≡C-、-N(R Y1B )2-, -O-, -S-, -C(=O)-, -S(=O)-, -S(=O)2-, -C(=O)O- -OC(=O)- -N(R) Y1B )-C(=O)- -C(=O)-N(R) Y1B )- -N(R) Y1B )-S(=O)- -S(=O)-N(R) Y1B )- -N(R) Y1B )-S(=O)2- or -S(=O)2-N(R) Y1B )- ; Indicates the connection point with ring B; The R Y1A Selected from -H, halogen, -C 1-6 Alkyl or halogenated C 1-6 alkyl; The R Y1B Selected from -H or -C 1-6 alkyl; Ring B is selected from 3-14 membered carbon rings, 3-14 membered heterocycles, 6-14 membered aromatic rings, or 5-14 membered heteroaromatic rings; R S1 R S2 Or R S3 Each occurrence is independently selected from halogens and -C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, -C 2-6 Alkoxy, halogenated C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl groups, 3-10 membered carbon rings, 3-10 membered heterocycles, 6-12 membered aryl groups, or 5-10 membered heteroaryl groups; wherein, the R group... S1 R S2 Or R S3 Independently selectable from halogens, -C 1-6 Alkyl, Halogenated C 1-6 Alkyl, -C 2-6 Alkoxy, halogenated C 2-6 Alkoxy, -C 2-6 alkenyl, -C 2-6 Alkyne, -CN, -NO2, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl group 2, -OH, -O(C) 1-6 Alkyl), -SH, -S(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl), -C(=O)OH, -C(=O)(OC 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 Alkyl), -C(=O)N(C 1-6 Alkyl)2、-NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -S(=O)(OC 1-6 Alkyl), -OS(=O)(C 1-6 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-6 Alkyl), -S(=O)N(C 1-6 Alkyl)2、-NHS(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)S(=O)(C 1-6 Alkyl), -S(=O)2(OC 1-6 Alkyl), -OS(=O)2(C 1-6 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-6 Alkyl group), -S(=O)2N(C 1-6 alkyl)2、-NHS(=O)2(C 1-6 alkyl), -N(C) 1-6 alkyl)S(=O)2(C 1-6 Alkyl group, 3-10 membered carbon ring, 3-10 membered heterocyclic ring, 6-12 membered aryl group or 5-10 membered heteroaryl group substituted with 1, 2, 3, 4, 5 or 6 substituents; n1 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; n2 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; n3 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; Each time the heterocycle appears, it independently contains 1, 2, 3, 4, 5 or 6 heteroatoms selected from N, O, S, S(=O), S(=O)2; Each occurrence of the heteroaryl group independently contains 1, 2, 3, 4, 5, or 6 heteroatoms selected from N, O, or S.

2. A compound of formula (I-1-1) or (I-2), its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives: in, R4, R5, R6, R7, R8, R9, R 10 Ring B, Y1, Y2, R S1 R S2 R S3 The definitions of n1, n2, n3, n4 and n5 are the same as those in claim 1.

3. A compound of formula (I-1-1), its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of its stereoisomers, pharmaceutically acceptable salts of its tautomers, or pharmaceutically acceptable salts of its deuterated derivatives: Equation (I-1-1) in, R8 is selected from -H, -NHC(=O)(R 81 -NHS(=O)(R) 81 -NHS(=O)2(R) 81 -C(=O)N(R) 81 )2、-C(=O)NH(R 81 -S(=O)N(R) 81 )2、-S(=O)NH(R 81 -S(=O)2N(R) 81 )2 or -S(=O)2NH(R 81 ); The R 81 Each is independently selected from 3-10 membered carbon rings, 3-10 membered heterocycles, phenyl, or 5-10 membered heteroaryl; the R 81 Can be selected from halogens, -C 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, oxo, -CN, -OH, -SH, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 The alkyl group, 3-7 membered carbon ring, 3-7 membered heterocyclic ring, phenyl group, or 5-10 membered heteroaryl group are substituted with one or more substituents. R9 is selected from -H, -(C 0-3 (alkylene)-R 91 -C(=O)-N(R) 92 )2、-S(=O)-N(R 92 )2、-S(=O)2-N(R 92 )2、-C(=O)(R 93 -S(=O)(R) 93 ) or -S(=O)2(R 93 ); The R 91 Each time, it is selected independently from -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 2-3 Alkoxy, halogenated C 2-3 Alkoxy, oxo, -CN, -OH, -SH, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl groups, 3-7 membered carbon rings, 3-7 membered heterocycles, phenyl groups, or 5-10 membered heteroaryl groups; The R 92 Each is independently selected from 3-7 membered carbon rings, 3-7 membered heterocycles, phenyl, or 5-6 membered heteroaryl; the R 92 Can be selected from halogens, -C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 Alkyne, oxo, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 The alkyl group, 3-7 membered carbon ring, 3-7 membered heterocyclic ring, phenyl group, or 5-10 membered heteroaryl group are substituted with one or more substituents. The R 93 Each halogen is selected independently; Only one of R8 and R9 is hydrogen; R7 is selected from hydrogen, halogens, and -C. 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 1-3 Alkoxy, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl groups, 3-7 membered carbon rings, 3-7 membered heterocycles, phenyl groups, or 5-10 membered heteroaryl groups; R 10 Selected from hydrogen, halogens, -C 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 1-3 Alkoxy, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl groups, 3-7 membered carbon rings, 3-7 membered heterocycles, phenyl groups, or 5-10 membered heteroaryl groups; R4, R5, R6, Y1, Ring B, R S1 R S2 The definitions of n1 and n2 are the same as those in claim 1.

4. The compound of formula (I) or (I-1-1) according to any one of claims 1-3, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R8 is selected from -C(=O)N(R) 81 )2、-C(=O)NH(R 81 -S(=O)N(R) 81 )2、-S(=O)NH(R 81 -S(=O)2N(R) 81 )2 or -S(=O)2NH(R 81 ); The R 81 Each time, it is independently selected from 3-7 membered carbon rings, 3-7 membered heterocycles, or 5-6 membered heteroaryl groups; the R 81 Can be selected from halogen, -CN, -C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C(=O)(OC) 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2 or -NHS(=O)2(C 1-3 One or more substituents of alkyl group are used for substitution; Preferably, R8 is selected from -C(=O)N(R 81 )2、-C(=O)NH(R 81 -S(=O)N(R) 81 )2、-S(=O)NH(R 81 -S(=O)2N(R) 81 )2 or -S(=O)2NH(R 81 ); The R 81 Each time, it is independently selected from 3-7 membered carbon rings, 3-7 membered heterocycles, or 5-6 membered heteroaryl groups; the R 81 Can be selected from halogen, -CN, -C 1-3 Alkyl or -C(=O)(OC) 1-3 One or more substituents of alkyl group are used for substitution; More preferably, R8 is selected from -NHC(=O)(R 81 -S(=O)2NH(R) 81 ) or -NHS(=O)2(R 81 ); The R 81 Selected from , , , , , Thiophene, furanyl, pyridinyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl-NHC(=O)(R) 81 -S(=O)2NH(R) 81 ) or -NHS(=O)2(R 81 ); The R 81 It can be substituted by one or more substituents selected from -Cl, -F, -Br, -CN, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C(=O)(OCH3), -C(=O)(OCH2CH3), -C(=O)(OCH2CH2CH3) or -C(=O)(OCH(CH3)2); More preferably, R8 is selected from , , , , , , , , , , , , , , , , , , , , or ; More preferably, R8 is selected from or .

5. The compound of formula (I) or (I-1-1) according to any one of claims 1-4, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R9 is selected from -H, -(C 1-3 (alkylene)-R 91 -C(=O)-N(R) 92 )2、-S(=O)-N(R 92 )2、-S(=O)2-N(R 92 )2、-C(=O)(R 93 -S(=O)(R) 93 -S(=O)2(R) 93 ), The R 91 Each time, it is independently selected from -CN, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl groups, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl)2, -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2, -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2, -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl) or -S(=O)2N(C 1-3 Alkyl)2; the R 92 Each is independently selected from phenyl or 5-10 heteroaryl groups; the R 93 Each halogen is selected independently; Preferably, R9 is selected from -H, -CH2-R 91 -CH2CH2-R 91 -CH2CH2CH2-R 91 -CH2(CH2)-R 91 -C(=O)-N(R) 92 )2、-S(=O)-N(R 92 )2、-S(=O)2-N(R 92 )2、-C(=O)(R 93 -S(=O)(R) 93 -S(=O)2(R) 93 ), the R 91 Each time, it is independently selected from -CN, -OH, -O-CH3, -O-CH2CH3, -O-CH2CH2CH3, -O-CH(CH3)2, -SH, -S-CH3, -S-CH2CH3, -S-CH2CH2CH3, -S-CH(CH3)2, -NH2, -NH(CH3), -N(CH3)2, -NH(CH2CH3), -C(=O)OH, -C(=O)(OCH3), -C(=O)(OCH2CH3), -C(=O)(OCH(CH3)2), -C(=O)NH2, -C(=O)NH(CH3), -C(=O )NH(CH2CH3), -C(=O)NH(CH2CH2CH3), -C(=O)NH(CH(CH3)2), -C(=O)N(CH3)2, -S(=O)NH2, -S(=O)NH(CH3), -S(=O)NH(CH2CH3), -S(=O)NH(CH2CH2 R 92 Each is independently selected from hydrogen, phenyl, pyrrolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, tetrazolyl, pyrazolyl, triazolyl, thiadiazolyl, oxadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, indole, isoindoleyl, or indoleazinyl; said R 93 Each time it is independently selected from -F, -Br, or -Cl; More preferably, R9 is selected from -CH2-CN, -CH2-OH, -CH2-O-CH3, -CH2-O-CH2CH3, -CH2-O-CH2CH2CH3, -CH2-O-CH(CH3)2, -CH2-SH, -CH2-S-CH3, -CH2-S-CH2CH3, -CH2-S-CH2CH2CH3, -CH2-S-CH(CH3)2, -CH2-NH2, -CH2-NH(CH3), -CH2-N(CH3)2, -CH2-NH(CH2CH3), -CH2-C (=O)OH, -CH2-C(=O)(OCH3), -CH2-C(=O)(OCH2CH3), -CH2-C(=O)(OCH2CH2CH3), -CH2-C(=O)(OCH(CH3)2), -CH2-C(=O)NH2, -CH2-C(=O)NH(CH3), -CH2-C(=O)NH(CH2CH3), -CH2-C(=O)NH(CH2CH2CH3), -CH2-C(=O)NH(CH(CH3)2), -CH2-C(=O)N(CH3)2, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , -C(=O)-Cl, -S(=O)-Cl or -S(=O)2-Cl; Preferably, R9 is selected from , , , or .

6. The compound of formula (I) or compound (I-1-1) according to any one of claims 1-5, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R7 is selected independently each time from -H, halogen, -C. 1-3 Alkyl or halogenated C 1-3 Alkyl group; preferably, R7 is independently selected from -H, -Cl, -F, -Br, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CHFCH3 or -CF2CH3; more preferably, R7 is -H.

7. The compound of formula (I) or compound (I-1-1) according to any one of claims 1-6, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R 10 Each time it is independently selected from -H, halogen, -C 1-3 Alkyl or halogenated C 1-3 Alkyl; preferably, R 10 Each time, it is independently selected from -H, -Cl, -F, -Br, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CHFCH3, or -CF2CH3; more preferably, R 10 It is -H.

8. The compound of formula (I) or compound (I-1-1) according to any one of claims 1-7, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Selected from , , , , , , , , , , , , , , , , , , , , , , , , , or ; Preferably, Selected from , , or .

9. A compound of formula (I-2), its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of its stereoisomers, pharmaceutically acceptable salts of its tautomers, or pharmaceutically acceptable salts of its deuterated derivatives: Equation (I-2) in, Y2 is selected from -C(R) Y2 )2-、-O-、-NR Y3 -、-S-、 -C(=O)NR Y4 -、 -NR Y4 C(=O)-、 -S(=O)NR Y4 -、 -NR Y4 S(=O)-、 -S(=O)2NR Y4 -or -NR Y4 S(=O)2-; Representation and fragment The connection point; R Y2 Selected from hydrogen, halogens, -C 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 1-3 Alkoxy, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl groups, 3-7 membered carbon rings, 3-7 membered heterocycles, phenyl groups, or 5-10 membered heteroaryl groups; R Y3 Selected from -H, -C 1-6 Alkyl group, -C(=O)(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), 3-7 membered carbon rings, 3-7 membered heterocycles, phenyl or 5-10 membered heteroaryl; the R Y3 It can be independently represented by 1, 2, 3, 4, 5, or 6 R's. Y31 replace; The R Y31 Each time, it is independently selected from halogens, -C 1-3 Alkyl, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-4 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-4 Alkyl), -C(=O)N(C 1-3 Alkyl)2, -S(=O)NH2, -S(=O)NH(C 1-4 Alkyl), -S(=O)N(C 1-3 Alkyl)2, -S(=O)2NH2, -S(=O)2NH(C 1-4 Alkyl) or -S(=O)2N(C 1-3 Alkyl)2; the R Y31 It can be independently represented by 1, 2, 3, 4, 5, or 6 R's. Y32 replace; The R Y32 Each time, it is selected independently from -C 2-3 Alkoxy, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl groups or 5-10 heteroaryl groups; R Y4 Selected from -H, -C 1-6 Alkyl group, -C(=O)(C 1-6 Alkyl), -S(=O)(C 1-6 Alkyl), -S(=O)2(C 1-6 Alkyl), 3-7 membered carbon rings, 3-7 membered heterocycles, phenyl or 5-10 membered heteroaryl; the R Y4 Independently selectable from halogens, -C 1-3 Alkyl, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-4 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-4 Alkyl), -C(=O)N(C 1-3 Alkyl)2, -S(=O)NH2, -S(=O)NH(C 1-4 Alkyl), -S(=O)N(C 1-3 Alkyl)2, -S(=O)2NH2, -S(=O)2NH(C 1-4 Alkyl) or -S(=O)2N(C 1-3 Alkyl)2 is substituted with 1, 2, 3, 4, 5 or 6 substituents; n4 is selected from 0, 1, 2, 3, 4, 5 or 6; n5 is selected from 0, 1, 2, 3, 4, 5 or 6; R4, R5, R6, Y1, Ring B, R S1 R S2 R S3 The definitions of n1, n2, and n3 are the same as those in claim 1.

10. The compound of formula (I) or (I-2) according to any one of claims 1-2 and 9, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Y2 is selected from -C(R) Y2 )2-、-O-、-S-、-NR Y3 -、 -C(=O)NR Y4 -or -NR Y4 C(=O)-; Representation and fragment The connection point; Preferably, Y2 is selected from -C(R) Y2 )2-, -O-, -S- or -NR Y3 - 11. The compound of formula (I) or (I-2) according to any one of claims 1-2 and 9-10, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, The compound is selected from any of the following formulas: , , , , or ; in, R4, R5, R6, R S1 R S2 R S3 n1, n2, n3, n4, n5, R Y2 R Y3 R Y4 The definitions of Y1 and ring B are the same as those in claim 1.

12. The compound of formula (I) or (I-2) according to any one of claims 1-2 and 9-11, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, n4 is selected from 0, 1, 2, 3 or 4; preferably, n4 is selected from 0, 1 or 2.

13. The compound of formula (I) or (I-2) according to any one of claims 1-2 and 9-12, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, n5 is selected from 0, 1, 2, 3 or 4; preferably, n5 is selected from 0, 1 or 2.

14. The compound of formula (I) or (I-2) according to any one of claims 1-2 and 9-13, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, n4 is 0 and n5 is 1; or n4 is 0 and n5 is 2; or n4 is 1 and n5 is 0; or n4 is 2 and n5 is 0; or n4 is 1, and n5 is 1; or n4 is 1 and n5 is 2; or n4 is 2 and n5 is 1; or n4 is 2, and n5 is 2.

15. The compound of formula (I) or (I-2) according to any one of claims 1-2 and 9-14, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, n4 is 1, and n5 is 1.

16. The compound of formula (I) or (I-2) according to any one of claims 1-2 and 9-15, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R Y2 Selected from -H, halogen, -C 1-3 Alkyl or halogenated C 1-3 alkyl; Preferably, R Y2 Selected from -H, -Cl, -F, -Br, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CHFCH3 or -CF2CH3; More preferably, R Y2 It is -H.

17. The compound of formula (I) or (I-2) according to any one of claims 1-2 and 9-16, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Selected from , , , , , , , , or ; Preferably, Selected from , or .

18. The compound of formula (I) or (I-2) according to any one of claims 1-2 and 9-15, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R Y3 Selected from -H, -C 1-3 Alkyl group, -C(=O)(C 1-3 Alkyl group), 3-7 membered carbon ring or 3-7 membered heterocycle; the R Y3 It can be independently represented by 1, 2 or 3 Rs Y31 replace; The R Y31 Each time, it is selected independently from -C 1-3 Alkyl, -OH, -O(C) 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-4 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-4 Alkyl) or -C(=O)N(C 1-3 Alkyl)2; the R Y31 It can be independently represented by 1, 2, 3, 4, 5, or 6 R's. Y32 Replace; the R Y32 Each time, it is selected independently from -C 2-3 Alkoxy, -OH, -O(C) 1-3 Alkyl groups or 5-10 heteroaryl groups; Preferably, R Y3 Selected from -H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C(=O)(CH3), -C(=O)(CH2CH3), -C(=O)(CH2CH2CH3), -C(=O)(CH(CH3)2), , , , , , , , , , or The R Y3 It can be independently represented by 1, 2 or 3 Rs Y31 Replace; the R Y31 Each time, it is independently selected from -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -OH, -O-CH3, -O-CH2CH3, -O-CH2CH2CH3, -O-CH(CH3)2, -C(=O)CH3, -C(=O)(CH2CH3), -C(=O)-CH(CH3)2, -C(=O)OH, -C(=O)(OCH3), -C(=O)(OCH2CH3), -C(=O)(OCH 2CH2CH3), -C(=O)(OCH(CH3)2), -C(=O)(OC(CH3)3), -C(=O)NH2, -C(=O)NH(CH3), -C(=O)NH(CH2CH3), -C( =O)NH(CH2CH2CH3), -C(=O)NH(CH(CH3)2), -C(=O)NH(C(CH3)3), -C(=O)N(CH3)2 or -C(=O)N(CH2CH3)2; the R Y31 It can be independently represented by 1, 2, 3, 4, 5, or 6 R's. Y32 Replace; the R Y32 Each time, it is independently selected from -CH3-O-CH3, -CH2CH3-O-CH3, -CH2-O-CH2CH3, -CH(CH3)-O-CH3, -OH, -O-CH3, -O-CH2CH3, -O-CH(CH3)2, thiophene, furanyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridininyl, pyrroleyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, or isoxazolyl; More preferably, R Y3 Selected from -H, -CH3, -CH2CH3, -C(=O)(CH3), , , or The R Y3 It can be independently represented by 1, 2 or 3 Rs Y31 replace; The R Y31 Each time, it is independently selected from -CH3, -CH2CH3, -OH, -C(=O)CH3, -C(=O)OH, -C(=O)(OC(CH3)3), -C(=O)NH2, -C(=O)NH(CH3), -C(=O)NH(CH2CH3), -C(=O)NH(CH(CH3)2) or -C(=O)NH(C(CH3)3); the R Y31 It can be independently represented by 1, 2 or 3 Rs Y32 Replace; the R Y32 Each group is independently selected from -OH, -O-CH3, or pyridinyl groups; More preferably, R Y3 Selected from -H, -CH3, -CH2CH3, -CH2COOH, -CH2CH2COOH, -CH2COOC(CH3)3, -CH2CH2COOC(CH3)3, -CH2CH2OH, -CH2-C(=O)-NH(CH3), -CH2C H2-C(=O)-NH(CH3), -CH2CH2-C(=O)-NH(CH2CH3), -CH2CH2-C(=O)-NH(CH(CH3)2), -CH2CH2-C(=O)-NH(C(CH3)3), -C(=O)-CH3, , , , , , , , , or ; More preferably, R Y3 Selected from -CH2CH2COOH, -CH2CH2OH, -C(=O)-CH3, , , or .

19. A compound of formula (I) or formula (I-2) according to any one of claims 1-2 and 9-15 and 18, wherein the stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, Selected from , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ; Preferably, Selected from , , , , , , , or .

20. A compound of formula (I) or (I-2), its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, according to any one of claims 1-2 and 9-15, wherein: Selected from , , , , , , or .

21. A compound of formula (I) or formula (I-2) according to any one of claims 1-2 and 9-15, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein: Selected from , , , , , , or .

22. A compound of formula (I) or formula (I-2) according to any one of claims 1-2 and 9-15, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R Y4 Selected from -H, -C 1-3 Alkyl or halogenated C 1-3 alkyl; Preferably, R Y4 Selected from -H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CHFCH3 or -CF2CH3; More preferably, R Y4 Yes, it's -H.

23. A compound of formula (I) or formula (I-2) according to any one of claims 1-2 and 9-15 and 22, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Selected from , , , , , , , , , , , , , , , , , , or ; Preferably, Selected from , , , , , , or .

24. The compound of formula (I) or formula (I-2) according to any one of claims 1-2, 9-15, and 22-23, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Selected from , , , , , , , , , , , , , , , , , , or ; Preferably, Selected from , , , , , , or .

25. A compound of formula (I) or formula (I-2) according to any one of claims 1-24, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Selected from , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ; Preferably, Selected from , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or .

26. A compound of formula (I) according to any one of claims 1-25, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Selected from , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or .

27. The compound of formula (I), formula (I-1-1), or formula (I-2) according to any one of claims 1-26, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Y1 is selected from non-existent, -C(R) Y1A )2-、-N(R Y1B -, -O-, -S-, -C(=O)-N(R) Y1B )- -S(=O)-N(R) Y1B )- -S(=O)2-N(R) Y1B )- -N(R) Y1B )-C(=O)- -N(R) Y1B )-S(=O)- or -N(R) Y1B )-S(=O)2- ; Indicates the connection point with ring B; Preferably, Y1 is selected from -N(R) Y1B )-、-N(R Y1B )-C(=O)- -N(R) Y1B )-S(=O)- or -N(R) Y1B )-S(=O)2- ; Indicates the connection point with ring B; more preferably, Y1 is selected from -N(R Y1B - or -N(R) Y1B )-C(=O)- ; Indicates the connection point with ring B; R Y1A Selected from -H, halogen, -C 1-3 Alkyl or halogenated C 1-3 Alkyl; preferably, R Y1A Selected from -H or -C 1-3 Alkyl; more preferably, R Y1A Selected from -H, -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2; more preferably, R Y1A Selected from -H or -CH3; R Y1B Selected from -H or -C 1-3 Alkyl; more preferably, R Y1B Selected from -H, -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2; more preferably, R Y1B Selected from -H or -CH3.

28. A compound of formula (I), formula (I-1-1), or formula (I-2) according to any one of claims 1-27, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Y1 is selected from non-existent, -O-, -S-, -CH2-, -CH(CH3)-, -NH2-, -NH(CH3)-, -NH-C(=O)- -N(CH3)-C(=O)- -NH-S(=O)- -N(CH3)-S(=O)- -NH-S(=O)2- -N(CH3)-S(=O)2- -C(=O)-NH- -C(=O)-N(CH3)- -S(=O)-NH- -S(=O)-N(CH3)- -S(=O)2-NH- -S(=O)2-N(CH3)- ; Preferably, Y1 is selected from -NH2-, -NH(CH3)-, and NH-C(=O)-. -N(CH3)-C(=O)- -NH-S(=O)- -N(CH3)-S(=O)- -NH-S(=O)2- -N(CH3)-S(=O)2- ; Indicates the connection point with ring B; More preferably, Y1 is selected from -NH2-, -NH(CH3)-, and -NH-C(=O)-. or -N(CH3)-C(=O)- ; This indicates the connection point with ring B.

29. A compound of formula (I), formula (I-1-1), or formula (I-2) according to any one of claims 1-28, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Y1 is selected from -NH2-.

30. A compound of formula (I), formula (I-1-1), or formula (I-2) according to any one of claims 1-28, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Y1 is selected from -NH-C(=O)- ; This indicates the connection point with ring B.

31. A compound of formula (I), formula (I-1-1), or formula (I-2) according to any one of claims 1-30, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R4 groups are independently selected from -H, halogen, and -C. 1-3 Alkyl or halogenated C 1-3 alkyl; Preferably, each R4 is independently selected from -H or -C. 1-3 alkyl; More preferably, each R4 is independently selected from -H, -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2; More preferably, each of the R4s is independently selected from -H or -CH3.

32. The compound of formula (I), formula (I-1-1), or formula (I-2) according to any one of claims 1-31, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R5 is independently selected from -H, halogen, and -C. 1-3 Alkyl or halogenated C 1-3 alkyl; Preferably, each R5 is independently selected from -H or -C. 1-3 alkyl; More preferably, each of the R5s is independently selected from -H, -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2; More preferably, each of R5 is independently selected from -H or -CH3.

33. The compound of formula (I), formula (I-1-1), or formula (I-2) according to any one of claims 1-32, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R4 is selected independently from -H or -C. 1-3 Alkyl group; and each of the R5 groups is independently selected from -H or -C. 1-3 alkyl; Preferably, each of R4 is independently selected from -H, -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2; and each of R5 is independently selected from -H, -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2; More preferably, each of R4 is independently selected from -H or -CH3; and each of R5 is independently selected from -H or -CH3; More preferably, each of R4 is independently selected from -H; and each of R5 is independently selected from -H.

34. The compound of formula (I) according to any one of claims 1-33, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, The compound is selected from any one of the following formulas: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ; in, R1, R2, R4, R5, R6, R7, R8, R9, R 10 R Y2 R Y3 R Y4 Ring B Y2 R S1 R S2 R S3 The definitions of n1, n2, n3, n4 and n5 are the same as those in any one of claims 1-33.

35. A compound of formula (I), formula (I-1-1), or formula (I-2) according to any one of claims 1-34, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R6 is selected independently from -H, halogen, and -C each time it appears. 1-3 Alkyl, -OC 1-3 Alkyl or halogenated C 1-3 alkyl; Preferably, R6 is independently selected from -H and -OC each time it appears. 1-3 Alkyl or halogenated C 1-3 alkyl; More preferably, R6 is independently selected from -H, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CHFCH3 or -CF2CH3 each time it appears; More preferably, R6 is independently selected from -H, -OCH3, or -CF3 each time it appears.

36. A compound of formula (I), formula (I-1-1), or formula (I-2) according to any one of claims 1-35, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R6 is selected independently from -CF3 each time it appears.

37. A compound of formula (I), formula (I-1-1), or formula (I-2) according to any one of claims 1-36, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Selected from , or .

38. A compound of formula (I), formula (I-1-1), or formula (I-2) according to any one of claims 1-37, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Selected from .

39. A compound of formula (I) according to any one of claims 1-38, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, The compound is selected from any one of the following formulas: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ; in, X1, X2, X3, X4, R1, R2, R4, R5, R7, R8, R9, R 10 R Y2 R Y3 R Y4 Ring B, Y2, R S1 R S3 The definitions of n1, n3, n4 and n5 are the same as those in any one of claims 1-38.

40. A compound of formula (I), formula (I-1-1), or formula (I-2) according to any one of claims 1-39, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Ring B is selected from phenyl or a 5-10 membered heteroaryl ring containing 1, 2, 3, 4, 5 or 6 heteroatoms, wherein the heteroatoms are selected from N, O or S; Preferably, ring B is selected from a 5-6 membered heteroaryl ring containing 1, 2, 3, 4, 5 or 6 heteroatoms, wherein the heteroatoms are selected from N, O or S; More preferably, ring B is selected from a 5-membered heteroaryl ring containing 1, 2 or 3 heteroatoms, or a 6-membered heteroaryl ring containing 1, 2 or 3 heteroatoms, wherein the heteroatoms are selected from N, O or S.

41. A compound of formula (I), formula (I-1-1), or formula (I-2) according to any one of claims 1-40, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Ring B is selected from , , , , , , , , or ; Preferably, ring B is selected from , , , , , or ; Preferably, ring B is selected from or ; Preferably, ring B is selected from .

42. The compound of formula (I), formula (I-1-1), or formula (I-2) according to any one of claims 1-41, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R S2 Each is independently selected from halogens, -C 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 Alkoxy, halogenated C 2-3 Alkoxy, -C 2-3 alkenyl, -C 2-3 Alkyne group, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), oxo, -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl), 3-7 membered cycloalkyl, 3-7 membered heterocycloalkyl, 6-10 membered aryl or 5-10 membered heteroaryl; the R S2 It may optionally be substituted with one or more substituents selected from halogens, -C 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C 1-3 Alkoxy, halogenated C 1-3 Alkyl, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -C(=O)(OC) 1-3 Alkyl) or -C (=O) (halogenated C) 1-3 alkyl); Preferably, R S2 Each is independently selected from halogens, -C 1-3 Alkyl, -CN, oxo, -C(=O)OH, -C(=O)(OC) 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2, -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2, -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 Alkyl group, 2-3-7-membered cycloalkyl group, 3-7-membered heterocycloalkyl group, phenyl group, or 5-6-membered heteroaryl group; wherein the heterocycloalkyl group contains 1, 2, or 3 heteroatoms selected from N, O, or S; wherein the heteroaryl group contains 1, 2, or 3 heteroatoms selected from N, O, or S; More preferably, R S2 Each is independently selected from -C 1-3 Alkyl, oxo, -CN; More preferably, R S2 Each is independently selected from -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CN, or oxo; More preferably, R S2 Each is independently selected from -CH3, -CH2CH3, -CH(CH3)2, -CN, or oxo.

43. The compound of formula (I), formula (I-1-1), or formula (I-2) according to any one of claims 1-42, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, n2 is selected from 0, 1, 2, 3, 4, 5 or 6; preferably, n2 is selected from 0, 1, 2, 3 or 4; more preferably, n2 is selected from 0, 1, 2 or 3; even more preferably, n2 is selected from 0, 1 or 2.

44. A compound of formula (I), formula (I-1-1), or formula (I-2) according to any one of claims 1-43, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Selected from , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ; Preferably, Selected from , , , , , , , , , or ; Preferably, Selected from or ; Preferably, Selected from .

45. A compound of formula (I) according to any one of claims 1-44, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, The compound is selected from any one of the following formulas: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ; in, R1, R2, R4, R5, R7, R8, R9, R 10 R Y2 R Y3 R Y4 , Y2 R S1 R S3 The definitions of n1, n3, n4 and n5 are the same as those in any one of claims 1-44.

46. ​​A compound of formula (I-1-1), its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of its stereoisomers, pharmaceutically acceptable salts of its tautomers, or pharmaceutically acceptable salts of its deuterated derivatives: ， Formula (I-1-1) in, R4 and R5 are each independently selected from -H or -C. 1-3 alkyl; R6 is selected from -H, halogen, -C 1-3 Alkyl or halogenated C 1-3 alkyl; R7 is independently selected from -H, halogen, and -C. 1-3 Alkyl or halogenated C 1-3 alkyl; R8 is selected from -C(=O)N(R) 81 )2、-C(=O)NH(R 81 -S(=O)N(R) 81 )2、-S(=O)NH(R 81 -S(=O)2N(R) 81 )2 or -S(=O)2NH(R 81 ); The R 81 Each is independently selected from 3-7-membered carbocycloalkyl, 3-7-membered heterocycloalkyl, or 5-6-membered heteroaryl; the R 81 It may optionally be substituted with one or more substituents selected from halogens, -CN, and -C. 1-3 Alkyl, -C 2-3 alkenyl, -C 2-3 alkynyl group, -C(=O)(OC) 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2 or -NHS(=O)2(C 1-3 alkyl); R9 is selected from -H, -(C 1-3 (alkylene)-R 91 -C(=O)-N(R) 92 )2、-S(=O)-N(R 92 )2、-S(=O)2-N(R 92 )2、-C(=O)(R 93 -S(=O)(R) 93 -S(=O)2(R) 93 ), The R 91 Each is independently selected from -CN, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl groups, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl)2, -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2, -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2, -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl) or -S(=O)2N(C 1-3 Alkyl)2; The R 92 Each is independently selected from phenyl or 5-10 heteroaryl groups; The R 93 Each is independently selected from halogens; Only one of R8 and R9 is hydrogen; R 10 Each is independently selected from -H, halogen, and -C. 1-3 Alkyl or halogenated C 1-3 alkyl; Y1 is selected from -N(R) Y1B )-、-N(R Y1B )-C(=O)- -N(R) Y1B )- S (=O)- or -N(R) Y1B )-S(=O)2- ; Indicates the connection point with ring B; R Y1B Selected from -H or -C 1-3 Alkyl; more preferably, R Y1B Selected from -H, -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2; more preferably, R Y1B Selected from -H or -CH3; Ring B is selected from 5-6 membered heteroaryl rings containing 1, 2 or 3 heteroatoms, wherein the heteroatoms are selected from N, O or S; R S2 Each is independently selected from halogens, -C 1-3 Alkyl, -CN, oxo, -C(=O)OH, -C(=O)(OC) 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2, -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2, -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 Alkyl group, 2-3-7-membered cycloalkyl group, 3-7-membered heterocycloalkyl group, phenyl group, or 5-6-membered heteroaryl group; wherein the heterocycloalkyl group contains 1, 2, or 3 heteroatoms selected from N, O, or S; wherein the heteroaryl group contains 1, 2, or 3 heteroatoms selected from N, O, or S; n2 is selected from 0, 1, 2, or 3; R S1 The definitions of n1 and n1 are the same as those in claim 1.

47. The compound of formula (I-1-1) according to claim 46, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Selected from , , , , , , , , , , , , , , , , , , , , , , , , , or ; Preferably, Selected from , , or .

48. A compound of formula (I-2), its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of its stereoisomers, pharmaceutically acceptable salts of its tautomers, or pharmaceutically acceptable salts of its deuterated derivatives: ， Formula (I-2) in, Y2 is selected from -C(R) Y2 )2-、-O-、-NR Y3 -、-S-、 -C(=O)NR Y4 -、 -NR Y4 C(=O)-、 -S(=O)NR Y4 -、 -NR Y4 S(=O)-、 -S(=O)2NR Y4 -or -NR Y4 S(=O)2-; Indicates with groups The connection point; R Y2 Selected from -H, halogen, -C 1-3 Alkyl or halogenated C 1-3 alkyl; R Y3 Selected from -H, -C 1-3 Alkyl group, -C(=O)(C 1-3 Alkyl), 3-7 membered carbocycloalkyl or 3-7 membered heterocycloalkyl; the R Y3 You can choose to be hit by 1, 2 or 3 Rs. Y31 replace; The R Y31 Each is independently selected from -C 1-3 Alkyl, -OH, -O(C) 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-4 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-4 Alkyl) or -C(=O)N(C 1-3 Alkyl)2; the R Y31 You can choose any 1, 2, 3, 4, 5 or 6 R's. Y32 replace; The R Y32 Each is independently selected from -C 2-3 Alkoxy, -OH, -O(C) 1-3 Alkyl groups or 5-10 heteroaryl groups; R Y4 Selected from -H, -C 1-3 Alkyl or halogenated C 1-3 alkyl; n4 is selected from 0, 1, 2, 3, or 4; n5 is selected from 0, 1, 2, 3, or 4; Y1 is selected from -N(R) Y1B -, -O-, -S-, -C(=O)-N(R) Y1B )- -S(=O)-N(R) Y1B )- -S(=O)2-N(R) Y1B )- -N(R) Y1B )-C(=O)- -N(R) Y1B )-S(=O)- or -N(R) Y1B )-S(=O)2- ; Indicates the connection point with ring B; R Y1B Selected from -H or -C 1-3 Alkyl; more preferably, R Y1B Selected from -H, -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2; more preferably, R Y1B Selected from -H or -CH3; R4 and R5 are each independently selected from -H or -C. 1-3 alkyl; R6 is selected from -H, halogen, -C 1-3 Alkyl or halogenated C 1-3 alkyl; Y1 is selected from -N(R) Y1B )-、-N(R Y1B )-C(=O)- -N(R) Y1B )-S(=O)- or -N(R) Y1B )-S(=O)2- ; Indicates the connection point with ring B; R Y1B Selected from -H or -C 1-3 Alkyl; more preferably, R Y1B Selected from -H, -CH3, -CH2CH3, -CH2CH2CH3 or -CH(CH3)2; more preferably, R Y1B Selected from -H or -CH3; Ring B is selected from 5-6 membered heteroaryl rings containing 1, 2 or 3 heteroatoms, wherein the heteroatoms are selected from N, O or S; R S2 Each is independently selected from halogens, -C 1-3 Alkyl, -CN, oxo, -C(=O)OH, -C(=O)(OC) 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2, -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2, -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 Alkyl group, 2-3-7-membered cycloalkyl group, 3-7-membered heterocycloalkyl group, phenyl group, or 5-6-membered heteroaryl group; wherein the heterocycloalkyl group contains 1, 2, or 3 heteroatoms selected from N, O, or S; wherein the heteroaryl group contains 1, 2, or 3 heteroatoms selected from N, O, or S; n2 is selected from 0, 1, 2, or 3; R S1 n1, R S3 The definitions of n3 and n3 are the same as those in claim 1.

49. A compound of formula (I-2-1), its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of its stereoisomers, pharmaceutically acceptable salts of its tautomers, or pharmaceutically acceptable salts of its deuterated derivatives: ， Formula (I-2-1) in, R4, R5, R6, R S1 R S2 R S3 n1, n2, n3, n4, n5, R Y2 The definitions of Y1 and ring B are the same as those in claim 48.

50. The compound of formula (I-2-1) according to claim 49, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R Y2 Selected from -H, halogen, -C 1-3 Alkyl or halogenated C 1-3 Alkyl; preferably, R Y2 Selected from -H, -Cl, -F, -Br, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CHFCH3 or -CF2CH3; more preferably, R Y2 Yes, it's -H.

51. A compound of formula (I-2) and formula (I-2-1), its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, according to any one of claims 49-50: Selected from or .

52. A compound of formula (I-2-2), its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of its stereoisomers, pharmaceutically acceptable salts of its tautomers, or pharmaceutically acceptable salts of its deuterated derivatives: ， Formula (I-2-2) in, R4, R5, R6, R S1 R S2 R S3 n1, n2, n3, n4, n5, R Y3 The definitions of Y1 and ring B are the same as those in claim 48.

53. The compound of formula (I-2-1) according to claim 52, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R Y3 Selected from -H, -C 1-3 Alkyl group, -C(=O)(C 1-3 Alkyl), 3-7 membered carbocycloalkyl or 3-7 membered heterocycloalkyl; the R Y3 You can choose to be hit by 1, 2 or 3 Rs. Y31 Replace; the R Y31 Each is independently selected from -C 1-3 Alkyl, -OH, -O(C) 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-4 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-4 Alkyl) or -C(=O)N(C 1-3 Alkyl)2; the R Y31 You can choose any 1, 2, 3, 4, 5 or 6 R's. Y32 Replace; the R Y32 Each is independently selected from -C 2-3 Alkoxy, -OH, -O(C) 1-3 Alkyl groups or 5-10 heteroaryl groups; Preferably, R Y3 Selected from -H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -C(=O)(CH3), -C(=O)(CH2CH3), -C(=O)(CH2CH2CH3), -C(=O)(CH(CH3)2), , , , , , , , , , or The R Y3 You can choose to be hit by 1, 2 or 3 Rs. Y31 replace; The R Y31 Each is independently selected from -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -OH, -O-CH3, -O-CH2CH3, -O-CH2CH2CH3, -O-CH(CH3)2, -C(=O)CH3, -C(=O)(CH2CH3), -C(=O)-CH(CH3)2, -C(=O)OH, -C(=O)(OCH3), -C(=O)(OCH2CH3), -C(=O)(OCH 2CH2CH3), -C(=O)(OCH(CH3)2), -C(=O)(OC(CH3)3), -C(=O)NH2, -C(=O)NH(CH3), -C(=O)NH(CH2CH3), -C( =O)NH(CH2CH2CH3), -C(=O)NH(CH(CH3)2), -C(=O)NH(C(CH3)3), -C(=O)N(CH3)2 or -C(=O)N(CH2CH3)2; the R Y31 You can choose any 1, 2, 3, 4, 5 or 6 R's. Y32 Replace; the R Y32 Each is independently selected from -CH3-O-CH3, -CH2CH3-O-CH3, -CH2-O-CH2CH3, -CH(CH3)-O-CH3, -OH, -O-CH3, -O-CH2CH3, -O-CH(CH3)2, thiophene, furanyl, pyridinyl, pyrimidinyl, pyridininyl, pyrrolyl, imidazole, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, or isoxazolyl; More preferably, R Y3 Selected from -H, -CH3, -CH2CH3, -C(=O)(CH3), , , or The R Y3 You can choose to be hit by 1, 2 or 3 Rs. Y31 Replace; the R Y31 Each is independently selected from -CH3, -CH2CH3, -OH, -C(=O)CH3, -C(=O)OH, -C(=O)(OC(CH3)3), -C(=O)NH2, -C(=O)NH(CH3), -C(=O)NH(CH2CH3), -C(=O)NH(CH(CH3)2) or -C(=O)NH(C(CH3)3); the R Y31 You can choose to be hit by 1, 2 or 3 Rs. Y32 Replace; the R Y32 Each group is independently selected from -OH, -O-CH3, or pyridinyl groups; More preferably, R Y3 Selected from -H, -CH3, -CH2CH3, -CH2COOH, -CH2CH2COOH, -CH2COOC(CH3)3, -CH2CH2COOC(CH3)3, -CH2CH2OH, -CH2-C(=O)-NH(CH3), -CH2C H2-C(=O)-NH(CH3), -CH2CH2-C(=O)-NH(CH2CH3), -CH2CH2-C(=O)-NH(CH(CH3)2), -CH2CH2-C(=O)-NH(C(CH3)3), -C(=O)-CH3, , , , , , , , , or ; More preferably, R Y3 Selected from -CH2CH2COOH, -CH2CH2OH, -C(=O)-CH3, , , or .

54. The compounds of formula (I-2) and formula (I-2-2) according to any one of claims 52-53, wherein the stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Selected from , , , , , , , , , , , , , , , , , , , , , , , , , or ; Preferably, Selected from , , , , , , , .

55. A compound of formula (I-2-3), its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of its stereoisomers, pharmaceutically acceptable salts of its tautomers, or pharmaceutically acceptable salts of its deuterated derivatives: ， Formula (I-2-3) in, The definitions of R4, R5, R6, RS1, RS2, RS3, n1, n2, n3, n4, n5, Y1, and ring B are the same as those in claim 48.

56. The compounds of formulas (I-2) and (I-2-3) according to claim 55, wherein the stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of the stereoisomers, pharmaceutically acceptable salts of the tautomers, or pharmaceutically acceptable salts of the deuterated derivatives, are wherein, Selected from , , , , or Preferably, Selected from .

57. The compounds of formula (I-2), (I-2-1), (I-2-2), and (I-2-3) according to any one of claims 1-56, wherein their stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of the stereoisomers, pharmaceutically acceptable salts of the tautomers, or pharmaceutically acceptable salts of the deuterated derivatives, wherein, Selected from , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or .

58. A compound of formula (I), its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives: ， Formula (I) in, R1 is independently selected from hydrogen, halogen, and -C. 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 Alkoxy, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)(OC 1-3 Alkyl), -OC (=O)(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2、-NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2、-NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl)2、-NHS(=O)2(C 1-3 Alkyl), 3-7 membered cycloalkyl, 3-7 membered heterocycloalkyl, phenyl, or 5-10 membered heteroaryl; wherein R1 may optionally be substituted with 1, 2, or 3 substituents, the substituents being selected from halogens, -C 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 Alkoxy, -CN, -NH2, -NH(C) 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)OH, -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -NHC(=O)(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -NHS(=O)(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl), -NHS(=O)2(C 1-3 Alkyl groups or 3-7 membered cycloalkyl groups; R2 is independently selected from -H, halogen, and -C. 1-3 Alkyl, Halogenated C 1-3 Alkyl, -C 2-3 Alkoxy, -CN, -C(=O)OH, -NH2, -NH(C 1-3 alkyl), -N(C) 1-3 Alkyl group 2, -OH, -O(C) 1-3 Alkyl), -SH, -S(C 1-3 Alkyl), -C(=O)(C 1-3 Alkyl), -S(=O)(C 1-3 Alkyl), -S(=O)2(C 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl groups), -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl groups), -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl groups or 3-7 membered cycloalkyl groups; R4, R5, R6, R S1 R S2 The definitions of n1, n2, Y1 and ring B are the same as those in claim 1.

59. The compound of formula (I) according to claim 58, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R1 is independently selected from hydrogen, halogen, and -C. 1-3 Alkyl, -CN, -C(=O)OH, -C(=O)(OC) 1-3 Alkyl), -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 Alkyl)2, -S(=O)NH2, -S(=O)NH(C 1-3 Alkyl), -S(=O)N(C 1-3 Alkyl)2, -S(=O)2NH2, -S(=O)2NH(C 1-3 Alkyl group), -S(=O)2N(C 1-3 alkyl), 2-phenyl, or 5-6-membered heteroaryl, wherein the heteroaryl contains 1, 2, or 3 heteroatoms selected from N, O, or S; wherein R1 may optionally be surrounded by 1, 2, or 3 -C atoms. 1-3 Alkyl substitution; Preferably, R1 is independently selected from hydrogen, halogen, -C 1-3 Alkyl, -CN, -COOH, -C(=O)NH2, -C(=O)NH(C 1-3 Alkyl), -C(=O)N(C 1-3 alkyl)2, or a 5-6-membered heteroaryl group, wherein the heteroaryl group contains one or two heteroatoms selected from N, O, or S; the 5-6-membered heteroaryl group may optionally be surrounded by one or two -C atoms. 1-3 Alkyl substitution; More preferably, R1 is independently selected from -H, -F, -Cl, -Br, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CN, -COOH, -C(=O)NH2, -C(=O)NH(CH3), -C(=O)NH(CH2CH3), -C(=O)NH(CH2CH2CH3), -C(=O)NH(CH(CH3)2), -C(=O)N(CH3)2, -C(=O)N(CH2CH3)2, , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ; More preferably, R1 is selected from -CH3, -CN, -Br, -C(=O)-NH2, -COOH, , or .

60. A compound of formula (I) according to any one of claims 58-59, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, R2 is independently selected from -H, halogen, and -C. 1-3 Alkyl, Halogenated C 1-3 Alkyl or -CN; Preferably, R2 is independently selected from -H and -C. 1-3 Alkyl or -CN; More preferably, each of the R2 groups is independently selected from -H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, or -CN; More preferably, R2 is selected from -H, -CH3, or -CN.

61. The compound of formula (I) according to any one of claims 58-60, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Selected from , , , , , , , , , , , , or .

62. The compound of formula (I-1) according to any one of claims 58-61, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, Selected from , , , , , , , , , , , , , , , or .

63. The compound of formula (I-1) according to any one of claims 1-62, wherein its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer, or pharmaceutically acceptable salt of the deuterated derivative, wherein, The compound is any one of the following formulas: ， ， ， ， ， ， ， ， ， ， ， ， ， ， ， ， ， ， ， ， ， ， ， 、 、 、 、 ， ， ， ， ， ， ， ， ， ， ， 、 ， ， ， ， ， ， ， ， ， 、 、 ， ， ， ， ， ， ， ， ， ， ， ， ， ， ， ， ， ， ， ， ， , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or .

64. Selected from the intermediates of the following formulas: 、 、 、 、 、 、 、 、 ; in, In each formula, R4, R5, R6, R7, R9, R 10 R Y2 Y1, ring B, R S1 R S2 R S3 The definitions of n1, n2, n3, n4, or n5 are the same as those of any one of claims 1-130; In each formula, LG6 is a leaving group, selected from halogens (such as -Cl, -Br or -I), -OMs, -OTs or -OTf; In each formula, Y4 is -C(=O)-, -S(=O)-, or -S(=O)2-; In each formula, LG2 is a leaving group or a group that can be converted into a leaving group; the leaving group is selected from halogens (such as -Cl, -Br or -I), -OMs, -OTs or -OTf; the group that can be converted into a leaving group is selected from -OH, which can be converted into leaving groups including but not limited to -Cl, -Br, -I, -OMs, -OTs or -OTf. Poc2 is a protecting group for nitrogen atoms, including but not limited to tert-butyloxycarbonyl; Preferably, the intermediate is selected from: 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 。 65. A method for preparing a compound of any one of claims 1-63 (I-2-1), its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, comprising the following reaction formula 3: Reaction 3 ， in, In each formula, R4, R5, R6, R Y2 Y1, ring B, R S1 R S2 R S3 The definitions of n1, n2, n3, n4, or n5 are the same as those of any one of claims 1-130; The LG3 in LG4 and LG5 in the text is a leaving group or a group that can be converted into a leaving group; in some embodiments, the leaving group is selected from halogens (such as -Cl, -Br or -I), -OMs, -OTs or -OTf; in some embodiments, the group that can be converted into a leaving group is selected from -OH, which can be converted into leaving groups including but not limited to -Cl, -Br, -I, -OMs, -OTs or -OTf. The Poc1 is a -NH2 protecting group, preferably, Poc1 is... ; Y5 is -C(=O)-, -S(=O)-, or -S(=O)2-.

66. A method for preparing a compound of formula (I-2-2), its stereoisomers, tautomers, deuterated derivatives, pharmaceutically acceptable salts, pharmaceutically acceptable salts of stereoisomers, pharmaceutically acceptable salts of tautomers, or pharmaceutically acceptable salts of deuterated derivatives, according to claim 1. -63 Any one of the following, including the following reaction formula 4: Reaction 4 ， in, In each formula, R4, R5, R6, R Y3 Y1, ring B, R S1 R S2 R S3 The definitions of n1, n2, n3, n4, or n5 are the same as those of any one of claims 1-130; The LG3 in LG4 and LG5 in the text is a leaving group or a group that can be converted into a leaving group; in some embodiments, the leaving group is selected from halogens (such as -Cl, -Br or -I), -OMs, -OTs or -OTf; in some embodiments, the group that can be converted into a leaving group is selected from -OH, which can be converted into leaving groups including but not limited to -Cl, -Br, -I, -OMs, -OTs or -OTf. Y5 is -C(=O)-, -S(=O)-, or -S(=O)2-; The Poc1 is a -NH2 protecting group, preferably, Poc1 is... ; Poc2 is a protecting group for nitrogen atoms; preferably, Poc2 is a tert-butyloxycarbonyl group.

67. A pharmaceutical composition comprising the compound of any one of claims 1-63, its stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt, pharmaceutically acceptable salt of the stereoisomer, pharmaceutically acceptable salt of the tautomer or a pharmaceutically acceptable salt of the deuterated derivative, and at least one pharmaceutically acceptable excipient.

68. A method of treating a subject with cancer associated with Fascin overexpression, the method comprising administering to the subject a therapeutically effective amount of any one of claims 1-63, its stereoisomer, its tautomer, its deuterated derivative, its pharmaceutically acceptable salt, a pharmaceutically acceptable salt of its stereoisomer, a pharmaceutically acceptable salt of its tautomer, or a pharmaceutically acceptable salt of its deuterated derivative, or the pharmaceutical composition of claim 67; preferably, the cancer is selected from breast cancer, central nervous system cancer, endometrial cancer, kidney cancer, colorectal cancer, lung cancer, esophageal cancer, tongue cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, mesothelioma, melanoma, fibrosarcoma, bladder cancer, rectal cancer, lymphoma, cervical cancer, head and neck cancer, upper respiratory tract or digestive tract cancer, colorectal cancer, urinary tract cancer, or colon cancer; more preferably, each cancer is independently selected from adenocarcinoma, squamous cell carcinoma. The cancers include: mixed adenosquamous carcinoma and undifferentiated carcinoma; more preferably, the ovarian cancer includes high-grade ovarian serous adenocarcinoma, ovarian mucinous cystadenocarcinoma, or malignant ovarian Brenner's tumor; the renal cancer includes clear cell renal cell carcinoma; the tongue cancer includes squamous cell carcinoma of the tongue; the lung cancer includes lung adenocarcinoma, lung adenosquamous carcinoma, lung squamous cell carcinoma, large cell lung cancer, small cell lung cancer, lung papillary adenocarcinoma, or non-small cell lung cancer; the pancreatic cancer includes pancreatic adenocarcinoma or pancreatic ductal adenocarcinoma; the esophageal cancer includes esophageal squamous cell carcinoma; the mesothelioma includes biphasic mesothelioma; the central nervous system cancers include glioma, glioblastoma, or glioblastoma multiforme; the gastric cancer includes gastric adenocarcinoma; the breast cancer includes ductal carcinoma, adenocarcinoma, or HR+ breast cancer; the bladder cancer includes bladder squamous cell carcinoma; the melanoma includes malignant melanoma; the colon cancer includes colonic adenocarcinoma; and the head and neck cancer includes small squamous cell carcinoma of the head and neck.

69. The use of any compound, stereoisomer, tautomer, deuterated derivative, pharmaceutically acceptable salt thereof, pharmaceutically acceptable salt of its stereoisomer, pharmaceutically acceptable salt of its tautomer, or pharmaceutically acceptable salt of its deuterated derivative, or the use of the pharmaceutical composition of claim 67 in the preparation of a medicament for treating cancers associated with Fascin overexpression; preferably, the cancer is selected from breast cancer, central nervous system cancer, endometrial cancer, kidney cancer, colorectal cancer, lung cancer, esophageal cancer, tongue cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, mesothelioma, melanoma, fibrosarcoma, bladder cancer, rectal cancer, lymphoma, cervical cancer, head and neck cancer, upper respiratory tract and digestive tract cancers, colorectal cancer, urinary tract cancer, or colon cancer; more preferably, each cancer is independently selected from adenocarcinoma, squamous cell carcinoma, mixed adenosquamous carcinoma, undifferentiated carcinoma, etc. More preferably, the ovarian cancer includes high-grade ovarian serous adenocarcinoma, ovarian mucinous cystadenocarcinoma, or malignant Brenner's tumor of the ovary; the renal cancer includes clear cell renal cell carcinoma; the tongue cancer includes squamous cell carcinoma of the tongue; the lung cancer includes lung adenocarcinoma, lung adenosquamous carcinoma, lung squamous cell carcinoma, large cell lung cancer, small cell lung cancer, lung papillary adenocarcinoma, or non-small cell lung cancer; the pancreatic cancer includes pancreatic adenocarcinoma or pancreatic ductal adenocarcinoma; the esophageal cancer includes esophageal squamous cell carcinoma; the mesothelioma includes biphasic mesothelioma; the central nervous system cancers include glioma, glioblastoma, or glioblastoma multiforme; the gastric cancer includes gastric adenocarcinoma; the breast cancer includes ductal carcinoma, adenocarcinoma, or HR+ breast cancer; the bladder cancer includes bladder squamous cell carcinoma; the melanoma includes malignant melanoma; the colon cancer includes colonic adenocarcinoma; and the head and neck cancer includes small squamous cell carcinoma of the head and neck.

70. The compound, its stereoisomer, its tautomer, its deuterated derivative, its pharmaceutically acceptable salt, a pharmaceutically acceptable salt of its stereoisomer, a pharmaceutically acceptable salt of its tautomer, or a pharmaceutically acceptable salt of its deuterated derivative, or the pharmaceutical composition of claim 69, for use in treating cancers associated with Fascin overexpression; preferably, the cancer is selected from breast cancer, central nervous system cancer, endometrial cancer, kidney cancer, colorectal cancer, lung cancer, esophageal cancer, tongue cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, mesothelioma, melanoma, fibrosarcoma, bladder cancer, rectal cancer, lymphoma, cervical cancer, head and neck cancer, upper respiratory tract or digestive tract cancer, colorectal cancer, urinary tract cancer, or colon cancer; more preferably, each cancer is independently selected from adenocarcinoma, squamous cell carcinoma, mixed adenosquamous carcinoma, or undifferentiated carcinoma; More preferably, the ovarian cancer includes high-grade ovarian serous adenocarcinoma, ovarian mucinous cystadenocarcinoma, or malignant Brenner's tumor of the ovary; the renal cancer includes clear cell renal cell carcinoma; the tongue cancer includes squamous cell carcinoma of the tongue; the lung cancer includes lung adenocarcinoma, lung adenosquamous carcinoma, lung squamous cell carcinoma, large cell lung cancer, small cell lung cancer, lung papillary adenocarcinoma, or non-small cell lung cancer; the pancreatic cancer includes pancreatic adenocarcinoma or pancreatic ductal adenocarcinoma; the esophageal cancer includes esophageal squamous cell carcinoma; the mesothelioma includes biphasic mesothelioma; the central nervous system cancer includes glioma, glioblastoma, or glioblastoma multiforme; the gastric cancer includes gastric adenocarcinoma; the breast cancer includes ductal carcinoma, adenocarcinoma, or HR+ breast cancer; the bladder cancer includes bladder squamous cell carcinoma; the melanoma includes malignant melanoma; the colon cancer includes colonic adenocarcinoma; and the head and neck cancer includes small squamous cell carcinoma of the head and neck.

Images